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Ribosomally synthesised and post-translationally modified peptides (RiPPs) are a 
structurally diverse class of natural product that display a range of clinically relevant 
bioactivities such as antimicrobial and anticancer. The full extent of RiPP biochemical 
complexity has not yet been fully explored. This is partly due to challenges associated 
with genome mining for RiPP biosynthetic gene clusters (BGCs), which is often 
hampered by poor detection of the short precursor peptides that are ultimately modified 
into the final metabolite. Microorganisms are therefore predicted to produce many more 
RiPPs than are currently known. 
 
In this thesis, a novel RiPP genome mining tool, RiPPER, is employed to identify novel 
RiPP precursor peptides near YcaO-domain proteins, enzymes that catalyse various 
RiPP post-translational modifications including heterocyclisation and thioamidation. 
From this analysis, I report the identification of a novel and diverse family of RiPP BGCs 
present in over 230 species of Actinobacteria and Firmicutes. 
 
A representative BGC from Streptomyces albus J1074 was characterised through 
cloning and expression of the pathway followed by genetic, metabolomic and structural 
studies. I thus report the identification of a novel RiPP, streptamidine, which contains a 
structurally rare amidine ring. The identification of this metabolite along with bioinformatic 
analysis of homologous pathways suggests that amidine-containing RiPPs might be 
widespread in nature, where previously only two examples have been characterised. 
Bottromycin and klebsazolicin are both antibiotic RiPPs whose activity has been 
attributed to their amidine rings. Amidines might therefore represent an important 
structural feature for antibiotics that can be explored in the future. 
 
Overall, these studies show that many more biochemically diverse natural products can 
be discovered through the use of targeted genome mining approaches, even in widely 
studied model organisms such as Streptomyces albus J1074. This represents an 
exciting prospect for the future of antimicrobial discovery. 
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This thesis was written during the 2020 Covid-19 pandemic. In developed countries we 
have become familiar with a way of life where infectious disease is not at the forefront of 
our minds, but the present situation is a stark reminder of the destruction that infectious 
disease can cause on lives, health, jobs and economies, when no medical treatments 
are available.  
 
In recent years, advances in medicine and public health measures have helped treat and 
reduce the prevalence of numerous infectious diseases. Widespread vaccination 
eradicated smallpox in 1979, and the second of three types of poliomyelitis virus was 
eradicated in 2019. Notably, one of the biggest breakthroughs in modern medicine was 
the discovery of antibiotics in the 1900s, which have played a huge role in treating deadly 
bacterial infections and enabling safe routine surgery to be carried out. 
 
The majority of antibiotics used in the clinic are so-called ‘natural products’ produced by 
wide-ranging microbes which have been exploited for decades due to their biosynthetic 
talents. Unfortunately, due to recent overuse and misuse of antibiotics, bacteria are 
increasingly evolving resistance mechanisms that render these metabolites inactive. As 
a result, multidrug resistant ‘superbugs’ are starting to emerge, and antimicrobial 
resistance is a growing threat to public health that is predicted to cause millions more 
deaths in the future. 
 
There is currently an urgent need for new antimicrobial metabolites to be discovered. 
Fortunately, the search from nature has by no means been exhausted. Recent analyses 
have shown that we are still scratching the surface of the huge biosynthetic capacity of 
microbes, indicating huge potential to discover new natural product antibiotics.  
 
The importance of this thesis is to thus demonstrate how a combination of new and old 
scientific approaches can be applied to the mining, discovery and characterisation of 






Chapter 1: Introduction 
 
1.1. Natural Products 
 
“The fact that certain species of bacteria have an inhibiting effect on the development 
of other species or varieties is too well known to need discussion.”  
L. A. Rogers, 1928 
 
1.1.1. Microbial Natural Products  
For hundreds of years, microorganisms have been shown to exert inhibitory effects on 
other species (1,2). The causative metabolites produced by these organisms are known 
as ‘natural products’. As many of these metabolites exhibit antimicrobial or cytotoxic 
effects, a large number of microbial natural products have been utilised by the 
pharmaceutical industry to produce a plethora of human medicines (3). The development 
of antimicrobials, in particular, has had a significant effect in reducing the number of 
deaths attributed to infectious disease over the last century. More broadly, microbial 
natural products have also been used in agriculture as antibiotics, growth hormones and 
pesticides (4,5). Aside from antimicrobials, natural products can display other diverse 
biological functions, with roles in metal uptake, signalling, quorum sensing and 
development (6,7). Therefore, as well as important medicinal uses, natural products also 
represent an interesting aspect of microbial ecology. Due to their wide-ranging functions, 
and to distinguish them from primary metabolism, natural products can also be referred 
to as ‘secondary metabolites’ or ‘specialised metabolites’ (7).  
 
The overarching theory of why microbes produce so many specialised metabolites with 
antimicrobial activity is that they act as a kind of defence mechanism, providing an 
advantage to microbes during warfare when fighting for nutrients and resources in their 
competitive natural environments. The protective role of natural products has been 
demonstrated in various ecological niches, such as in fungus-farming ants (8), beewolf 
diggerwasps (9) and southern pine beetles (10). In these cases, the insects are 
associated with antibiotic-producing actinomycete bacteria that protect mutualistic 
fungus against microbial predators. There are also theories that the antimicrobial activity 
of natural products is a secondary function to more important biological roles. For 
example, thiopeptide antibiotics were recently shown to stimulate biofilm formation in 
Bacillus subtilis (11), which is an important growth state for bacterial colonisation (12). 
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1.1.2. A History of Microbial Natural Products as Antibiotics 
The start of the antibiotic era is often hallmarked by the discovery of penicillin from the 
fungus Penicillium chrysogenum, reported in 1929 (13) and later characterised in 1940 
(14). However, the use of microbial extracts to treat disease has been alluded to much 
earlier on in history. For example, mouldy bread was listed as a remedy on the Eber’s 
papyrus, the oldest preserved medical document from 1550 BC (15). In 1899, Emmerich 
and Löw reported that Bacillus pycaneus (now called Pseudomonas aeruginosa) could 
inhibit the growth of other microbes such as the causative agents of typhus and cholera 
(1). The extract produced by this bacterium was one of the first used as an antibacterial 
drug. Initially thought to be an enzyme, the ‘pyocyanase’ metabolite produced by P. 
aeruginosa were later confirmed to be pyocyanin and the 2-alkyl-4-quinolones, which are 
quorum sensing metabolites (16). Antibiosis between microbes was also reported by 
Pasteur in the early 1900s, who was one of the first scientists to propose that microbes 
might secrete metabolites to kill off other bacteria (17). A year before Fleming reported 
penicillin, a paper by Rogers from 1928 references the discovery of nisin, with the 
observation that Lactococcus lactis displays inhibitory activity against Lactobacillus 
bulgaricus (2). Nisin has now been used as a food preservative for over 50 years (18). 
 
After the discovery of penicillin, several more antibiotics were subsequently isolated from 
microbes. In 1939, Dubos discovered tyrothricin, an antibiotic mixture of gramicidin and 
tyrocidine from the soil bacterium Bacillus brevis (19,20). Inspired by this, Selman 
Waksman started searching for further antibacterial metabolites from soil microbes by 
screening extracts for inhibitory activity. This approach, often referred to as ‘the 
Waksman platform’, led to the discovery of numerous antibiotics that are still in clinical 
use today, and earnt Waksman the title of the ‘father of antibiotics’ (21). One of the first 
antibiotics discovered by Waksman, Bugie and Schatz was streptomycin, isolated from 
the soil bacterium Streptomyces griseus in 1943 (22). Streptomycin was another 
landmark antibiotic discovery as, unlike penicillin, it was active against Mycobacterium 
tuberculosis, whose infection was rife during and following the second world war. 
Following streptomycin, a number of other Streptomyces-derived antibiotics were 
isolated by Waksman’s team throughout the 1940s-‘60s, a period that has been coined 
the ‘golden age’ of antibiotic discovery (23,24). 
 
Since Waksman’s early work, it has been increasingly demonstrated that Streptomyces 
species and other members of the Actinobacteria phylum are particularly prolific 
producers of secondary metabolites. Natural products from Streptomyces species and 




1.1.3. The Streptomyces Genus 
The Streptomyces genus lies within the Streptomycetaceae family, Streptomycetales 
order and Actinobacteria class. Members of the Streptomycetales order are often 
referred to as actinomycetes, which represent a large group of filamentous and aerobic 
Gram-positive bacteria (25). The first actinomycete was described in 1875 by Cohn, who 
isolated a bacterium then named Strepthrotrix foersteri from a human tear duct (26). 
Later in 1943, Waksman and Henrici proposed a new genus classification for the group 
of actinomycetes that form characteristic branching hyphae, which included S. foersteri. 
This genus was named Streptomyces, which means “twisted fungus” (27). Today, the 
Streptomyces genus is particularly well studied, predominantly because members are 
talented producers of a range of secondary metabolites. Owing to this, streptomycetes 
have a relatively large genome for bacteria, typically eight megabases or larger (25), 
which forms a characteristic linear chromosome (28,29). Most Streptomyces bacteria 
live as saprophytes in the soil (30), from which many species have been selectively 
isolated. Actinobacteria make up 2-6% of the soil microbiome, as determined by 16S 
rRNA analysis of metagenomic samples (31). Many streptomycetes also inhabit other 
environmental niches such as fresh water, the desert, and marine environments 
including coral and sponges (32). The majority of Streptomyces species are non-
pathogenic, but some act as animal or plant pathogens such as Streptomyces scabies, 
which is responsible for common potato scab disease (33). Streptomycetes can be 
classified based on phenotypic traits such as their spore-derived structures and the 
pigmentation of spores and hyphae that give a characteristic colour to mature colonies 
(25). For example, the distinctive blue colour of Streptomyces coelicolor colonies comes 
from a blue pigment related to production of the antibiotic actinorhodin (34). This species 
is named coelicolor as it is Latin for “heavenly coloured” or “sky coloured” (26). 
 
1.1.3.1. Streptomyces development 
As well as their complex secondary metabolism, Streptomyces bacteria possess a 
fascinating growth and life cycle, which has also been of particular research interest. 
Much of the pioneering work on Streptomyces genetics was carried out by Sir David 
Hopwood and co-workers at the John Innes Centre. Streptomyces bacteria were 
originally thought to be fungi, partly because of their similar cell shape and filamentous 
growth pattern. The morphology of streptomycetes was confirmed through several 
electron microscopy experiments throughout the 1950s-‘60s (35–38). Streptomyces cells 
grow as branching hyphae that form a complex, tightly woven matrix, resulting in 
vegetative mycelium (25). From mycelial colonies, aerial hyphae form, which act as 
reproductive structures allowing the dispersal of environmentally resistant spores (30). 
The spores form as a result of septum formation in the multinucleate aerial hyphae, which 
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causes separation into individual cells (25). Thus, the Streptomyces lifecycle 
encompasses three developmental stages, from spore to vegetative mycelium to aerial 
mycelium. The transcription factors controlling the complex regulatory network of 
sporulation are encoded by the bld and whi genes (30,39,40). It was recently shown that 
the secondary messenger metabolite cyclic di-GMP signals through BldD and the sigma 
factor σWhiG to control both the formation of reproductive aerial hyphae, and their 
differentiation into spore chains (41). 
 
Recently, another interesting growth form of Streptomyces bacteria was observed, 
described as the ‘explorer’ phenotype, which is thought to be triggered by fungal 
interactions (42). Explorer cells are so-called because of their ability to rapidly spread 
across both biotic and abiotic surfaces via a non-branching hyphal growth state. Explorer 
cells can communicate even when physically separated, due to production of the volatile 
signalling metabolite trimethylamine (42,43). Exploratory growth therefore represents an 
intriguing method by which Streptomyces bacteria might colonise new habitats in the 
environment. 
 
1.1.3.2. Natural products from Streptomyces 
As discussed previously, many Streptomyces-derived antibiotics were discovered during 
the golden age of antibiotics, including chloramphenicol from Streptomyces venezuelae 
(44), and tetracyclines such as aureomycin from Streptomyces aureofaciens (45). Some 
important antibiotics for treating multi-drug resistant infections are also produced by 
streptomycetes, such as daptomycin from Streptomyces roseosporus (46,47). 
Streptomyces avermitilis produces avermectins, which are anti-parasitic metabolites 
used to treat malaria. The development of these drugs led to the award of the 2015 Nobel 
Prize in Physiology or Medicine to Campbell and Ōmura (48). An anthelmintic metabolite, 
milbemycin, is produced by Steptomyces bingchenggensis (49). Some important 
antifungal natural products are also produced by streptomycetes, including polyene 
macrolides such as pimaricin (50) and amphotericin B (51). Other more recently 
discovered antifungals include the reveromycins from Streptomyces sp. 3-10 (52) and 
the linearmycins produced by Streptomyces sp. Mg1 (53). Actinomycin is another 
important natural product that is produced by Streptomyces antibioticus, which became 
the first bacterial agent used to treat cancer (54). Streptomyces bacteria also produce 
natural products with other important ecological functions, such as the desferrioxamine 
siderophores that are important for iron-uptake and are also used in medicine to help 




1.1.4. Natural Products from other Kingdoms of Life 
1.1.4.1. Fungal natural products  
Fungi produce a range of secondary metabolites including maleidrides (56), tropolones 
(57) and nonribosomal peptides (58,59). As well as producing important antibiotics such 
as penicillin (13) (Figure 1), fungi are also responsible for medicinal metabolites such as 
the immunosuppressant cyclosporin, produced by Tolypocladium inflatum (60). Genera 
of fungi that have been frequently exploited include Penicillium, Aspergillus and 
Fusarium (59). However, it is thought that the vast majority of fungal species have not 
been described or cultured under laboratory conditions (61,62). Much of the early fungal 
natural product work was carried out by Harold Raistrick (59). 
 
1.1.4.2. Archaeal natural products 
Although less well studied, archaea also produce a range of secondary metabolites such 
as archaeocins and diketopiperazines. Archaea are not known to produce some of the 
key natural product classes seen in bacteria and fungi such as nonribosomal peptides, 
but many archaeal natural products show biotechnological potential as antimicrobials, 
cosmetics and food additives (63).  
 
1.1.4.3. Animal natural products 
Animals produce natural products such as defensins, which are cyclic antimicrobial 
peptides crosslinked by disulphide bonds. These form part of the innate immune system 
(64). Nematodes such as Caenorhabditis elegans were recently shown to produce hybrid 
polyketide-nonribosomal peptides such as the nemamides (65) (Figure 1). Other animal-
derived natural products include casein, chitosan and collagen, metabolites with unusual 
structures and broad applications in industry including catalysis, drug delivery and tissue 
engineering (66–69). 
 
1.1.4.4. Plant natural products 
Like microbes, plants also produce a plethora of natural products, many of which have 
been utilised in medicine. One of the earliest plant natural products to be developed into 
a drug was morphine, produced by the ‘opium’ poppy Papaver somniferum, marketed by 
Merck in 1826 (70,71). Another early and eminent example of a plant natural product is 
salicin (Figure 1), isolated from the tree bark of Salix alba (white willow), which was 
developed into aspirin as a semi-synthetic drug by Bayer in 1899 (70,72). Plants are also 
particularly prolific producers of terpenes, which have been developed into flavours, 





Figure 1: Examples of natural products produced by diverse organisms. Nemamide A is a polyketide-
nonribosomal peptide hybrid metabolite produced by Caenorhabditis elegans. Salicin is a natural product 
isolated from Salix alba tree bark which is a precursor for the production of aspirin. Penicillin is a β-lactam 
antibiotic isolated from the fungus Penicillium chrysogenum. 
 
1.1.5. Antimicrobial Resistance 
A growing problem that is threatening the effectiveness of antimicrobial drugs is 
antimicrobial resistance. This is the ability of microbes to evolve resistance to 
antimicrobial drugs through a variety of different mechanisms. Where antibiotics are 
naturally produced by microbes to kill off their competitors, it follows that microorganisms 
have also evolved ways to combat this. Fleming famously warned of antibiotic resistance 
in his 1945 Nobel Lecture: “It is not difficult to make microbes resistant to penicillin in the 
laboratory by exposing them to concentrations not sufficient to kill them, and the same 
thing has occasionally happened in the body.” This was an early caution for the 
resistance crisis that is emerging today. 
 
Mechanisms of antimicrobial resistance are diverse, and include modification of a drug 
target, limitation of uptake, drug inactivation and active efflux from cells. Resistance can 
also be defined as either intrinsic or acquired (76). Bacteria may be intrinsically resistant 
to an antibiotic if, for example, they do not naturally harbour the molecular target of the 
given drug, or because of natural activity of efflux pumps that export the antibiotic. Gram-
negative bacteria are also intrinsically resistant to many antibiotics due to the thick 
lipopolysaccharide layer that reduces permeability of the outer membrane (77,78). 
Acquired resistance refers to the gaining of genetic material through horizontal gene 
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transfer that confers resistance (76), but it can also arise spontaneously. The spread of 
acquired resistance is accelerated through increased exposure to antimicrobials. For this 
reason, the over-subscribing and misuse of antibiotics in clinical and agricultural settings 
is largely attributed to the rising prevalence of antimicrobial resistance (79). However, 
evidence also suggests that resistance even predates human usage of antibiotics. For 
example, antibiotic resistance elements have been found in ancient DNA dating from the 
Pleistocene epoch (80), in deep sea environments (81) and in a cave that had been 
secluded for 4 million years prior to investigation (82). 
 
As laid out in the 2016 O’Neill report, it is often reported that by 2050 there will be more 
than 10 million deaths per year from antimicrobial resistance (83). But how predictable 
is the future? There are many unpredictable factors that could rapidly change the 
resistance landscape, which are described by David Livermore as ‘Black Swan’ events. 
These include the escape of new resistance genes from environmental bacteria and their 
uptake by promiscuous mobile genetic elements (84). An example of this is the escape 
of the vanHAXY operon, putatively from Paenibacillus spp. to Tn1546, resulting in the 
unexpected emergence of vancomycin-resistant Enterococci (VRE) (85), which now 
represent major clinical pathogens. The unpredictable nature of antimicrobial resistance 
makes it an even more pressing issue, and it is vital that we are equipped to deal with 
future challenges.  
 
1.1.6. Approaches to Natural Products Discovery 
Whilst tackling antimicrobial resistance requires a multifaceted approach, one essential 
element is the discovery of new antimicrobial agents. Antibiotic discovery comes with 
many practical, regulatory and economical challenges, and as a result the 
pharmaceutical industry has largely cut investment in antibiotic and natural product 
discovery programs (86). However, there is still a huge amount of potential in natural 
products from microorganisms. Recently, with the inception of the genomic era, it has 
been revealed through analysis of microbial genomes that their biosynthetic capacity has 
not been fully explored, and that they are capable of producing many more natural 
products than are currently characterised (87,88). For this reason, natural products 
research remains a promising arena in which to discover novel antimicrobials and other 
useful natural products, while also developing a deeper understanding of their 
biosynthesis and ecological functions. A common problem with traditional activity-based 
screening for antimicrobials is the high rate of rediscovery of already known metabolites. 
Waksman wrote about this duplication problem in 1965 (89). This has led to research 
groups taking alternative approaches to natural products discovery in recent years. One 
way to discover new natural products is through genome mining for novel biosynthetic 
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gene clusters, which is discussed in detail in Chapter 2. Other approaches are described 
in the following sections. 
 
1.1.6.1. Exploring new environments 
Some natural product research has focused on studying diverse and more extreme 
environments, such as desert (90), arctic (91) and marine (92) habitats, in order to isolate 
novel microorganisms and investigate their biosynthetic capacity. Other research has 
also focused on investigating interesting ecological niches where microorganisms co-
exist in a symbiotic relationship with other species. One example is that of the leafcutter 
ants, which harbour unique Streptomyces species on their surfaces. When isolated, it 
was found that these bacteria produce several types of antibiotic metabolites including 
the fasamycins and formicamycins (93). The genomes of the newly identified 
Streptomyces species were also analysed indicating that they were taxonomically 
distinct, and contain many biosynthetic gene clusters for natural products that were not 
seen in other species (94). This suggests that investigating bacteria from unique habitats 
is a promising way to identify structurally novel metabolites. This is also exemplified with 
the recent discovery of the antibiotic darobactin, which was isolated from Photorhabdus 
khanii HGB1456. Photorhabdus is an underexplored genus that live symbiotically within 
entomopathogenic nematodes (95).  
 
1.1.6.2. Novel isolation methods 
Whilst the identification of novel bacterial species is an exciting venture, one problem 
that thwarts microbial natural products discovery is that a large proportion of microbes 
are difficult to grow and are deemed uncultivatable under lab conditions: the so-called 
‘great plate count anomaly’ (96). This can make subsequent isolation and investigation 
of any natural products challenging. However, some novel approaches have been taken 
to try to overcome the cultivation problem. One of these is the development of the 
isolation chip (iChip), a device containing wells that is placed in a natural environment 
such as the soil, allowing microorganisms to directly grow in the presence of natural 
nutrients and growth factors (97). This approach was developed by Kim Lewis’s lab 
leading to the isolation of a previously undiscovered bacterium Eleftheria terrae, which 
produced the novel antibiotic teixobactin. Teixobactin has activity against some Gram-
positive pathogens such as methicillin-resistant Staphylococcus aureus (MRSA), and is 
thought to be unlikely to induce resistance as it adopts a unique interaction with the 




1.1.6.3. Direct analysis of environmental samples 
Another approach to overcome cultivation problems is the direct capture of metagenomic 
DNA from environments such as the soil, in order to assemble genomes, identify 
biosynthetic gene clusters and express them for further characterisation. This approach 
has been taken by the Brady lab who identified the fasamycin antibiotics (99). In some 
cases environmental samples have also been directly analysed by mass spectrometry 
(92), and natural products were detected from these with the help of public mass spectral 
databases such as GNPS (Global Natural Products Social) molecular networking (100) 
(discussed in further detail in Chapter 2). 
 
1.1.7. Natural Product Classes 
Natural products are grouped into different subclasses based on their biosynthetic and 
structural features and can be broadly divided into nonpeptides and peptides. 
Nonpeptide natural products include polyketides and terpenes, and peptide natural 
products include nonribosomal peptides and ribosomally synthesised peptides. 
 
1.1.7.1. Polyketides 
Polyketides are a major natural product class comprising metabolites such as polyethers, 
polyenes, polyphenols, macrolides and enediynes. They have diverse bioactivities 
including antimicrobial, anticancer, immunosuppressive, anti-cholesterol and anti-
inflammatory. Polyketides are produced by a range of organisms including bacteria, 
fungi, plants, protists, insects molluscs and sponges (101–103). The biosynthesis of 
polyketides is similar to that of fatty acids and follows assembly-line biosynthesis. 
Assembly-lines consist of complexes of large proteins comprising repetitive peptide 
sequences, each of which encode individual enzyme domains. There are several 
different architectures of the polyketide synthase (PKS) assembly line: type I PKSs 
(T1PKS) e.g. erythromycin (Figure 2) (104), type II PKSs (T2PKS) e.g. actinorhodin and 
type III PKSs (T3PKS) e.g. plant chalcone synthase. PKSs can also be categorised as 
iterative or noniterative, depending on whether each ketosynthase domain catalyses 
more than one round of elongation during biosynthesis (102). PKSs typically consist of 
a ketosynthase (KS)-domain, an acyltransferase (AT)-domain and an acyl carrier protein 
(ACP). In T1PKSs, the AT-domain uptakes acyl-coenzyme A (CoA) substrates, which 
are then transferred to the phosphopantetheine of the ACP. The KS-domain is then 
transacylated with the growing polyketide chain, enabling malonyl ACP Claisen 
condensation with the acyl KS-substrate. Each PKS module thereby incorporates a C2 
acetyl unit, and the newly formed β-keto group usually undergoes reduction from a 
ketoreductase, dehydratase or enoyl reductase (105,106). In T2PKSs, acetate is 
incorporated into the ACP and then transferred to the active site of a KS, which then 
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undergoes iterative elongation by Claisen condensation with derivatives of malonyl CoA 
(107). The polyketide is then cyclised to produce polycyclic metabolites (102).  
 
1.1.7.2. Terpenes 
Terpenes, or isoprenoids, are the largest and most diverse class of small metabolite 
natural products, produced by almost all kingdoms of life, particularly plants. They carry 
out a range of biological functions in defence, photosynthesis and electron transfer 
(73,108). Terpenes originate from the C5 substrates dimethylallyl diphosphate (DMAPP) 
and isopentenyl diphosphate (IPP). DMAPP is usually condensed with one or more IPP 
metabolites in a head-to-tail manner to form geranyl diphosphate (GPP) (C10), farnesyl 
diphosphate (FPP) (C15) or geranylgeranyl diphosphate (GGPP) (C20). FPP and GGPP 
can then condense in a head-to-head manner to form dehydrosqualene, squalene or 
phytoene. These serve as the precursors for carotenoids, sterols and hopanoids. 
Isoprenoids can also be cyclised to produce terpene natural products such as 
monoterpenes, diterpenes and sequiterpenes (108). Plants can also convert DMAPP 
into isoprene, a potential source of renewable fuel (73,109). DMAPP and IPP can be 
made via two different pathways: the mevalonate pathway, utilised by most eukaryotes 
and Archaea, or the methylerythritol phosphate pathway, utilised by most bacteria (108). 
Plants have been found to utilise both pathways (110). Enzymes involved in terpene 
biosynthesis include prenyl transferases, terpene synthases and 4Fe-4S reductases 
(109). In plants, it has also been found that non-terpene synthase enzymes can catalyse 
the formation of terpenes (111). An example of a microbial terpene is geosmin (Figure 
2), produced by cyanobacteria and actinomycetes from the sesquiterpene precursor 
farnesyl pyrophosphate (112). 
 
1.1.7.3. Nonribosomal peptides 
Nonribosomal peptides are peptide natural products produced by nonribosomal peptide 
synthetases (NRPSs), which are mainly found in bacteria and fungi. Nonribosomal 
peptides include a range of structurally complex metabolites, such as head-to-tail 
cyclised peptides, lipocyclopeptides and linear peptides of varying size. Nonribosomal 
peptides can also undergo extensive structural modifications by tailoring enzymes, 
producing many antibiotic nonribosomal peptides including the β-lactams and 
glycopeptides such as vancomycin (Figure 2) (113). Nonribosomal peptides also display 
other biological functions, acting as siderophores, toxins, antifungal and antitumour 
agents (114). Nonribosomal peptide biosynthesis involves three main stages: building 
block assembly, NRPS-mediated peptide assembly and post-NRPS modification and 
decoration. NRPSs are multi-modular enzymes with each typical module including an 
adenylation (A)-domain, condensation (C)-domain and thiolation (T)- or peptidyl carrier 
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protein (PCP)-domain. The A domain activates the building block by adenylation, and 
the activated building block is transferred to the pantetheine thiol group of the PCP. The 
C domain transfers an aminoacyl or peptidyl group from an upstream carrier protein 
domain to the primary amine of an amino acid that has been previously loaded onto the 
downstream carrier domain. The thioesterase domain catalyses either hydrolysis or 
cyclisation of the peptide to release it from the final carrier protein domain (114,115).  
 
 
Figure 2: Examples of metabolites from different natural product classes. Erythromycin A is a type 1 
polyketide antibiotic produced by Streptomyces erythreus (104), vancomycin is a nonribosomal glycopeptide 
antibiotic produced by Nocardia orientalis (113) and geosmin is an irregular sesquiterpene that has a 
characteristic earthy odour, produced by actinomycetes and cyanobacteria (112). 
 
1.1.7.4. Ribosomally synthesised and post-translationally modified peptides 
(RiPPs) 
Other peptide natural products include the ribosomally-synthesised and post-
translationally modified peptides (RiPPs). RiPPs are the focus of this thesis, and will 







1.2.1. General Biosynthetic Logic 
RiPPs are a class of peptide natural product that are synthesised on the ribosome and 
subject to extensive post-translational modifications, giving rise to a high degree of 
structural complexity and biological diversity. RiPPs are produced from a short precursor 
peptide, which is typically 50-150 amino acids in length. This precursor usually comprises 
a leader region and a core region. The core region includes the amino acid residues that 
are ultimately post-translationally modified by a series of RiPP tailoring enzymes, which 
decorate the peptide backbone with various structural features (116,117). Once the core 
region has been fully modified, it is cleaved from the leader region, yielding the 
biologically active final natural product (116,117) (Figure 3).  
 
The leader region of the precursor peptide has been suggested to play multiple roles in 
RiPP biosynthesis. Firstly, it has been shown to be important for the binding of RiPP 
tailoring enzymes, which contain domains called RiPP precursor peptide recognition 
elements. These recognition elements are thought to be specific to certain classes of 
biosynthetic enzymes (118–120). The leader peptide has also been suggested to be 
involved in protection, preventing the core region from proteolytic cleavage before the 
biosynthetic modifications are complete. In some rare cases, RiPP precursors contain a 
follower region instead of a leader region, as is seen in bottromycins (121). In other 
cases, precursors contain both a follower and leader region, as is the case for pantocin 
A (122), α-amanitin (123), thiovarsolins (124) and some cyanobactins (125). As with 
other microbial natural products, the biosynthetic genes for RiPPs typically cluster 
together tightly on the genome, and the precursor peptide is generally denoted as ‘xxxA’. 
Due to the diversity of RiPP metabolites, they are grouped into various different 
subclasses based on their biosynthetic and structural features. 
 
 
Figure 3: General biosynthetic logic of ribosomally synthesised and post-translationally modified peptides 
(RiPPs). A precursor peptide comprising a core peptide and leader and/or follower peptide is subject to post-
translational modifications in the core region by a series of RiPP tailoring enzymes. The leader/follower 
peptide is then cleaved from the core peptide to yield the mature modified peptide.  
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1.2.2. RiPP Subclasses 
1.2.2.1. Linear azol(in)e-containing peptides (LAPs) 
Linear azol(in)e-containing peptides (LAPs) are a class of RiPP characterised by the 
presence of azole or azoline heterocycles on a linear peptide backbone. The first LAP 
discovered was the β-haemolytic factor streptolysin S, produced by Streptococcus 
pyogenes, which was first observed in 1901. The defining genetic and structural features 
were not reported until 2000 (126). Another well-studied LAP is microcin B17 (Figure 4), 
a bactericidal peptide produced by Escherichia coli which was first observed in 1976 
(127), and displays narrow spectrum antibacterial activity targeting DNA gyrase (128). 
Microcin B17 is a large metabolite deriving from a 43-residue core amino acid sequence, 
which is modified to contain four oxazole and four thiazole heterocycles. A more recently 
discovered example of a LAP is klebsazolicin, which was identified following genome 
mining for homologues of the microcin B17 biosynthetic proteins (129). Klebsazolicin 
was isolated from Klebsiella pneumoniae sp. ozaenae in 2017 and displays antibiotic 
activity via ribosome inhibition. Klebsazolicin derives from a shorter 23-residue core 
amino acid sequence, which is modified to contain one oxazole and three thiazole 
heterocycles, as well as an additional N-terminal amidine ring (129).  
 
1.2.2.2. Thiopeptides 
Thiopeptides, also known as thiazolylpeptides, are characterised by a macrocyclic core 
comprising a central six-membered nitrogen-containing heterocycle and a series of 
thiazoles. Further biosynthetic features include the dehydration and cyclodehydration of 
serine, threonine and cysteine residues (116). Thiopeptides have a range of biological 
activities such as antibacterial and anticancer (130,131), antiplasmodial (132) and 
immunosuppressive (133). One of the first thiopeptides identified was micrococcin (134), 
which was isolated in 1948 from sewage water (135), and is produced by 
Bacillus and Micrococcus species (136). Micrococcin is an antibiotic which also displays 
inhibitory activity against the malaria parasite Plasmodium falciparum (137). Another 
early example of a thiopeptide is thiostrepton, isolated from Streptomyces azureus in 
1954 (138) and produced by several other Streptomyces species (139). The structure of 
thiostrepton (Figure 4) was elucidated by Dorothy Crowfoot Hodgkin in 1970 using X-
ray crystallography (140). Other examples of thiopeptides include the thiocillins, 
produced by Bacillus cereus (141).  
 
1.2.2.3. Cyanobactins 
Cyanobactins are RiPPs produced by cyanobacteria, whose structural transformations 
often include heterocyclisation, oxidation or prenylation of amino acid residues. The most 
well-studied cyanobactins are the patellamides (Figure 4) and trunkamides, which 
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display cytotoxic activities. The patellamides are produced by Prochloron species, (142) 
and trunkamide was isolated from Lissoclinum patella in 1996 (143). Patellamides 
contain pseudosymmetrical cyclic dimers with thiazole and oxazoline heterocycles 
installed in between nonpolar amino acids. Trunkamides often contain proline, 
thiazolines and prenylated serine and threonine derivatives (142). While many 
cyanobactins are cyclic peptides, more recently several linear cyanobactins have also 
been reported. Scytodecamide is a linear decapeptide cyanobactin produced by the 
freshwater cyanobacterium Scytonema sp. UIC 10036, which was reported in 2019 
(144). Scytodecamide contains an N-terminal N-methylation and a C-terminal amidation 
(144). As well as cyanobactins, cyanobacteria also produce a class of RiPP called 




Figure 4: Chemical structures of RiPPs containing (methyl)oxazole and thiazole heterocycles. Microcin B17 
is an antibiotic linear azol(in)e-containing peptide (LAP) produced by Escherichia coli, bottromycin A2 is an 
antibiotic produced by Streptomyces species, thiostrepton A is a thiopeptide antibiotic produced by 
Streptomyces species and patellamide A is a cyanobactin produced by Prochloron species. Oxazoles are 
highlighted in red and thiazoles are highlighted in blue. Other highlighted post-translational modifications 
include methylation (purple) and amidine ring formation (orange) in bottromycin, and dehydration (green) 
and nitrogen-containing heterocycle formation (pink) in thiostrepton A.  
 
1.2.2.4. Bottromycins 
Bottromycins, exemplified by bottromycin A2 (Figure 4), are a small subclass of RiPP 
metabolites that have been of great research interest due to their unique structure and 
antibiotic activity. Bottromycin was first isolated from Streptomyces bottropensis in 1967 
(145) and is produced by other Streptomyces species such as S. scabies and 
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Streptomyces sp. WMMB272 (146). Bottromycin exerts antibiotic activity via ribosome 
inhibition and has been shown to be effective against MRSA and VRE. The structure of 
bottromycin includes a unique N-terminal macroamidine ring, as well as a C-terminal 
thiazole heterocycle. Derivatives of bottromycin contain differing methylation patterns: 
bottromycin A2 contains a single C-methylation on proline, bottromycin B lacks any 
methylation on proline and bottromycin C contains a doubly methylated proline (147). 
 
1.2.2.5. Thioamitides 
Thioviridamide is a thioamidated RiPP produced by Streptomyces olivoviridis NA005001. 
Its unique structure includes structurally rare thioamide bonds and two unusual amino 
acids: β-hydroxy-N1,N3-dimethylhistidinium (hdmHis) and S-[(Z)-2-aminovinyl]-D-
cysteine (AviCys) (148). Thioviridamide was first isolated in 2006 (148), but its gene 
cluster was not reported until 2013 (149). Thioviridamide possesses potent 
antiproliferative activity against cancer cells, which is attributed to its unusual structure 
(148). Recent genome mining approaches have unveiled several further thioviridamide-
like metabolites, which have recently been termed thioamitides (150). These include 
thioalbamide from Amycolatopsis alba (151) (Figure 5) and the thioholgamides from 
Streptomyces malaysiense (152). These recently identified thioamitides also appear to 
exhibit cytotoxic activity against cancer cell lines (151,152).  
 
 
Figure 5: Chemical structure of thioalbamide, a recently reported thioamitide produced by Amycolatopsis 
alba. The characteristic thioamide bonds are highlighted in green. The structure also features the unusual 




Lanthipeptides are a large and well-studied group of RiPPs characterised by the 
presence of sulphur-to-β-carbon thioether cross-links named lanthionines (Lan) and 
methyllanthionines (MeLan). Lanthipeptides are divided into five classes (I-V), based on 
the biosynthetic machinery responsible for installing the thioether rings. Lanthipeptides 
display diverse activities, and those with antibiotic properties are termed lantibiotics. A 
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characteristic lanthipeptide is the polycyclic antibiotic peptide nisin (Figure 6). Its 
structure derives from a 34-residue core peptide, which is post-translationally modified 
to contain Lan and MeLan as well as the unusual amino acids didehydroalanine (Dha), 
didehydroaminobutyric acid (Dhb) and α-aminobutyric acid (Abu) (153). A more recently 
reported lantibiotic is kyamicin, which was isolated following heterologous expression of 
a cryptic biosynthetic gene cluster from a plant-ant derived Saccharopolyspora species. 
Kyamicin displays antibiotic activity against Bacillus subtilis EC1524 (154). Whilst 
lanthipeptides have been widely studied for many years, the class V lanthipeptides were 
only recently defined in 2020, with the discovery of a novel metabolite with unique 
biosynthetic machinery from Streptomyces pristinaespiralis ATCC 25468 (155). 
 
1.2.2.7. Sactipeptides 
Another class of RiPP that harbours thioether linkages are the sactipeptides. In this class 
the thioether bonds comprise sulphur-to-α-carbon cross-links. This was first reported in 
2003 with the structural elucidation of subtilosin A, produced by B. subtilis (156). Since 
then, many other sactipeptides have been discovered such as thurincin H from Bacillus 
thuringiensis (157) and ruminococcin C, an anti-clostridial metabolite produced by 
Ruminococcus gnavus, a bacterium found in the human microbiome (158). Sactipeptides 
with antibiotic activity are termed sactibiotics (116). 
 
1.2.2.8. Linaridins 
Linaridins are linear dehydrated peptides, which are a small but growing subclass of 
RiPP. The archetypal member of this class is cypemycin (Figure 6), isolated from 
Streptomyces sp. OH-4156 in 1993 (159). Cypemycin displays antibiotic activity and was 
originally considered a lantibiotic due to the presence of Dhb and AviCys residues in its 
structure. However, further genetic studies showed that these modifications are carried 
out via unusual biosynthetic steps unrelated to lanthipeptide biosynthesis (160). 
Cypemycin was thus described as the founding member of the new linaridin class. As 
well as Dhb and AviCys, cypemycin also contains unusual N,N-dimethylalanine and allo-
isoleucine residues installed onto the 22 amino acid core peptide (161). Following 
cypemycin discovery, further homologues were reported, including grisemycin from 
Streptomyces griseus (162) and legonaridin from Streptomyces sp. CT34 (163). More 
recently in 2019, the salinipeptides were discovered from Streptomyces sp. GSL-6C, a 





Figure 6: Chemical structures of nisin A and cypemycin. Nisin A is a lanthipeptide with antibiotic activity 
produced by Streptococcus lactis, and cypemycin is a linaridin with antibiotic activity produced by 
Streptomyces sp. OH-4156. Less common amino acids in these metabolites are highlighted, including 
didehydroalanine (Dha, orange), didehydroaminobutyric acid (Dhb, blue), aminobutyric acid (Abu, purple) 
and allo-isoleucine (green). Other post-translational modifications include (methyl)lanthionine bonds in nisin 
A (red) and an S-[(Z)-2-aminovinyl]-D-cysteine (AviCys) moiety in cypemycin (red). Cypemycin also contains 
an unusual N,N-dimethylalanine moiety (pink). 
 
1.2.2.9. Lanthidins 
Recently in 2020, a new subclass of RiPP was described with the identification of a novel 
metabolite cacaoidin, which harbours elements of both lanthipeptides and linaridins. 
Cacaoidin features several D-amino acids, an unusual glycosylated tyrosine residue and 
a unique N,N-dimethyllanthionine residue. Cacaoidin also displays antimicrobial activity 
against clinical pathogens such as Clostridium difficile. Although this metabolite contains 
elements of lanthipeptides and linaridins, the biosynthetic gene cluster of cacaoidin 
shows low homology to these classes, suggesting that lanthidins are a unique new family 
of RiPP (165). 
 
1.2.2.10. Lasso peptides 
Lasso peptides are cyclic metabolites that display antibiotic activities and contain a 
characteristic knotted ‘lasso’ structure. This is made up of a right-handed N-terminal 
macrolactam ring comprising seven to nine amino acid residues, through which a linear 
C-terminal peptide tail is threaded through in a noncovalent interaction (166). There are 
three different subclasses of lasso peptide based on the number of disulphide bonds in 
the metabolite. Class I lasso peptides contain two disulphide bonds, class III contain one 
disulphide bond and class II have no disulphide bonds (167). A model lasso peptide is 
microcin J25 (Figure 7), an RNA inhibitor identified from E. coli in 1992, which is active 
against Gram-negative bacteria (168). Microcin J25 derives from a 21-residue peptide, 
but the exact structural confirmation of the mature metabolite was contested for some 
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years (169), initially thought to comprise a head-to-tail cyclised backbone, before two 
research groups proved the lasso tail structure in 2003 (166,170). Lasso peptides 
discovered more recently in 2019 include ubonodin, which has antimicrobial activity 
against members of the Burkholderia cepacia complex (171), and pandonodin, a lasso 
peptide with an unusually long 18-residue C-terminal tail (172). 
 
 
Figure 7: Chemical structure of microcin J25, a characteristic lasso peptide produced by E. coli. The 
structure includes a macrolactam ring through which the C-terminal tail is threaded. 
 
1.2.2.11. Streptide and darobactin 
Streptide is a macrocyclic peptide that contains an unusual lysine-to-tryptophan carbon-
carbon crosslink (Figure 8). Streptide was first reported in 2007 as a modified nine-
residue peptide termed Pep1357, produced from Streptococcus thermophilus (173). The 
peptide is excreted as a pheromone and its transcription is controlled via quorum sensing 
(173). In 2015, detailed biosynthetic and structural elucidation of streptide was finally 
reported, revealing the novel crosslinking between lysine and tryptophan side chains 
(174) and further stereochemistry was confirmed in 2019 (175). Until recently, streptide 
was a structurally unique RiPP, but in 2019 a novel metabolite called darobactin was 
reported (Figure 8), which also features lysine-to-tryptophan crosslinking. In addition, 
darobactin also harbours an unprecedented aromatic–aliphatic ether link between two 
tryptophan residues in the core peptide. Darobactin displays antibiotic activity against 
Gram-negative pathogens including E. coli, Klebsiella and Pseudomonas species (95). 





Figure 8: Chemical structures of streptide and darobactin. Streptide is a pheromone produced by 
Streptococcus thermophilus and darobactin is an antibiotic produced by Photorhabdus khanii. The 
tryptophan-lysine crosslinking unique to these metabolites is highlighted in red, and the unusual ether bond 
in darobactin is highlighted in purple. 
 
1.2.2.12. Proteusins 
Proteusins are exemplified by the polytheonamides, first reported in 1994 (176). These 
metabolites are produced by the Japanese sponge Theonella swinhoei, which harbours 
a range of symbiotic bacteria. Polytheonamides are large and highly complex 
metabolites, containing several nonproteinogenic and D-configured amino acids and an 
unusual N-acyl moiety. Other post-translational modifications include dehydration, 
methylation and hydroxylation (176–178). Polytheonamides are highly cytotoxic owing 
to their ability to form membrane channels by adoption of a β-helical secondary structure 
(179). 
 
1.2.2.13. Other bacterial RiPPs 
As well as the diverse subfamilies described thus far, bacteria produce many more 
classes of RiPP. These include the relatively large bacterial head-to-tail cyclised 
peptides, and much smaller metabolites such as the bacterial cofactor pyrroloquinoline 
quinone (PQQ) (180), the pantocins (122) and thyroid hormones such as 3,30,5,50-
tetraiodothyronine (T4) (116). Whilst the majority of these RiPPs are produced by 
bacteria, further RiPP subfamilies have also been described from other organisms. 
 
1.2.2.14. Fungal RiPPs 
In fungi, four different families of RiPP have been described. The amatoxins and 
phallotoxins were first reported in 2007, and are produced by basidiomycete genera such 
as Amanita, Glaerina, Lepiota and Conocybe (181–183). Amatoxins, exemplified by α-
amanitin, are highly toxic to insects, nematodes and mammals, acting via RNA inhibition 
(183). Amatoxins and phallotoxins consist of eight or seven amino acid residues 
respectively, forming a bicyclic structure due to crosslinking between cysteine and 
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tryptophan residues (123). This crosslink is called a tryptathionine (184). Other post-
translational modifications include hydroxylations and epimerisation (183). In 2016 the 
dikaritins were defined, which are cyclopeptides produced by fungi of the Dikarya 
subkingdom. These RiPPs are cyclised via ether bridges between the hydroxyl group of 
tyrosine and the β-carbon of isoleucine, phenylalanine or tyrosine (183,185). Another 
fungal RiPP family are the borosins, recently described in 2017. The founding member, 
Omphalotin A, is a toxic cyclic dodecapeptide produced by the basidiomycete 
Omphalotus olearius. Nine of the 12 backbone residues in this metabolite undergo N-
methylation (186–188). Another fungal RiPP family are the epichloëcyclins, which are 
cyclic nonapeptides produced by Epichloë ascomycetes. These metabolites are cyclised 
between a conserved tyrosine and proline or isoleucine at the aminoterminus. 
Dimethlyation occurs on a conserved lysine (183,189).  
 
1.2.2.15. Plant RiPPs 
In plants, several cyclic RiPP families have been described. Cyclotides are head-to-tail 
cyclised peptides with three disulphide bonds, forming a characteristic cyclic cysteine 
knot structure. Cyclotides have been isolated from Viola and Oldenlandia species (190). 
PawS-derived peptides are cyclotides with one disulphide bond, which are widespread 
in the Asteraceae family (191). Orbitides are another subclass of head-to-tail cyclised 
peptide that do not contain disulphide bonds, and are produced by Linum 
usitatissimum L. (flaxseed) (192). A further plant RiPP family, the lyciumins, has also 
recently been defined. Lyciumins feature a distinctive N-terminal pyroglutamate and a 
rare macrocyclic linkage between a C-terminal nitrogen from tryptophanindole and a 
glycine α-carbon (193). Lyciumins are produced by plants such as Lycium barbarum and 
Ceolsia argentea, and are used as a Chinese medicine to treat hypertension, acting via 





1.2.3. Biosynthesis of Post-Translational Modifications in RiPPs 
1.2.3.1. Understanding RiPP biosynthesis 
The focus of this thesis is to identify and characterise novel RiPP biosynthetic gene 
clusters. In order to mine for gene clusters that might produce structurally novel 
metabolites, it is important to understand the classes of enzyme that produce the wide-
ranging post-translational modifications of RiPPs. For example, how widespread are the 
biosynthetic genes in nature? How promiscuous or diverse is the enzyme’s catalytic 
activity? Is there potential to expand on a structural class that is currently underexplored? 
The biosynthetic machinery responsible for many common RiPP post-translational 
modifications are described in the following sections. 
 
1.2.3.2. Oxazol(in)e and thiazol(in)e rings 
Azole and azoline heterocycles are characteristic features of RiPPs such as LAPs, 
thiopeptides and cyanobactins. (Methyl)oxazolines are oxygen-containing rings derived 
from the side chains of serine and threonine residues, while thiazolines are sulphur-
containing rings derived from the side chain of cysteine. These rings can then be oxidised 
to the respective (thi/ox)azole heterocycle. Much of the understanding of azol(in)e 
biosynthesis comes from the study of the LAP microcin B17. Azoline ring formation is 
catalysed by a YcaO-domain protein in collaboration with a partner protein, which is often 
annotated in genomes as an E1-ubiquitin activating enzyme or an Ocin-ThiF-like protein 
(195). The YcaO-domain protein is responsible for enzymatic cyclodehydration, while the 
partner protein is a docking element thought to be involved in peptide recognition. YcaO 
proteins use ATP as a substrate, phosphorylating the amide backbone via a 
hemiorthoamide intermediate before subsequent ring formation and elimination of the 
phosphate (Figure 9A)  (196–198). While many YcaO-domain proteins are standalone 
enzymes, in some cases the YcaO and E1 proteins function as a fused 
cyclodehydratase. This is seen in the cyanobactin enzymes TruD and PatD, which 
catalyse the biosynthesis of trunkamides and patellamides respectively (75,86). 
(Methyl)oxazolines and thiazolines can be oxidised by a flavin mononucleotide (FMN)-
dependent dehydrogenase to the respective (methyl)oxazoles and thiazoles. The 
dehydrogenase, E1-like protein and YcaO-domain protein are sometimes described as 
a TOMM (thiazole/oxazole-modified microcin) synthetase (200) or a BCD complex: the 
dehydrogenase (B) protein, E1-like (C) protein and YcaO-domain (D) protein were 
named based on the order of genes in the microcin B17 gene cluster, alongside the 





Figure 9: Mechanisms of YcaO-domain protein-mediated catalysis. A: oxazoline (X=O) and thiazoline (X=S) 
ring formation (197), B: thioamide bond formation (203), C: amidine ring formation via a one-step mechanism 
(204) and D: amidine ring formation via a possible two-step mechanism (205). 
 
1.2.3.3. Thioamide bonds 
Thioamidation is a rare post-translational modification of RiPPs, where the oxygen atom 
in an amide bond is replaced with sulphur. One example of thioamidation is known 
outside of natural products, in the archaeal protein methyl-coenzyme M reductase (206). 
In thioviridamide and other thioamitidies, thioamidation is catalysed by a YcaO-domain 
protein with a TfuA partner protein (124,197,207). It is thought that thioamidation occurs 
through a similar mechanism to azoline formation, via an O-phosphorylated 
hemiorthoamide intermediate (203). Subsequently, an exogenous source of sulphide 
acts as a second nucleophile, attacking the activated carbonyl to form a tetrahedral 
intermediate, followed by elimination of the phosphate (Figure 9B) (196–198). The TfuA 
partner protein might act to facilitate binding to the peptide substrate, or to help deliver 
sulphide units (208). Interestingly, some RiPPs contain thioamide moieties but lack a 
YcaO-domain protein in the biosynthetic pathway, such as for the chalkophore 
methanobactin. This suggests that alternative pathways exist for the formation of 
thioamides. The methanobactin biosynthetic gene cluster consists of a mbnABC operon, 
encoding the precursor peptide (MbnA) and a heterodimer comprising a DUF692 family 
iron enzyme (MbnB) and a protein from a previously unknown family (MbnC). It was 
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shown that the oxazolone-thioamide moiety in methanobactin was introduced through 
dioxygen-dependent four-electron oxidation of the precursor peptide via a 
metalloenzyme-mediated radical mechanism (203,209). 
 
1.2.3.4. Amidine rings 
Amidine rings are another rare post-translational modification found in two known RiPPs, 
bottromycin (147) and klebsazolicin (129). Amidines are nitrogen-containing 
heterocycles derived from the dehydration reaction between amine and carbonyl groups 
of amino acids in the core peptide. In the two known RiPP examples, amidine formation 
is also biosynthesised by a YcaO-domain protein. In bottromycin biosynthesis, one of 
two divergent standalone YcaO-domain proteins in the biosynthetic gene cluster is 
responsible for macroamidine formation, while a different YcaO-domain protein 
catalyses thiazoline formation (204). In klebsazolicin biosynthesis, a single YcaO-domain 
protein catalyses formation of the 5-membered amidine ring as well as the azole 
heterocycles (205). In bottromycin, the macroamidine is formed in a one-step mechanism 
with direct nucleophilic attack of the N-terminal amino group (204). For klebsazolicin, 
Travin et al proposed two possible mechanisms for amidine ring formation in 
klebsazolicin: a one-step bottromycin-like mechanism (Figure 9C), or a two-step 
mechanism involving YcaO-dependent attack of the serine side chain adjacent to the 
amidine-forming residue, followed by attack of the N-terminal amino group and 
subsequent rearrangement to form the amidine ring (Figure 9D) (205). 
 
1.2.3.5. Methylations 
Methylation is a common post-translational modification found in multiple RiPP classes, 
where a methyl group is transferred to a carbon, oxygen or nitrogen atom in the 
metabolite. C-methylation occurs on many RiPPs, and is catalysed by radical S-
adenosylmethionine (rSAM) enzymes (210). Two classes of rSAM enzyme have been 
implicated in RiPP biosynthesis: class B (B12-dependent) and class C. Class B rSAM 
enzymes catalyse C-methylation in bottromycin (121), thiostrepton (211), 
polytheonamide (212) and siomycin (213), while class C enzymes catalyse C-
methylation in nosiheptide (214), thiomuracin (215) and nocathiacin (214). The general 
rSAM-mediated mechanism involves production of a 5’-deoxyadenosyl (5’-dA) radical 
following cleavage of the SAM domain, which then abstracts a β-carbon hydrogen atom 
(216). Unusually, in thiostrepton A biosynthesis, the 5’-dA radical is not produced, and 
an external electron donor is not required for catalysis. Instead, a class B rSAM called 
TsrM catalyses the transfer of a methyl group from SAM to carbon-2 of tryptophan, during 
the first step of the quinaldic moiety ring expansion (211).  
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N-methylation is seen in RiPPs such as linaridins, LAPs and cyanobactins, and is 
catalysed by SAM-dependent methyltransferases. For example, cypemycin contains α-
N-methylation at the N-terminus catalysed by the SAM-dependent methyltransferase 
CypM (217). Polytheonamides contain N-methylation on asparagine residues, catalysed 
by a SAM-dependent asparagine N-methyltransferase. This enzyme is highly 
promiscuous as it selectively methylates eight asparagine residues within the metabolite 
(177). In the biosynthesis of omphalotin A, which has a characteristic N-methylated 
backbone, a fusion protein OphMA autocatalytically and regioselectively methylates its 
own C-terminus (187,188). O-methylation is also catalysed by SAM-dependent 
methyltransferases following a similar mechanism, and is seen in bottromycins, LAPs 
and cyanobactins. SAM-dependent O-methyltransferases work by increasing the 
nucleophilicity of the target oxygen by lowering the pKa, so that the electrophilic methyl 
group can then be transferred (218).  
 
1.2.3.6. Lysine-to-tryptophan cross-linking 
Lysine-to-tryptophan crosslinking is an unusual modification that is found in streptide and 
darobactin. The streptide biosynthetic gene cluster only encodes for one plausible 
modification enzyme, StrB, which is an rSAM enzyme. StrB was therefore hypothesised 
to catalyse the crosslinking between lysine and tryptophan, and this was confirmed 
through insertional mutagenesis of the S. thermophilus chromosome. StrB is thought to 
harbour only one auxiliary iron-sulphur [4Fe-4S] cluster, bound by its modified SPASM 
motif, in additional to the canonical SAM-activating cluster (174). A mechanistic model 
was proposed for streptide biosynthesis whereby reductive activation of SAM leads to 
formation of the 5′-dA radical, which abstracts a lysine β-hydrogen. The radical reacts 
with the indole side chain to create the crosslink and an indolyl radical. Deprotonation, 
rearomatisation and reduction of the auxiliary Fe-S cluster completes the synthesis of 
the crosslinked core peptide (174). The biosynthetic gene cluster for darobactin also 
encodes an rSAM enzyme, DarE, which is thought to be responsible for the lysine-to-
tryptophan crosslinking in this metabolite. However, despite containing the SAM and 
SPASM domains, DarE has little overall homology with StrB. Additionally, DarE is 
thought to catalyse the unusual ether bond in darobactin, as there is no additional 
modification enzyme encoded in the dar operon that could carry out this reaction (95). 
 
1.2.3.7. Lanthionine bonds 
Lanthionine and methyllanthionine residues are installed onto serine and threonine 
residues via a two-step biosynthetic process. First, serine and threonine are dehydrated 
to Dha and Dhb respectively. Secondly, cysteine thiols are added to the unsaturated 
residues via a Michael-type addition to form (Me)Lan (219) (Figure 10). Different types 
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of enzyme have been found to catalyse dehydration and cyclisation of lanthipeptides, 
which form the basis for categorisation of lanthipeptide subclasses. LanB and LanC 
enzymes are involved in class I lanthipeptide biosynthesis, LanM for class II, LanKC for 
class III and LanL for class IV (220). LanB proteins are dehydratases that act via 
glutamation and elimination, and LanC is a cyclase. LanM is a fused synthetase that 
contains both an N-terminal dehydratase domain and a C-terminal cyclase domain. 
LanKC and LanL are both trifunctional enzymes containing an N-terminal lyase domain, 
a central kinase domain and a C-terminal cyclase domain (221,222). LanC and the 
cyclase domains of LanM and LanL contain a conserved zinc-binding motif (Cys-Cys-
His/Cys), whereas the C-terminal domain of LanKC lacks these residues (223). In the 
recently described class V lanthipeptides, the corresponding gene clusters did not 
contain any of these typical lanthipeptide biosynthetic enzymes. Instead, dehydration 
and cyclisation are proposed to be catalysed by SprH3 and SprPT, enzymes that show 
homology to uncharacterised proteins in the thioviridamide biosynthetic pathway. As 
thioviridamide contains an AviCys moiety requiring serine dehydration, it was suggested 
that these enzymes might catalyse this modification in both cases (155). 
 
 




As RiPPs derive from standard proteinogenic amino acid building blocks, the residues 
are initially installed in L-configuration. However, many RiPP metabolites contain D-
amino acids, which are introduced via epimerisation of α-carbons within core amino 
acids. As well as giving rise to further structural complexity, this alternative 
stereochemistry is thought to contribute to structural confirmation (224), bioactivity (225), 
and resistance to proteolysis (226). Incorporation of D-amino acids into natural products 
is usually achieved through either a deprotonation-protonation (227) or a radical 
mechanism (228) (Figure 11). In lanthipeptides, several other mechanisms have also 
been observed. For example, lactocin S contains D-alanine residues that are converted 
from genetically encoded L-serine residues (229). Based on the mechanism of (Me)Lan 
formation, the conversion of L-serine to D-alanine was suggested to occur via initial 
LanM-catalysed dehydration of L-serine to Dha followed by diastereoselective 
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hydrogenation of Dha by LanJ to yield D-alanine (230). This biosynthetic mechanism 
was also observed for lacticin 3147 (231). Epipeptides and proteusins also contain D-
amino acids (216,232), which are introduced by an rSAM enzyme. Notably, 
polytheonamides contain 18 D-amino acids introduced by a single rSAM-like enzyme 
PoyD (233). rSAM-mediated catalysis follows abstraction of an α-hydrogen from carbon 
to form a stabilized amino acyl radical, followed by hydrogen donation from the opposite 
side of the residue to yield the epimer (116,216). In the recently discovered salinipeptides 
of the linaridin class, which contain nine D-amino acids, the genome of the producing 
organism does not contain the expected epimerases, suggesting that novel enzymology 
may be involved in producing these residues (164).   
 
In some cases, azoline rings are capable of spontaneous epimerisation, which has been 
observed in bottromycin and cyanobactins (116). In bottromycin, an aspartate residue 
precedes the thiazoline ring, and it was proposed that only the D-form of aspartate is an 
appropriate substrate for the P450 decarboxylase enzyme. The P450-catalysed 
oxidation of the thiazoline locks the aspartate into D-form, as spontaneous epimerisation 
cannot happen preceding an azole ring (121). This is also observed in patellamides 
(234). In bottromycin biosynthesis, it was recently shown that BotH, an α/β-hydrolase 
fold enzyme, is responsible for the post-translational epimerisation of L-Asp to D-Asp, 
thus defining a new group of unusual peptide epimerases (235). 
 
 
Figure 11: Mechanisms of epimerisation. A: epimerisation via dehydration and reduction of L-serine (R = H) 
or L-threonine (R =CH3) to D-alanine (R =H) or D-2-aminobutyrate (R =CH3) (227). B: Epimerisation via 




1.2.3.9. Removal of leader peptide 
A post-translational modification common to almost all RiPPs is cleavage of the leader 
and/or follower peptides to yield the mature RiPP metabolite. This is usually the final step 
of RiPP biosynthesis, as the leader and follower peptides are important for enzyme 
binding and core peptide stability. Leader peptide removal is usually catalysed by a 
dedicated protease from the biosynthetic pathway, but non-specific peptidases are also 
sometimes recruited. Overall, a range of different mechanisms of core peptide excision 
have been observed.  
 
For biosynthesis of some LAPs such as microcin B17 and klebsazolicin, a ‘molecular 
pencil sharpener’ mechanism is adopted for leader peptide removal, exemplified by the 
TldD/E protease (236). This protease, a zinc or iron metalloprotein, is formed from two 
proteins that assemble into a spherical heterodimer. A narrow cleft in the centre then 
allows entry of unstructured peptides such as leader peptides, which are digested by an 
internal cleavage site (129,205). In the case of bottromycin, two separate proteases 
remove the C-terminal follower peptide and a single methionine residue at the N-
terminus of the precursor peptide. The follower peptide is cleaved by an aminohydrolase, 
and the methionine is removed by a methionine aminopeptidase (121,237). For 
thiopeptides that contain pyridine rings, leader peptides are removed by elimination 
rather than hydrolysis. The [4+2] Diels-Alderase catalyses elimination of the leader 
peptide as a carboxamide, resulting in the subsequent dehydrogenation required to form 
the pyridine ring (238). 
 
In lanthipeptide biosynthesis, a LanP protease is adopted to cleave leader peptides, 
which is sometimes coupled with export of the final metabolite (230). For class I and 
class II lanthipeptides, a subtilisin-like serine peptidase is often recruited for leader 
peptide cleavage (230). In other cases, a bifunctional LanTP enzyme from the ABC 
transporter maturation and secretion family catalyses proteolysis followed by export 
(239,240). Cinnamycin is an unusual example of a class II lanthipeptide whose leader 
peptide is removed by a protease from the general secretory (Sec) system (241). In fact, 
many lanthipeptide gene clusters from streptomycetes appear to lack lanthipeptide-
specific proteases (242). Proteases for class III and IV lanthipeptides are less well 
characterised. In some cases, endogenous proteases catalyse leader peptide digestion 
(243), whereas in other cases a prolyl oligopeptidase selectively cleaves leader peptides 
from the mature metabolite (244). Recently, it was shown that a bifunctional zinc-
dependent protease is responsible for processing of class III lanthipeptides, and 
homologues of this protein were also found in class IV lanthipeptide pathways (245). For 
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class V lanthipeptides, an M16-domain peptidase is thought to excise the mature RiPP 
(155). 
1.2.3.10. Biosynthesis of cyclic plant RiPPs 
During cyclotide biosynthesis, disulphide bonds are formed by protein disulphide 
isomerases in the endoplasmic reticulum of the plant cell (246). The modified core 
peptide is then cleaved at the N- and C-terminus and cyclised by an asparagine-specific 
endopeptidase in the plant vacuole (247). Orbitides are produced in a similar way, with 
endoproteolytic cleavage of the N-terminus of the core peptide followed by C-terminal 
proteolysis and cyclisation catalysed by serine proteases (248,249). Lyciumin precursor 
peptides contain a C-terminal BURP domain (193), which is usually associated with 
abiotic stress response in plants (250). The precursors also contain multiple core 
sequences, producing several lyciumin analogues. The core peptides are cyclised 
between each tryptophan and glycine via a radical-oxidative cyclisation mechanism, and 
then cleaved at the N-terminus by an endopeptidase. Finally, the peptides are protected 






1.3. Thesis Aims 
 
1.3.1. Importance of RiPP Discovery 
RiPPs are a structurally diverse class of natural product and are of particular interest for 
their potential as chemotherapeutic agents, with many antibiotic RiPPs having recently 
been reported (95,129,154,165,171,172,251). Moving forward, it is important to identify 
metabolites with novel structural scaffolds, as antibiotic resistance mechanisms will 
evolve more easily to metabolites that are structurally similar to those currently in clinical 
use. Additionally, highly modified metabolites are much less susceptible to proteolysis in 
vivo, improving their pharmacokinetic potential. Therefore, the chemical complexity of 
RiPPs makes this class an exciting group of metabolites to explore for future drug 
candidates. The discovery of novel RiPPs also enables further study of their 
biosynthesis, helping to elucidate how and why these fascinating natural products are 
produced so widely in nature. 
 
1.3.2. Gaps in Current Understanding 
Previous analyses of bacterial genomic data have demonstrated that there is a 
considerable amount of untapped biosynthetic diversity within the RiPP landscape 
(124,251–253). It is also widely appreciated that numerous natural product biosynthetic 
gene clusters are transcriptionally silent or ‘cryptic’ under laboratory conditions, and 
many of these remain uncharacterised. Additionally, although widely studied, there are 
several aspects of RiPP biosynthesis that are still unknown. Particularly, YcaO-domain 
proteins are widely present in bacterial genomes, but the exact biosynthetic role of many 
of these enzymes remains unknown (124,197,198). 
 
1.3.3. Aims and Objectives of Thesis 
The overall aim of this thesis is to investigate the unexplored diversity of RiPPs by 
genome mining for novel RiPP biosynthetic gene clusters and characterising their 
products. This research project is based on the following objectives: 
(i) Identify novel RiPP biosynthetic gene clusters associated with YcaO-domain proteins 
(ii) Characterise a novel RiPP following genetic manipulation of a model pathway 
 
1.3.4. Thesis Outline 
Chapter 2 discusses RiPP genome mining and describes the discovery of novel gene 
clusters using a newly developed mining tool. Chapters 3 and 4 describe the genetic, 
metabolomic, structural and biological analyses carried out to characterise a novel RiPP. 
Chapter 5 will discuss the wider implications of these results on future RiPP discovery. 
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Chapter 2: Genome Mining for 





2.1.1. Genome Mining and the Genomic Era 
As discussed in Chapter 1, microorganisms and plants produce a plethora of specialised 
metabolites which have important uses in medicine, agriculture and the food industry 
(3,5). In order to discover more of these useful metabolites, one approach that has been 
increasingly utilised in natural products discovery is genome mining. Genome mining is 
a computational method for the automatic detection and annotation of biosynthetic gene 
clusters from genomic data (254).  
 
The first bacterial genome was sequenced in 1995 from Haemophilus influenzae (255), 
a Gram-negative coccobacillus and human pathogen that causes diseases such as 
pneumonia, meningitis and otitis media (256). This historic sequencing project was led 
by Craig Venter at The Institute for Genomics Research in Rockville, USA. Seven years 
later in 2002, the first Streptomyces genome was published from Streptomyces coelicolor 
A3(2) (257). This was a huge sequencing effort led by Sir David Hopwood from the John 
Innes Centre in collaboration with the Sanger Institute in Cambridge. This genome 
sequence gave the first insights into the fascinating genetics and biosynthetic potential 
of streptomycetes, and S. coelicolor A3(2) remains an important model organism for 
Streptomyces research today. This genome was shortly followed by that of Streptomyces 
avermitilis in 2003 (258), a project led by Satoshi Ōmura in Japan. S. avermitilis is an 
important industrial microorganism that produces the antimalarial avermectin 
metabolites (258). The analysis of these early streptomycete genomes indicated that 
actinomycetes contain many more gene clusters for specialised metabolites than 
previously thought (259), with both S. coelicolor and S. avermitilis genomes encoding 
~10 times the number of natural products than had been identified from culture 
fermentations. An analysis by Baltz suggested that actinomycetes encode 25-50 
biosynthetic gene clusters for secondary metabolites, a number that increases with the 
size of the organisms genome (260). 
 
In the last 25 years, sequencing technologies have become increasingly more advanced, 
accessible and cheaper. As a result, the number of prokaryotic genomes that are publicly 
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available exceeds 250,000 (Figure 12), of which over 23,000 are from Actinobacteria 




Figure 12: Cumulative number of prokaryotic genomes deposited in the NCBI database. Data collected 
between 1995 and 2019. Source: NCBI genome reports, downloaded February 2020. 
 
This wealth of sequence information paved the way for numerous bioinformatic platforms 
to aid biological research such as genome visualisation software (261–263), alignment 
tools (264,265), homology search platforms (266) and prediction tools for open reading 
frames and protein functions (267,268). Databases of known natural products have also 
been put together, such as NP atlas. This contains key structural data and information 
about the origin of many known RiPP metabolites. Several genome mining tools and 
databases of biosynthetic gene clusters have also been developed. Genome mining 
tools comprise algorithms that are based on knowledge of natural product biosynthetic 
machinery, which are used to survey genomic data and identify novel biosynthetic 
pathways. As well as identifying new metabolites from microorganisms that are known 
to be talented producers of natural products, genome mining is also a valuable tool to 
help understand the biosynthetic potential of underexplored genera. Overall, there is 
great potential for genome mining strategies to revitalise the antibiotic pipeline, at a time 





2.1.2. Genome Mining for RiPP Biosynthetic Gene Clusters 
As outlined in Chapter 1, ribosomally synthesised and post-translationally modified 
peptides (RiPPs) are a structurally complex class of natural product produced from 
diverse biosynthetic machineries (116,117). Due to the biosynthetic logic of RiPPs, 
genome mining for novel RiPP gene clusters presents several challenges. Unlike other 
classes of natural product such as polyketides and nonribosomal peptides that are 
produced by multi-modular complexes, there are very few conserved biosynthetic 
features across the RiPP class. The RiPP tailoring enzymes responsible for 
modifications vary between different RiPP subfamilies. Furthermore, the precursor 
peptides are very small, typically fewer than 100 amino acids, and are rarely annotated 
in genomes. As a result, many genome mining tools that were initially developed for 
natural product discovery were less successful at identifying RiPP gene clusters 
compared to other classes. More recently, several further genome mining tools have 
been developed that are optimised for RiPP discovery. These comprise algorithms built 
from the ever-increasing knowledge of RiPP tailoring enzymes and precursor peptide 
sequences. The use of more bespoke genome mining tools represents a powerful 
strategy to discover previously untapped biosynthetic diversity within this natural product 
class. 
 
The RiPP genome mining tools that have been developed can take a variety of different 
inputs as a starting point for analysis, including whole genomes, precursor peptide 
sequences and individual tailoring enzymes. These are then analysed to identify and 
annotate associated RiPP gene clusters. A number of tools also provide additional 
outputs such as prediction of precursor peptide sequences, leader peptide cleavage 
sites, post-translational modifications and molecular structures. As well as genomic 
analysis, some tools also analyse and integrate mass spectrometry data. RiPP genome 
mining tools that are currently available are summarised in the following sections, 
highlighting their various features. These are described in order of when they were 
released. 
 
2.1.2.1. Analysis of whole genomes to identify RiPP biosynthetic gene clusters 
2.1.2.1.i. BAGEL 
BAGEL (BActeriocin GEnome mining tool, https://bagel4.molgenrug.nl/) was the first 
genome mining tool built with specific rules for RiPP and bacteriocin identification, 
released in 2006 (269). BAGEL works by first identifying areas of interest in the genome 
based on information about the genetic context of accessory genes. Then, small open 
reading frames are searched for within these regions, and blasted against knowledge-
based peptide and motif databases (269). Since its first release, software updates have 
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provided further optimisation for RiPP identification, such as updated peptide and motif 
databases (270) and extended Hidden Markov Models (HMMs) for RiPP classes such 
as cyanobactins, sactipeptides and linaridins (271). The latest version, BAGEL4, was 
updated with improved RiPP protein domain information (272).  
 
2.1.2.1.ii. antiSMASH 
One of the most widely used genome mining tools is antiSMASH (antibiotics and 
Secondary Metabolite Analysis Shell, https://antismash.secondarymetabolites.org), 
which has processed over 750,000 jobs at the time of writing. antiSMASH has the 
capacity to identify 52 types of natural product biosynthetic gene cluster, including those 
for RiPPs. antiSMASH works by comparing encoded gene products with a library of 
profile HMMs (pHMMs), which describe a range of biosynthetic genes. Gene clusters are 
then identified by assigning key enzymes to “specialised metabolism clusters of 
orthologous groups” (273). Further analyses are then carried out to annotate accessory 
genes and predict cluster boundaries, substrate specificity and molecular structures 
(273,274). antiSMASH was first released in 2011 (273) and has since been updated 
several times (274–277), incorporating improved detection rules for RiPPs including 
thiopeptides, sactipeptides, lanthipeptides, lasso peptides, LAPs and radical SAM-
associated RiPPs. Many genome mining tools are limited to bacterial genomes, but 
iterations of the antiSMASH software have also been developed for fungal (fungiSMASH 
(276)) and plant (plantiSMASH (278)) genome mining. 
 
2.1.2.1.iii. RiPP-PRISM 
RiPP-PRISM (http://grid.adapsyn.com/prism/#!/prism) is a genome mining tool that 
identifies gene clusters of 21 RiPP families (252). It was first reported in 2013, integrating 
with the previously developed PRISM (PRediction Informatics for Secondary 
Metabolomes) software (279,280), which identifies non-ribosomal peptide and polyketide 
gene clusters. RiPP-PRISM comprises libraries of motifs, HMMs and putative tailoring 
modifications specific to RiPPs, which are used to predict precursor peptide cleavage 




released in 2016, is a tool that identifies 13 different families of RiPP gene cluster and 
helps to predict molecular structures for metabolites such as lanthipeptides, lasso 
peptides, cyanobactins and thiopeptides (281). RiPPMiner comprises predictive power 
from support vector machine and random-forest classifiers trained on over 500 
experimentally characterised RiPPs. These are used to discriminate genuine precursor 
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peptides from other small peptides, and classify these into a particular subfamily. 
RiPPMiner encompasses two different platforms for genome and peptide analysis. 
RiPPMiner-peptide analyses precursor sequences providing predictions about class, 
structure, crosslinks and cleavage sites. RiPPMiner-genome identifies gene clusters 
from a genomic sequence and predicts associated chemical structures.  
 
2.1.2.1.v. DecRiPPter 
DecRiPPter (Data-driven Exploratory Class-independent RiPP TrackER) (155) is a 
recently developed tool that combines machine learning and pan-genomic analysis to 
identify novel RiPP biosynthetic gene clusters. A Support Vector Machine identifies 
putative RiPP precursor peptides from the accessory genome of a genus to identify those 
that are encoded within operon-like pathways. Gene clusters are then prioritised based 
on the presence of novel enzymology and patterns of biosynthetic gene conservation 
across species (155). 
 
2.1.2.2. Mass spectrometry-guided mining tools for RiPPs 
Mass spectrometry (MS) has become an increasingly powerful method in natural product 
research and discovery (282). As a result, MS-based analyses have been integrated into 
several recently developed genome mining tools to improve detection of novel 
metabolites. In the context of peptidic natural products such as RiPPs, analysing 
metabolomic data can provide useful clues about amino acids present in a metabolite 
based on molecular fragmentation patterns from MS/MS data. Additionally, post-
translational modifications present in a metabolite can correspond to characteristic mass 
losses, providing further structural clues.  
 
A notable tool that aids MS-based natural product discovery is Global Natural Products 
Social (GNPS) molecular networking (https://gnps.ucsd.edu/) (100). This tool uses 
tandem MS (MS/MS) to identify families of related metabolites in spectra the user 
uploads, and compares this to a large database of MS/MS spectra. Networks of related 
metabolites are created which can be visualised to help identify connections within 
metabolomic datasets. GNPS has also opened up the potential to utilise a vast amount 
of publicly available metabolomic datasets for natural product discovery, which are 
uploaded by the community. Since its release, over 1,500 datasets have been 
contributed to GNPS (as of April 2020), corresponding to 35 terabytes of data. A search 
for common RiPP compound names in the ‘molecular explorer’ function of GNPS did not 
reveal any spectral matches to the library, suggesting that these metabolites are not 
currently commonly annotated in mass spectral networks. However, searching the 
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GNPS-MassIVE dataset repository reveals some metabolic datasets for RiPPs such as 
bottromycin and thiostrepton. 
 
2.1.2.2.i. Natural product peptidogenomics 
One of the first examples of MS-guided genome mining was reported by Kersten et al. 
in 2011, who developed Natural Product Peptidogenomics (NPP) (283). This tool aimed 
to connect chemotypes of peptide natural products with their biosynthetic genes, 
combining advances in mass spectrometry, genomics and knowledge of natural product 
biosynthesis. NPP works by carrying out an initial MALDI-TOF MS analysis, which 
searches for uncharacterised small peptide masses between 1,500-5,000 Da. Putative 
peptides are picked out based on fragmentation patterns, which are used to define 
sequence “search tags”. These are then compared to a six-frame translation of the 
genome to identify putative precursor peptides. Further analytical steps use biosynthetic 
knowledge to ensure that fragmentation-based connections to genome-derived 
structures makes sense biosynthetically.  
 
2.1.2.2.ii. RiPPquest and MetaMiner 
RiPPquest, released in 2014, is another tool that combines metabolomic and genomic 
data to discover RiPPs, with particular optimisation for lanthipeptides (284). One 
disadvantage of the NPP approach is that macrocyclic RiPPs might be overlooked by 
the sequence search tag method, and so RiPPquest was built to overcome this. 
RiPPquest works by first predicting lanthipeptide biosynthetic gene clusters and putative 
precursor peptides from a genomic input. MS/MS spectra for all potential lanthipeptide 
structures are calculated based on conceivable post-translational modifications on 
putative core peptides. Then, peptide-spectrum matches are scored in order to connect 
metabolomic and genomic data. Finally, a molecular network is generated from the 
fragmentation data, in order to identify homologues of characterised lanthipeptides and 
families of related peptides.  
 
Although a useful tool, RiPPquest was limited to the discovery of lanthipeptides from 
small datasets with predefined sets of post-translational modifications. An updated tool, 
MetaMiner, was released in 2019 (285), which expanded RiPP discovery to search for 
lanthipeptides, LAPs, lasso peptides, linaridins, glycocins, cyanobactins, proteusins, 
phenol-soluble modulins and auto-inducing peptides. MetaMiner is integrated into GNPS 
(http://gnps.ucsd.edu/ProteoSAFe/static/gnps-theoretical.jsp) as well as the Natural 
Product Discovery tools package on Github (https://github.com/ablab/npdtools). 
MetaMiner works by first analysing the paired genome/metagenome assemblies and 
fragmentation data from a given input. From this, putative biosynthetic gene clusters and 
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associated precursor peptides are identified using antiSMASH (273) and Bacteriocin 
Operon and gene block Associator (286). Target and decoy putative RiPP structure 
databases are then constructed, which are used to search for likely precursor peptides. 
Tandem mass spectra are then compared against these databases, and mass spectral 
networking is employed to expand the set of described RiPPs.  
 
2.1.2.2.iii. CycloNovo 
Recently in 2020, CycloNovo was reported, a tool for the discovery of cyclic peptides 
including cyclic RiPPs from large datasetes (287). The software is integrated into GNPS 
(https://gnps.ucsd.edu/ProteoSAFe/index.jsp?params=%7B%22workflow%22:%22CY
CLONOVO%22%7D) as well as the Natural Product Discovery tools package on Github 
(https://github.com/bbehsaz/cyclonovo). Fragmentation of cyclic peptides is more 
unpredictable than for linear peptides, as it can occur at any amide bond producing a 
complex series of ions that might not necessarily match the primary amino acid 
sequence. CycloNovo overcomes this problem by using de Bruijn graph representations 
of spectra. This involves calculation of putative k-mers (strings of k consecutive amino 
acids) for putative cyclopeptides, which are then scored against input spectra (287). 
Cyclospectra that are identified by CycloNovo can be further analysed with GNPS-hosted 




Another tool reported in 2020 is DeepRiPP (http://deepripp.magarveylab.ca/), which 
combines a range of genomic and metabolomic information to automate discovery of 
biosynthetic gene clusters and associated RiPP structures (290). DeepRiPP comprises 
three platforms that can be used individually or as a combined full workflow. The first 
platform is NLPPrecursor, a deep neural network (DNN)-based tool which identifies 
precursor peptides and predicts their RiPP class and cleavage sites. The second 
platform comprises the BARLEY (Basic Alignment of Ribosomal Encoded Products 
Locally) algorithm, which compares biosynthetic loci to known RiPP gene clusters. This 
deduces post-translational modifications within the biosynthetic gene cluster and 
compares the putative RiPP product with a database of known RiPPs. A similarity score 
is provided between the identified gene cluster and RiPP database, which thereby aims 
to prioritise RiPP novelty. The third platform, CLAMS (Computational Library for Analysis 
of Mass Spectra), employs an algorithm that compares mass spectrometry data with 
candidate RiPP gene clusters. This works by taking the exact mass of a predicted RiPP 




2.1.2.3. Bespoke approaches to RiPP genome mining 
2.1.2.3.i. RODEO 
RODEO (Rapid ORF Description and Evaluation Online, https://ripp.rodeo/index.html) is 
a tool released in 2017 that analyses RiPP gene clusters and predicts precursor peptides 
and molecular structures (253). Unlike the previously developed tools that use whole 
genomes or MS data as input, RODEO centres its analysis on a protein of interest, 
capturing the surrounding genomic environment. Within this genomic region, nearby 
biosynthetic genes are identified, piecing together a gene cluster. The RODEO algorithm 
combines pHMM and motif-based analysis, heuristic scoring and machine learning to 
identify precursor peptides and predict cleavage sites. RODEO was initially built for lasso 
peptide identification, but the software has also been subsequently optimised for 
thiopeptide and sactipeptide recognition (251,253,291). 
 
2.1.2.3.ii. NeuRiPP 
NeuRiPP (https://github.com/emzodls/neuripp), reported in 2019, is a tool that identifies 
precursor peptides and distinguishes genuine RiPP precursors from false positives 
(292). This approach might be useful if a given tool identifies multiple putative precursor 
peptide sequences. NeuRiPP comprises a DNN trained on positive and negative 
precursor peptide datasets of over 9,000 sequences. The positive dataset included 
experimentally validated sequences from tools including PRISM (279), ThioFinder (293), 
RODEO (253), RiPPER (124) and antiSMASH (277), while the negative dataset 
comprised sequences known not to be genuine RiPP precursors. Once trained, the DNN 
was used to categorise short sequences on their likelihood of being genuine RiPP 
precursor. NeuRiPP has been successful at identifying precursor peptides enriched with 
HMMs for known RiPPs, as well as precursors for RiPP classes it was not trained on, 
with over 99% accuracy. 
 
2.1.2.3.iii. RRE-Finder 
Another recently developed tool, RRE-finder (294), was built for the identification of RiPP 
recognition elements (RREs), which can then be used to help discover novel RiPP 
classes. RRE-Finder has two modes of operation: “precision” and “exploratory”. 
Precision mode utilises 35 custom pHMMs designed to detect RRE domains in a class-
dependent manner. These pHMMs are built from known RRE-containing proteins that 
have been verified to bind their cognate precursor peptide. Precision mode can be used 
to predict the presence of an RRE domain as well as the RiPP class that the cognate 
precursor peptide belongs to. Exploratory mode uses a shortened version of the HHpred 
workflow (295) with a custom database of detected RREs. This mode can be used to 
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identify a wider range of putative RRE-containing proteins to assist in the discovery of 
novel RRE-dependent RiPP classes (294). 
 
2.1.2.4. Application of recently developed genome mining tools to discover novel 
RiPPs 
The genomic and MS-based tools described above have been widely applied to microbial 
genomes, which has led to the discovery of several new natural products with important 
bioactivities and novel structural features. Furthermore, the application of these tools has 
demonstrated the vast number of RiPP biosynthetic gene clusters present in genomes 
that were previously unknown, identifying new RiPP families and highlighting that RiPPs 
occupy a much larger genetic space than previously appreciated, and are produced in a 
range of different environments. 
 
2.1.2.4.i. Expanding RiPP chemical space 
In 2013, RiPP-PRISM was applied to over 65,000 prokaryotic genomes leading to 
identification of over 30,000 previously uncharacterised RiPP gene clusters. This 
analysis suggested that, at the time, at least 82% of genetically encoded RiPPs were 
uncharacterised (252). In 2017, RODEO was used to survey the genomic space 
occupied by lasso peptides, leading to the identification of 1,400 lasso peptide gene 
clusters (253). In 2018, RODEO analysis expanded the thiopeptide class by a factor of 
four (251) and further updates to the software led to discovery of a new RiPP family 
related to sactipeptides, called the ranthipeptides (radical non-α thioether peptides) 
(291).  In 2020, DeepRiPP was used to investigate the presence of lanthipeptide gene 
clusters in over 65,000 bacterial genomes, leading to the identification of over 19,000 
novel RiPPs (290). The recently developed decRiPPter tool analysed 
1,295 Streptomyces genomes, leading to the identification of 42 putative new RiPP 
families that could not be found with existing genome mining programmes (155). 
 
In terms of MS-based discovery, MetaMiner was applied to mass spectrometry 
databases to identify seven unknown RiPPs in some unusual sources including the 
sponge microbiome, the International Space Station and the human microbiome, 
demonstrating that these tools can be applied to diverse datasets (285). CycloNovo 
identified over 400 previously unreported cyclic peptides from GNPS datasets and was 
also used to analyse a human stool dataset leading to the discovery of several bioactive 
cyclic peptides that had remained stable throughout the gastrointestinal system. This 




2.1.2.4.ii. Discovery of structurally novel RiPPs 
As well as assessing the genetic space occupied by RiPPs, many of these genome 
mining tools have also led to the isolation of novel metabolites. antiSMASH analysis 
guided the discovery of a novel class IV lanthipeptide streptocollin (296). RiPP-PRISM 
analysis led to the characterisation of aurantizolicin from Streptomyces aurantiacus, a 
cyclic azoline-containing metabolite closely related to the YM-216391 family (252) 
(Figure 13). RODEO analysis led to the discovery of novel lasso peptide from 
Nocardiopsis alba which forms a novel ‘handcuff’ topology due to co-location of two 
cysteine residues on the lasso tail. A further lasso peptide was isolated from 
Streptomyces albulus NRRL B-3066, called citrulassin A, which harbours a unique post-
translational modification where a genetically encoded arginine residue is modified to 
citrulline (253). RODEO analysis also identified a novel thiopeptide called saalfelduracin 
from Amycolatopsis saalfeldensis NRRL B-24474, which contains a structurally unique 
piperidine and a rare thioamide moiety. Saalfelduracin also exhibited strong antibacterial 
activity against VRE and MRSA (251). A novel sactipeptide called huazacin was also 
isolated following RODEO analysis, which displayed growth-suppressive activity against 
Listeria monocytogenes (291). RODEO analysis has also identified novel lanthipetpides, 
such as LP2006 (291) (Figure 13). RiPPquest analysis led to characterisation of a new 
class II lanthipeptide called informatipeptin from Streptomyces viridochromogenes (284), 
and DeepRiPP analysis led to identification of deepstreptin, a lasso peptide, and two 
lanthipeptides called deepflavo (Figure 13) and deepginsen (290). The application of 
decRiPPter to Streptomyces genomes led to the discovery of the novel class V 
lanthipeptide subfamily (155). 
 
 
Figure 13: Examples of RiPP natural products discovered by genome mining. LP2006 is a novel 
lanthipeptide discovered from a RODEO analysis (291), aurantizolicin is an azoline-containing metabolite 




2.1.3. RiPPER: a Novel Gene-led Genome Mining Tool for RiPPs 
Whilst some of the metabolites described above harbour structural novelty, many of the 
RiPPs discovered using currently available tools are limited to known RiPP classes. This 
is partly due to the fact that they are trained on sequence information and biosynthetic 
logic of known RiPPs. Therefore, the opportunity to identify truly novel RiPP metabolites 
with unique structural and biosynthetic features might be missed. RODEO is one tool 
that has been particularly successful at identifying structural and biological novelty, 
whose algorithm analyses genomic regions centred on a target protein. This suggests 
that a bespoke gene-led approach might be a promising tool for novel RiPP discovery. 
With this in mind, a new genome mining tool was developed by Andrew Truman and 
Govind Chandra at the John Innes Centre, which aimed to provide unbiased RiPP 
precursor peptide detection. This tool was called RiPPER (RiPP Precursor Peptide 
Enhanced Recognition) (124). 
 
2.1.3.1. RiPPER workflow 
RiPPER takes a known or putative RiPP tailoring enzyme as an input, and uses this to 
capture surrounding biosynthetic genes and annotate short peptides that could be novel 
precursor peptides (124). To achieve this, RiPPER uses the RODEO2 (251) script to 
capture genomic regions surrounding the ‘bait’ tailoring gene. A modified version of 
Prodigal (297) called Prodigal-short is then employed to re-annotate the captured 
biosynthetic gene cluster for short protein-coding open reading frames that could encode 
RiPP precursor peptides. The peptides with the highest Prodigal-short scores are 
retrieved and assessed for several characteristics, including conserved domains such as 
Pfam domains and RiPP-specific HMMs from NCBI. The annotated genomic regions 
captured by RiPPER can be visualised with Artemis (Figure 14) (261), where the ‘bait’ 
gene is highlighted in green, and putative precursor peptides are highlighted in red. A 
colour scale of light to dark red is used to indicate the highest scoring precursor peptides, 





Figure 14: RiPPER output of an annotated microbial genome viewed with Artemis. The bait protein that the 
analysis is centred on is highlighted in green and putative precursor peptides are highlighted in varying 
intensities of red based on their precursor peptide “score”, which is calculated based on features such as 
GC content and presence of ribosome binding sites. Existing knowledge of RiPP biosynthesis can also be 
used to help validate the gene clustering observed in the RiPPER output. 
 
For each tailoring enzyme submitted, the three highest scoring nearby precursor 
peptides are retrieved by RiPPER. The identified precursor peptides can then be 
analysed via molecular networking using EGN (Evolutionary Gene and genome 
Network) (298), which helps to identify families of related precursor peptides. RiPPER is 
therefore useful for analysis of multiple related biosynthetic gene clusters and precursor 
peptides, and was shown to identify families of lasso peptides, thiopeptides and 
microviridins without any prior knowledge of their precursor peptide sequence motifs. 
Due to the use of user-defined protein accessions as a starting point for analysis, 
RiPPER is a flexible tool that can be applied to various RiPP classes and can be used 
to identify precursor peptides that have no homology to known families of RiPP, as well 
those with known RiPP precursor domains. RiPPER also provides an accurate re-
annotation of genomic loci for small genes missed by automated genome annotations. 
 
2.1.3.2. RiPPER-led discovery of the thiovarsolins 
RiPPER was successfully used by Santos-Aberturas et al to study the unexplored 
diversity of thioamidated RiPPs, which was achieved by using an input of TfuA-like 
proteins from Actinobacteria (124). As discussed in Chapter 1, TfuA proteins are partners 
to YcaO-domain proteins, which together catalyse thioamidation in the peptide backbone 
of RiPPs such as thiopeptides (207,251) and thioamitides (150,151,208). This RiPPER 
analysis led to the retrieval of 743 precursor peptides nearby bait TfuA proteins, which 
were subsequently grouped into 74 distinct precursor networks (124) using EGN (298). 
A model biosynthetic gene cluster from one of these networks was characterised through 
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cloning and heterologous expression of the pathway from Streptomyces varsoviensis. 
Four metabolites produced by the gene cluster were identified by metabolomic analysis, 
which were isolated and characterised as the thiovarsolins A-D (Figure 15). These 
metabolites feature three interesting post-translational modifications: thioamidation, N-
acetylation and an unusual dehydrogenation. These metabolites thus describe a new 
structural class of thioamidated RiPP (124).  
 
The RiPPER-led discovery of the thiovarsolins, as well as several other networks of 
unknown RiPP precursor peptides, shows that this genome mining approach is 
successful at identifying previously uncharacterised RiPP gene clusters using a bait 




Figure 15: Chemical structures of thiovarsolins A-D, novel RiPPs identified though genome mining using 
RiPPER. Post-translational modifications are highlighted on each structure: thioamide bonds (green), 
dehydrogenation (red), N-acetylation (blue). Thiovarsolins A and B also contain an additional methyl group 
(highlighted in orange) compared with thiovarsolins C and D, due to the presence of alanine instead of 








2.2. Chapter Aims 
 
RiPPs are a largely underexplored class of natural product, partly due to the challenges 
encountered when genome mining for RiPP pathways. The aim of this chapter is to 
examine the presence of YcaO-domain proteins in microbial genomes and use these to 
guide the discovery of novel RiPP biosynthetic gene clusters. To achieve this, the 
specific objectives of this chapter were: 
 
(i) Carry out a comparative analysis of genome mining tool outputs 
(ii) Use RiPPER to retrieve precursor peptides associated with YcaO-domain proteins 
(iii) Carry out bioinformatic analyses of identified precursor peptides and associated 




2.3. Results and Discussion 
 
2.3.1. Comparative Analysis of Genome Mining Outputs from the Genome 
of Streptomyces albus J1074 
In order to compare the outputs of different genome mining tools, I used the genome 
sequence of Streptomyces albus J1074 as input for tools that analyse whole genomes 
(antiSMASH5, BAGEL4, DeepRiPP, PRISM4 and RiPPMiner). I chose this organism as 
it is a widely used model streptomycete and its biosynthetic capacity is well-studied 
(299,300), therefore it would be interesting to see the differences in gene cluster 
identification by the different tools.  
 
Considering the outputs of all five tools (Appendix Figure 78Figure 82), five distinct 
RiPP biosynthetic gene clusters were identified in total (Figure 16). Surprisingly, only 
two of these five clusters were identified by all five tools: BGC2 and BGC5, which are 
both lanthipeptide gene clusters. This suggests that these genome mining tools harbour 
good predictive power for lanthipeptide RiPPs, although interestingly the tools varied in 
their description of the precise lanthipeptide class. For BGC2, all five tools provided a 
predicted precursor peptide sequence, but these peptides also varied across the outputs. 
antiSMASH, DeepRiPP and PRISM identified the same precursor peptide sequence, but 
only antiSMASH and PRISM highlighted the predicted core peptide. antiSMASH also 
highlighted residues that are dehydrated to Dha or Dhb. BAGEL identified a similar 
precursor peptide but with an earlier alternative start codon, but also highlighted the 
same core peptide as PRISM. RiPPMiner provided a much longer precursor peptide with 
a short core peptide, which is likely to be incorrect. For BGC5, only DeepRiPP, PRISM 
and RiPPMiner provided precursor peptide sequences for the lanthipeptide, but these 
sequences were all different. This highlights the variability of precursor peptide prediction 
across different tools, even when a similar biosynthetic gene cluster is identified. BGC1 
is a LAP/thiopeptide cluster identified by all tools except BAGEL. The same precursor 
peptide sequence was provided by DeepRiPP, PRISM and RiPPMiner, but DeepRiPP 
predicted a shorter core peptide compared to the other two tools. BGC3 is for a 
hypothetical linaridin, which was only identified by RiPPMiner. Similarly, BAGEL was the 
only tool to identify BGC4, a linocin M18-like bacteriocin cluster. This demonstrates that 
utilising different tools with the same genome can be a useful way to identify otherwise 
unidentifiable gene clusters. As well as the RiPP gene clusters, antiSMASH identified 19 
other natural product biosynthetic gene clusters and PRISM identified 12 other natural 





BGC Tool Description Predicted precursor peptide 
1 antiSMASH LAP/Thiopeptide   
 





















DeepRiPP Lanthipeptide class III/IV MALLDLQAMDTPQEEAVGDLATGSQISLLICEYSSLSVTLCTP 
 
PRISM Lanthipeptide class III/IV MALLDLQAMDTPQEEAVGDLATGSQISLLICEYSSLSVTLCTP 
 





3 antiSMASH Not identified   
 
BAGEL Not identified   
 
DeepRiPP Not identified   
 





4 antiSMASH Not identified   
 
BAGEL Linocin M18-like   
 
DeepRiPP Not identified   
 
PRISM Not identified   
 
RiPPMiner Not identified   
5 antiSMASH Lanthipeptide   
 
BAGEL Lanthipeptide class IV   
 













Figure 16: Genome mining outputs from analysis of the Streptomyces albus J1074 genome. Predicted core 




2.3.2. Using RiPPER to Identify Novel RiPP Gene Clusters Associated with 
YcaO-domain Proteins 
As discussed previously, it is known that RiPP gene clusters can be difficult to detect by 
genome mining, and the comparative analysis of tools described above highlights that 
not every available tool identifies every RiPP gene cluster. Following the success of the 
TfuA-led genome mining with RiPPER, we were interested to assess further unexplored 
diversity of RiPP gene clusters associated with YcaO-domain proteins. Although YcaO-
domain proteins have several characterised catalytic roles including azoline formation, 
thioamide formation and amidine formation (116,204,205), the genetic and chemical 
context of many of these enzymes still remains uncharacterised, representing a large 
untapped source of potentially novel biochemical diversity. In order to investigate this, 
we decided to use Actinobacterial YcaO-domain proteins as ‘bait’ sequences for a 
RiPPER analysis. 
 
2.3.2.1. Analysis of Actinobacterial YcaO-domain proteins 
Using CDART (Conserved Domain Architecture Retrieval Tool) (301) on NCBI Genbank, 
I identified over 9,000 standalone proteins (i.e. those not fused to an additional domain) 
containing YcaO-domains. These were present predominantly in bacteria and archaea, 
with some also identified in fungi, plants and animals. For the focus of this study, I filtered 
these proteins down to those present in Actinobacteria, of which there were 2,574 
sequences. Proteins fewer than 350 amino acids in length were excluded so that the 
results were not skewed by incomplete or truncated sequences. The remaining 2,338 
sequences were then analysed with EFI-EST (Enzyme Similarity Tool) (302), applying a 
95% maximum identify cut off to account for sequence duplications. The resulting 
sequence similarity network (SNN) obtained from EFI-EST contained 1,514 proteins, 






Figure 17: EFI-EST analysis of Actinobacterial YcaO-domain proteins. Image shows sequence similarity 
network (SSN) of 1,514 Actinobacterial YcaO-domain proteins retrieved from CDART. Blue nodes represent 
five or fewer protein IDs, green nodes represent 6-10 protein IDs, orange nodes represent 11-18 protein 






2.3.2.2. Retrieval and analysis of precursor peptides associated with YcaO-domain 
proteins 
In order to identify some of the biosynthetic gene clusters associated with the 
uncharacterised Actinobacterial YcaO proteins, I first wanted to identify the associated 
precursor peptides. To achieve this, a RiPPER (124) analysis was carried out by Andrew 
Truman and Govind Chandra using the previously obtained 1,514 protein sequences as 
the input (methods described in section 6.3.2.1.). In total, 2,492 putative precursor 
peptides were retrieved, corresponding to short peptides within 6 kb of each YcaO-
domain protein analysed. These peptides were subjected to an EGN (298) analysis 
carried out by Andrew Truman, with the resulting peptide networks shown in Figure 18. 
A 40% identity cut-off was used for creation of networks, as this resulted in clustering of 
known RiPP subfamilies. I annotated these networks based on the NCBI HMM domains 
associated with each precursor peptide. This showed that the precursor peptides within 
network 8 display homology to thiocillins, as do the majority of precursors within network 
2. Precursor networks 11 and 13 show homology to thiazolylpeptides and network 12 
shows homology to bottromycins. A subfamily of network 6 shows homology to 
thioamitides. Interestingly however, many of the precursor peptide networks did not show 
homology to known RiPP families, indicating that the RiPPER analysis had uncovered 
several previously unknown RiPP subfamilies. Several studies have highlighted 
expansion of the known biosynthetic landscape of RiPPs (252,253,303,304), but these 
data obtained from RiPPER contribute even further RiPP biosynthetic diversity that has 
not been previously reported. After submitting representative precursor sequences from 
networks 3, 4, 5, 7, 9 and 10 to RiPPMiner (281) and DeepRiPP NLPPrecursor (290), 
the majority of these precursors were predicted as “non-RiPP”. Despite this, the genetic 
context of these precursor peptides suggest that they are associated with genuine RiPP 
biosynthetic pathways, with the co-occurrence of putative RiPP tailoring genes within an 
operon. Therefore, it is likely that the prediction tools are not optimised for identification 







Figure 18: Precursor peptide networks identified from RiPPER analysis of Actinobacterial YcaO-domain 
proteins. Sequences were analysed by EGN using a minimum sequence identity cut-off of 40% and 
visualised on Cytoscape. This percentage identity cut-off was chosen as it resulted in network clustering of 
known RiPP precursor families. Peptides associated with known RiPP families are highlighted: green= 
bottromycin family (NCBI HMM domain NF033414), brown= thiopeptide family (NF033400 and NF033399), 
red= thioamitide family (NF033415), purple= thiocillin-like family (NF033482 and NF033401), dark blue= 





2.3.2.3. Phylogenetic analysis of associated YcaO-domain proteins 
The 1,514 YcaO-domain protein sequences associated with the identified precursor 
peptides were aligned using MUSCLE (264) followed by construction of a phylogenetic 
tree using RAxML on the CIPRES Science Gateway (305) (methods described in section 
6.3.1.2.). The tree was then annotated based on the presence of known NCBI HMM 
domains in the precursor peptides identified by RiPPER. This annotation shows that 
YcaO proteins involved in biosynthesis of certain RiPP families are clustered within 
subclades of the phylogenetic tree (Figure 19). This includes YcaO proteins involved in 
the biosynthesis of bottromycins (two separate clades for BtmE-like and BtmF-like 
proteins), thioamitides, thiocillin-like metabolites and thiopeptides. Notably however, the 
biosynthetic potential of the majority of these YcaO proteins is unknown, based on the 
absence of known HMM domains. These enzymes might therefore carry out potentially 
rare or novel biochemical transformations.  
 
 
Figure 19: Phylogenetic tree of standalone YcaO-domain proteins from Actinobacteria. Proteins with 
homology to known RiPP biosynthetic classes are highlighted: green= bottromycin family (NCBI HMM 
domain NF033414), brown= thiopeptide family (NF033400 and NF033399), red= thioamitide family 
(NF033415) and purple= thiocillin-like family (NF033482 and NF033401). 
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2.3.3. Bioinformatic Analysis of a Novel RiPP Precursor Peptide Family 
The largest precursor peptide network identified by RiPPER (network 1) is the focus of 
this thesis. This network represents 260 precursor peptide sequences associated with 
Actinobacterial YcaO-domain proteins. Like many of the other peptides identified with 
RiPPER, these sequences do not show homology to known RiPP classes, and 
DeepRiPP and RiPPMiner predicted the majority of sequences to be non-RiPP. The fact 
that these peptides are the most abundant precursors associated with standalone 
Actinobacterial YcaO proteins, and yet do not appear to belong to known RiPP families 
makes these an intriguing group of RiPPs to study. The precursor sequences within this 
network are therefore studied in further detail in the following sections. 
 
2.3.3.1. Sequence alignment and motif identification 
Out of the 260 precursor peptides in network 1, 29 sequences were duplications due to 
the presence of more than one YcaO protein in the associated gene clusters. These 
sequences were therefore removed prior to further analysis. The remaining 231 
precursor sequences varied greatly in length, between 31 and 89 amino acid residues, 
indicating diversity within this network of peptides. The sequences were aligned using 
MUSCLE (264) (Appendix Figure 83), which highlighted that an ‘ALV’ (alanine-leucine-
valine) motif was conserved across 216/231 sequences. This suggested that these 
peptides are related and are likely to be genuine precursors from a large novel RiPP 
family. Intrestingly, some of these peptides contained two or three repetitions of the ALV 
motif, which could suggest that multiple metabolites might be produced by a single 
precursor peptide. This was observed with the thiovarsolins, whose precursor peptides 
contained repetitive ‘APR’ motifs (124). To investigate precursor motifs further, all 231 
sequences were subjected to a MEME analysis (306), searching for up to five motifs 
within the sequences (Appendix Figure 84). This analysis also showed that ALV-
containing motifs were present in the majority of sequences (Figure 20).  
 
 
Figure 20: MEME analysis of peptide sequences from novel RiPP precursor network 1, identified following 
RiPPER analysis of Actinobacterial YcaO-domain proteins. Figure shows the top motif identified from the 




Interestingly, manual analysis of the peptide sequences indicated that most of the 
peptides contained either a ‘QGPQT’-like motif (motif A) or a ‘HxSAxH’-like motif (motif 
B) adjacent to the conserved ALV. The distribution of these two motifs corresponds to 
the two peptide sub-networks within network 1 (Figure 21). I separately submitted the 
sequences within each of these sub-networks for a MEME analysis, and the top resulting 
motif in each case highlights this observation (Figure 21). These two groups of peptides 
might therefore produce related yet structurally distinct final metabolites. The other 
loosely connected nodes did not appear to have a similar conserved motif. These 




Figure 21: Comparison of precursor network 1 with corresponding sequence motifs. Precursor peptide sub-
networks correspond to the presence of one of two conserved sequence motifs identified from MEME 
analysis of peptide sequences within each sub-network. 
 
2.3.3.2. Distribution of identified precursor peptides in nature 
Although all of the identified precursor peptides from network 1 were retrieved from 
Actinobacteria, a further BLAST analysis of the YcaO-domain proteins associated with 
these precursors revealed that six further related peptides are encoded in Firmicutes 
genomes: three from Bacillus and three from Paenibacillus species. These sequences 
were therefore included in all further analyses, bringing the total number of precursor 
peptides to 237. Overall, these precursor peptides and associated biosynthetic gene 
clusters are widespread in nature, present in two bacterial phyla, eight orders, 22 families 
and 57 different genera. The majority of the precursor peptides (86/237) were present in 
Streptomycetaceae genomes: 84 from Streptomyces species and two from 
Kitasatospora species. The second most abundant family were Microbacteriaceae 
(40/237 sequences), including the Clavibacter and Microbacterium genera. Other 
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bacterial families containing these precursor peptides included Pseudonocardiaceae 
(22/237 sequences), Nocardiaceae (20/237 sequences), Nocardiopsaceae (13/237 
sequences) and Frankiaceae (12/237 sequences). Other bacterial families containing 
fewer than ten representative precursor peptides include Actinomycetaceae, 
Micrococcaceae, Bacillaceae, Dermatophilaceae, Streptosporangineae, 
Actinosynnemataceae, Nocardioidaceae, Cryptosporangiaceae, 
Promicromonosporaceae, Dermabacteraceae, Jiangellaceae, Glycomycetaceae, 
Geodermatophilaceae, Nakamurellaceae, Propionibacteriaceae and 
Thermomonosporaceae. The fact that these novel gene clusters are conserved across 
so many bacterial families suggests that the RiPPs being produced are playing an 
important biological function for the producing organisms. Interestingly, the species 
harbouring these gene clusters also occupy a range of ecological niches. This includes 
soil-dwelling streptomycetes and symbiotic nitrogen-fixing Frankia species that live in 
nodules of actinorhizal plants (307). 
 
In order to analyse the phylogenetic relationship of these precursor peptides in more 
detail, a further EGN analysis was carried out using a lower sequence identify cut-off of 
80%. The 19 resulting networks of peptide subfamilies are shown in Figure 22. Each of 
the nodes are colour-coded based on the bacterial family that the precursor peptide 
derives from in order to give a visual representation of the evolution and phylogenetic 
relationship of each peptide. The peptides containing either motif A or motif B are also 
indicated. This analysis shows that the majority of precursor peptides cluster into 
networks relating to the bacterial family they belong to, suggesting that these sequences 
might have co-evolved. However, there are also some examples of networks containg 
precursor peptides from a variety of different bacterial families, such as sub-family 2. 
This analysis also highlights that not all precursors within a given bacterial family have 
similar sequences. For example, sub-familes one and five are distinct from each other 
whilst both representing Streptomycetaceae species. Similarly, peptides from 
Microbacteriaceae are present in sub-familes two, four, nine, 11 and 13. This could be 





Figure 22: EGN networking analysis of precursor peptides within network 1 (shown in Figure 18). Networks 
analysed using a lower sequence identify cut-off of 80%. Nodes are colour-coded by bacterial family and the 






2.3.3.3. Relationship between newly identified precursor peptides and their 
corresponding YcaO-domain proteins 
Following the evolutionary analysis of the precursor peptides identified by RiPPER, I was 
interested to see how this related to the YcaO-domain proteins that are present in the 
associated biosynthetic gene clusters of each of the precurors present in network 1. The 
sequences of all of the YcaO-domain proteins associated with the identified precursor 
peptides were therefore aligned using MUSCLE (264) and a phylogenetic tree was 
created using RAxML on the CIPRES Science Gateway (305) (methods described in 
section 6.3.1.2.). Each leaf is colour-coded by bacterial family, showing that the YcaO-
domain proteins cluster in a similar way as the corresponding precursor peptide sub-
networks (Figure 23). 
 
 
Figure 23: Phylogenetic tree of YcaO-domain proteins associated with precursor network 1. Precursor 
peptide networks from Figure 22 are mapped onto the tree highlighting the relationship between YcaO 
phylogeny and precursor peptide evolution. Nodes are colour-coded by bacterial family (as in Figure 22). 
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2.3.4. Comparison of Gene Cluster Architectures 
2.3.4.1. MultiGeneBlast analysis 
In order to put the identified precursor peptides and corresponding YcaO proteins in the 
context of full biosynthetic gene clusters, a MultiGeneBlast (308) analysis was carried 
out by Andrew Truman. For the input, all genes that were likely to form the novel RiPP 
biosynthetic gene cluster from S. albus J1074 were used. This included a hypothetical 
protein homologous to an oxidoreductase, four iron transporter genes with homology to 
the FecBCDE system, the putative precursor peptide, a conserved hypothetical protein 
homologous to an E1-ubiquitin activating enzyme, a hydrolase, the YcaO-domain 
protein, a flavin-dependent dehydrogenase, and two ABC transporters. The first ~90 
gene clusters retrieved by MultiGeneBlast show close homology to the S. albus J1074 








Figure 24: Example BGCs homologous to that of S. albus J1074. Obtained from MultiGeneBlast analysis 
using the S. albus J1074 pathway as input. Precursor peptides are indicated by pink stars, other biosynthetic 





The majority of precursor peptides retrieved by RiPPER were not annotated in the 
MultiGeneBlast output. Interestingly, a further analysis by Govind Chandra revealed that 
only 78 of the identified precursor peptides (33%) were originally annotated in genomes, 
demonstrating that this novel genome mining approach can successfully detect and 
annotate previously unknown RiPP precursor peptides. Beyond the biosynthetic gene 
clusters showing close homology to the S. albus J1074 pathway, numerous additional 
gene clusters display further biosynthetic diversity (Figure 25). For example, several 
gene clusters contain two YcaO-domain proteins, indicating that the resulting 
metabolites might contain different or additional post-translational modifications. Many 









Figure 25: Example biosynthetic gene clusters that are related to that of S. albus J1074. Obtained from 
MultiGeneBlast analysis using the S. albus J1074 pathway as input. Pathways contain the conserved YcaO-
domain protein but show genetic diversity in comparison to the input gene cluster.  
 
2.3.4.2. Pathway regulation 
In the model S. albus J1074 gene cluster, a MarR regulator is encoded next to the 
proposed minimal biosynthetic gene cluster, which could plausibly be involved in 
regulation of this RiPP. However, despite the fact that the core biosynthetic genes are 
conserved across approximately 90 pathways, this MarR gene is only conserved in one 
other gene cluster, from Streptomyces sp. FR-008, according to the MultiGeneBlast 
output. Some other pathways contain regulatory genes within the vicinity of the core gene 
cluster, but these vary in position and nature. For example, some of these regulators are 
annotated as CynR-like, DeoR-like, TetR-like or LuxR-like. This suggests that the 
regulation of these gene clusters might greatly vary, despite the conserved nature of 




2.3.4.3. Comparison of gene cluster architecture with the associated YcaO and 
precursor phylogeny 
Based on the observation of gene cluster diversity, I was interested to assess whether 
this corresponded to the different precursor peptide sub-networks. I manually compared 
precursor peptides containing motif A or B to their corresponding gene cluster, and then 
compared this to the location of corresponding YcaO-domain proteins on the 
Actinobacterial YcaO phylogenetic tree. These comparisons are show in Figure 26. 
 
 
Figure 26: Comparison of YcaO phylogeny, gene clusters and precursor sub-networks. Actinobacterial 
YcaO phylogenetic tree (as in Figure 19, with branch lengths not shown) with examples of corresponding 
biosynthetic gene clusters and their relationship to precursor peptide sub-networks (from Figure 21). 
 
From this analysis, it is clear that there is a direct link between the precursor peptide 
sequence, genetic architecture and location of the corresponding YcaO protein on the 
phylogenetic tree. Precursor peptides containing sequence motif B are present in gene 
clusters similar to that of S. albus J1074, containing one YcaO-domain protein. Precursor 
peptides containing sequence motif A are present in a second distinct group of 
biosynthetic genes clusters, which typically contain two YcaO-domain proteins. The 
YcaO-domain proteins associated with these two groups of gene cluster also tightly map 
to two distinct subclades on the YcaO phylogenetic tree. Taking these results together, 
it is likely that in the majority of cases the newly identified precursor peptides and YcaO-
domain proteins co-evolved together within their biosynthetic gene clusters. Overall, 
these data represent a large amount of biochemical diversity among a widespread novel 





2.4. Chapter Summary 
 
This chapter describes a range of different genome mining tools for RiPPs and 
demonstrated how these can be applied to the discovery of novel RiPP precursor 
peptides and associated biosynthetic gene clusters. The key finding from this chapter 
was the discovery of novel families of RiPP precursor peptides associated with 
standalone YcaO-domain proteins from Actinobacteria, using the recently developed 
RiPPER tool. The majority of these precursor peptides were previously uncharacterised, 
with no homology to known RiPP classes. The largest precursor peptide network 
retrieved by RiPPER was analysed in closer detail through motif analysis and 
biosynthetic gene cluster comparison. The widespread nature of these novel RiPP 
pathways as well as their sequence and genetic diversity make these gene clusters an 
intriguing point of focus for this thesis. A comparative analysis of genome mining tools 
was also carried out using the whole genome of Streptomyces albus J1074, a model 
streptomycete that contains one of the newly identified RiPP biosynthetic gene clusters. 
This demonstrated that different genome mining tools vary in their ability to identify 
particular RiPP gene clusters and precursor peptides. Furthermore, none of the tools 
identified the novel RiPP gene cluster discovered from our RiPPER analysis. Overall, 
these analyses highlight that many currently available genome mining tools have 
overlooked untapped RiPP diversity, and the use of more targeted gene-led tools such 
as RiPPER is a valuable approach for identifying true RiPP novelty. 
 
The following chapter will focus on the characterisation of one of the novel RiPP 
biosynthetic gene clusters identified.
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Chapter 3: Cloning and Expression 
of a Novel RiPP Gene Cluster from 





Following the genome mining experiments described in Chapter 2, this chapter will focus 
on the characterisation of one of the novel RiPP gene clusters identified with RiPPER, 
using a combination of cloning, genetic experiments and metabolomic screening.  
 
3.1.1. Genetic Manipulation of Natural Product Biosynthetic Gene Clusters 
The genetic study and manipulation of microorganisms has historically been hindered by 
the variable ability of microbes to uptake foreign plasmids, but recent advances in genetic 
engineering have made the direct study of microbial gene clusters increasingly more 
achievable. The development of a range of genome editing tools has allowed for 
manipulation of biosynthetic gene clusters in situ, and molecular techniques based on 
homologous recombination and nuclease activity have allowed for efficient deletion and 
disruption of biosynthetic genes. Several recombination-based techniques have been 
developed based on the lambda (λ) Red system in E. coli (309–311),  which are often 
referred to as recombineering (recombination-mediated genetic engineering) 
approaches. This includes techniques such as PCR-targeting that was first developed 
for the deletion of genes from the E. coli K-12 chromosome (312) and later adapted for 
Streptomyces species with development of the ReDirect method (309). Early nuclease-
based editing included the use of meganucleases such as 18 bp cutter I-SceI (313) to 
introduce double strand breaks at target DNA sites. Later approaches explored the use 
of zinc finger nucleases (314) and transcription activator-like effector nucleases 
(TALENs) (315). More recently, advances in CRISPR (Clustered Regularly Interspaced 
Short Palindromic Repeat DNA sequences) technology have revolutionised genome 
editing in both eukaryotes and prokaryotes. CRISPR-associated (Cas) endonuclease 
genes such as Cas9 can be programmed to target specific DNA sequences in bacteria 
using custom made guide RNAs (319,320). CRISPR has also been optimised for use in 
Streptomyces species with the construction of the pCRISPomyces plasmids in 2015 
(317). Many molecular microbiology approaches also rely on phage integrases for the 
expression of genes. These enzymes mediate site-specific recombination between two 
DNA recognition sequences, and include the tyrosine integrases such as the E. coli λ 
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phage (318), and the serine integrases such as the φC31 phage from Streptomyces 
lividans (319) and the φBT1 phage from S. coelicolor (320). 
 
3.1.2. Cloning Natural Product Biosynthetic Gene Clusters 
Whilst genetic engineering approaches allow the study of biosynthetic gene clusters in 
their native context, another common approach in natural products research is to clone 
a whole biosynthetic gene cluster for heterologous expression. This can be useful if the 
native producer of a gene cluster is difficult to directly genetically manipulate. Whilst PCR 
amplification of large DNA fragments is becoming increasingly more accurate, it can be 
difficult to clone large biosynthetic gene clusters, and many pathways for nonribosomal 
peptides and polyketides contain highly repetitive DNA regions that are challenging for 
PCR amplification (321). Recently, a direct pathway cloning (DiPaC) approach was 
described (322), which relies on long-range PCR and in vitro DNA assembly. Another 
cloning method is transformation-associated recombination (TAR) cloning, which takes 
advantage of the high levels of homologous recombination that occurs between the ends 
of DNA sequences in yeast cells during transformation (323). TAR cloning was first 
developed for the cloning of mammalian DNA (324,325), and later adapted for use in 
prokaryotes by integrating an autonomously replicating sequence (ARS) element into the 
TAR vector to allow it to act as an artificial chromosome (326). Another method for cluster 
cloning is Cas9-assisted targeting of chromosome segments (CATCH), which relies on 
an RNA-guided Cas9 nuclease which is directed to cut at two designated loci in the target 
genome (327). 
 
3.1.3. Streptomyces albus J1074 as a Model Organism 
The genome mining analyses described in Chapter 2 identified over 230 novel RiPP 
biosynthetic gene clusters present in a wide range of Actinobacteria and Firmicutes. As 
an exemplar pathway for this study, I chose to investigate the gene cluster from 
Streptomyces albus J1074 (formally reclassified as Streptomyces albidoflavus J1074 
(328)). The genetic architecture of the cluster from S. albus J1074 represents one of the 
most common pathways of those identified, with over 90 gene clusters with identical 
architectures identified by MultiGeneBlast (Chapter 2, Figure 24). Another reason S. 
albus J1074 was chosen for study is that it is a widely used model streptomycete that is 
known to be genetically tractable, and has a relatively fast growth rate for Streptomyces 
bacteria (329). The favourable growth traits of S. albus J1074 are partly due to its 
naturally minimised genome, owing to a low number of gene and operon duplicates 
(299). S. albus J1074 has one of the smallest known genomes for streptomycetes at 
6,841,649 bp, which codes for 5,832 genes. The chromosome contains a large central 
core region and two small arms that are 0.3 Mb (left) and 0.4 Mb (right) in length (299).   
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3.2. Chapter Aims 
 
The RiPP biosynthetic gene clusters identified from genome mining with RiPPER 
(Chapter 2) are hypothesised to represent novel RiPP families. The overall aim of this 
chapter was to investigate the metabolite(s) produced by an exemplar biosynthetic gene 
cluster from S. albus J1074, which represents one of a large novel RiPP family. To 
achieve this, the specific objectives of this chapter were: 
 
(i) TAR clone the model biosynthetic gene cluster from S. albus J1074 
(ii) Express the cloned gene cluster in a heterologous host for metabolomic analyses 
(iii) Construct a pathway mutant in S. albus J1074 to investigate metabolomic profiles of 
the native host 






3.3. Results and Discussion 
 
3.3.1. Overview of the Streptomyces albus J1074 Biosynthetic Gene Cluster 
The putative biosynthetic genes within the S. albus J1074 biosynthetic gene cluster (ami) 
were analysed using BLAST (266), CDART (301) and Phyre2 (267) to determine their 
likely enzymatic functions. A minimal biosynthetic gene cluster was also proposed, based 
on the genes that were conserved across several pathway homologues (indicated from 
the MultiGeneBlast analysis shown in section 2.3.4.1.) (Figure 27). This proposed 
minimal cluster comprises a putative oxidoreductase, a four-component iron transporter 
system, a precursor peptide, an E1-ubiquitin-like enzyme, a hydrolase, the YcaO-domain 
protein, a flavin-dependent dehydrogenase and two ABC transporters. Details of these 
genes are summarised in Table 1. The tight clustering of genes encoding the putative 
precursor peptide, E1-like protein, YcaO-domain protein and dehydrogenase is typical 
of gene clusters for linear azoline-containing peptides (LAPs) such as microcin B17 (330) 
and klebsazolicin (205). The hydrolase enzyme encoded in between the E1 and YcaO 
proteins could theoretically act as a peptidase that cleaves the modified core peptide 
from the leader and/or follower regions. The two transport systems could represent a 
coordinated import and export mechanism for the associated natural product, or for 
elements required for biosynthesis of the RiPP metabolite. The iron transport system 
could also indicate an important role for iron or other metals during biosynthesis of the 
associated RiPP, or could suggest a potential siderophore-like function of the metabolite. 
The gene encoding the oxidoreductase was indicated from MultiGeneBlast analysis to 
be conserved across gene clusters similar to the S. albus J1074 pathway (section 
2.3.4.1. MultiGeneBlast analysis.), therefore this enzyme could play an important 
biosynthetic role. However, oxidoreductases are not typically seen in LAP gene clusters. 
Finally, the MarR regulator could be involved in regulation of the pathway, but this 
regulator was not conserved across similar biosynthetic gene clusters, suggesting that it 
may not be essential. 
 
In S. albus J1074, this novel RiPP gene cluster is located in the small right-hand arm of 
the chromosome. According to the genome mining outputs from the S. albus J1074 
genome (described in section 2.3.1.) the gene cluster is flanked tightly by two other 
metabolic pathways: a class IV lanthipeptide and a linocin M18-like bacteriocin. This is 
typical of secondary metabolite biosynthetic pathways that are often clustered together 





Figure 27: Putative RiPP biosynthetic gene cluster (ami) from S. albus J1074. Key genes proposed to be 
involved in biosynthesis of the final pathway-related metabolite are indicated. 
 



















Oxidoreductase 417 43.35 




amiF2 WP_085479277.1 PF01032 Iron transporter (permease) 344 34.78 
amiF3 WP_085479276.1 PF01032 Iron transporter (permease) 351 34.6 











E1-like protein 281 29.05 
amiC WP_129865485.1 PF02129 Hydrolase 508 54.26 




Dehydrogenase 435 44.98 
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3.3.2. TAR Cloning of the S. albus Biosynthetic Gene Cluster 
The first aim of this chapter was to clone the model biosynthetic gene cluster from S. 
albus J1074. Although several methods for gene cluster cloning have been developed, 
such as PCR-based direct pathway cloning (DiPaC) (322) and Cas9-assisted targeting 
of chromosome segments (CATCH) (327), I chose TAR cloning as a method as it has 
previously been successfully used to capture large biosynthetic gene clusters from 
Actinobacteria, including by members of our lab group (124,151,331). The pCAP03 
vector (332) was used as the backbone for capture of the gene cluster. pCAP03 is a 
shuttle vector containing elements that allow propagation and transfer in yeast cells, E. 
coli and Streptomyces species. These include a tryptophan auxotrophic marker (TRP1), 
an ARSH4/CEN6 region and the yeast URA3 gene encoding orotidine 5-phosphate 
decarboxylase (ODCase). This enzyme allows counter-selection using 5-FOA, which 
minimises false positive colonies that result from high levels of vector re-circularisation 
due to non-homologous end joining (326). The vector also contains a pUC ori for 
replication in E. coli and a kanamycin resistance gene (aph(3)II) for selection in E. coli 
and Streptomyces species. For conjugal transfer and chromosome integration in 
Streptomyces species, the vector contains an origin of transfer (oriT) and a φC31 
integrase and integration site. 
 
3.3.2.1. TAR cloning design 
As well as the set of biosynthetic genes proposed to comprise the target RiPP 
biosynthetic gene cluster, I designed my TAR cloning in such a way that some additional 
genes on either side of this cluster were also captured, including an oxygenase, peptide 
methionine reductase and two acetyltransferase genes (Figure 27). This was to ensure 
that all pathway elements required for biosynthesis of the target metabolite were 
incorporated into the expression vector. Restriction enzyme cut sites were identified (NsiI 
and SmlI) that would enable excision of this target genomic region (18.5 kbp) following 
digestion of S. albus J1074 genomic (g)DNA with these two enzymes. Regions of 
homology immediately adjacent to the cut sites were then used for design of the gene 
cluster capture vector to promote successful recombination, as DNA ends are highly 
recombinogenic in yeast (333).  
 
3.3.2.2. Construction of pCAP03-derived capture vector (pSalbCAP) 
The oligonucleotides designed as 50 bp capture arms for the target genomic region were 
cloned into pCAP03 (332) via Gibson assembly (334) (method described in section 
6.4.1.1.). Two colonies were obtained on selective agar, from which plasmid DNA was 
isolated and screened by PCR for presence of the expected insert. In each case, a band 
of the expected size (364 bp) was observed (Figure 28), indicating that the capture arms 
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had been successfully incorporated into pCAP03 to yield pSalbCAP. Plasmid DNA was 
also sequenced to confirm that the capture arms were of the expected sequence 
(Appendix Figure 87). 
 
 
Figure 28: PCR screen of Image of plasmids isolated after Gibson assembly of pSalbCAP. Agarose gel 
image shows the amplified DNA fragment with the expected size (364 bp) to indicate successful 
incorporation of the capture arms into the pCAP03 backbone. 
 
3.3.2.3. Spheroplast transformation and screening of cluster capture 
Once the capture vector was constructed, the Moore 2.0 TAR cloning protocol (309) was 
followed to capture the target genomic region from digested S. albus J1074 gDNA via 
spheroplast transformation of Saccharomyces cerevisiae VL6-48N (methods described 
in sections 6.4.1.2. and 6.4.1.3.). In order to confirm successful capture of this genomic 
region to yield pCAPSalbC, a two-step PCR screening process was carried out, as a 
large number of colonies were obtained following negative selection with 5-FOA. First, 
five batches of 20 individual colonies were pooled into five single PCR reactions, for 
amplification of a target internal DNA fragment. Two of these pooled samples appeared 
to yield a positive result based on amplification of a DNA fragment of the expected size 
(~400 bp) (Figure 29). The 20 individual colonies from one of these pooled samples 
were then individually screened by PCR. This revealed that eight of these 20 colonies 
contained the successfully captured gene cluster based on amplification of a target 
internal fragment (Figure 30). To further confirm that the whole target genomic region 
had been captured, an analytical restriction digest was carried out on plasmid DNA 
purified from six individual clones, using restriction enzymes HindIII and SrfI that cut in 
various locations in the pCAPSalbC construct. This yielded the expected pattern of DNA 
bands following agarose gel electrophoresis, indicating that the full 18.5 kbp fragment 





Figure 29: PCR screen of pooled colonies following TAR cloning. Agarose gel image shows amplification 
of DNA fragments from samples 4 and 5 which are the expected size of the target internal fragment (~400 
bp), indicating successful capture of the S. albus J1074 gene cluster, yielding pCAPSalbC.  +C= positive 
control (S. albus J1074 genomic DNA). 
 
Figure 30: PCR screen of individual colonies following pooled batch screening. Agarose gel image shows 
amplification of DNA fragments obtained from colonies 1, 3, 9, 10, 12, 14, 17 and 18 which are the expected 
size of the target internal fragment (~400 bp), indicating successful capture of the Streptomyces albus J1074 





Figure 31: Analytical restriction digest of pCAPSalbC construct. Agarose gel image shows each plasmid 
sample digested with SrfI and HindIII yielding the five expected DNA fragments, indicating successful 
capture of the whole biosynthetic gene cluster from Streptomyces albus J1074 into pCAP03. The fragments 





3.3.3. Heterologous Expression and Metabolomic Screening 
After confirming successful capture of the S. albus J1074 gene cluster into the pCAP03 
vector, the next step was to introduce this construct into a heterologous host for 
expression and metabolomic analysis. 
 
3.3.3.1. Deletion of precursor peptide gene from pCAPSalbC 
In order create a negative control for metabolomic screening, PCR targeting (309) was 
employed to engineer an individual in-frame deletion of the precursor peptide gene 
(amiA) within the pCAPSalbC construct (method described in section 6.4.4.). Individual 
colonies obtained after antibiotic selection were picked for plasmid extraction and the 
DNA was sequenced to confirm successful deletion of the precursor peptide gene. 
Figure 32 shows a screenshot of the sequencing alignment showing that the precursor 
gene had been deleted and replaced with the expected 81 bp scar region, whilst the in-
frame start and stop codons of the precursor peptide were retained. 
 
 
Figure 32: Sequence alignment showing deletion of precursor peptide gene from the pCAPSalbC. Top 
sequence corresponds to a fragment of the ‘wild type’ S. albus J1074 gene cluster where the precursor 
peptide gene has been replaced with a random 81 bp sequence (hypothetical ‘scar’ region) between the 
start and stop codons. Bottom sequence corresponds to the sequence obtained following Sanger 
sequencing of the pCAPSalbCΔamiA mutant. Alignment of the two sequences indicate that the gene has 
been successfully deleted. 
 
3.3.3.2. Heterologous expression 
The construct containing the whole biosynthetic gene cluster from S. albus J1074 
(pCAPSalbC) and the mutant construct lacking the precursor peptide gene 
(pCAPSalbCΔamiA) were introduced via conjugation into four heterologous host strains: 
Streptomyces lividans, Streptomyces laurentii, Streptomyces scabies and Streptomyces 
coelicolor M1146 (method described in section 6.4.2.). I tested multiple heterologous 
hosts in order to increase the chances of observing pathway-related metabolite 
production. These particular strains were chosen as they have been previously utilised 
as heterologous hosts, and their genomes do not naturally contain the RiPP gene cluster 
of interest. Metabolomic screening was carried out with all four hosts, but the strain that 
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yielded an observable difference in metabolite production between the gene cluster and 
precursor peptide mutant was the Streptomyces superhost S. coelicolor M1146 (336). 
This strain was therefore used as a host for all further experiments.  
 
3.3.3.3. Untargeted metabolomic screening 
In order to identify pathway-related metabolites, wide-scale fermentations and liquid 
chromatography-mass spectrometry (LC-MS)-based screening were carried out 
(methods described in sections 6.2.4. and 6.4.7.). The two strains constructed (S. 
coelicolor M1146-pCAPSalbC and S. coelicolor M1146-pCAPSalbCΔamiA) were grown 
in a range of culture media (BPM, R5, SM14) in order to identify optimal culture 
conditions for the pathway-associated metabolite. Associated metabolomic profiles were 
obtained following LC-MS analysis of culture extracts, taken at various time points over 
10 days. These data were compared by overlaying MS base peak chromatograms and 
carrying out comparative metabolomic analyses using the Shimadzu Profiling Solution 
software. Initially, it was difficult to identify differences in metabolite production in any 
media tested, but upon screening in an additional medium (SM12), one particular 
metabolite could be observed from S. coelicolor M1146-pCAPSalbC but not the 
precursor peptide mutant, as observed after overlaying MS chromatograms from the two 
strains (Figure 33). This metabolite had a mass-to-charge ratio (m/z) of 272.16, which 
could be indicative of a small RiPP such as a tripeptide-derived metabolite.  
 
 
Figure 33: Comparison of base peak chromatograms (BPCs) from LC-MS analysis of S. coelicolor M1146-
pCAPSalbC (black) and S. coelicolor M1146-pCAPSalbCΔamiA (lilac). A peak with a retention time of 0.8 
minutes corresponds to m/z 272.16, a metabolite produced by the strain expressing the whole cluster but 





Although this result looked interesting, a subsequent Profiling Solution analysis revealed 
that several other metabolites were also produced by the strain expressing the gene 
cluster (Figure 34). These metabolites eluted very early (less than 30 seconds into the 
LC-MS run) and were partially masked by other abundant metabolites such as sugars 
that elute within this early time period. 
 
 
Figure 34: Profiling Solution analysis of metabolites produced by S. coelicolor M1146-pCAPSalbC and S. 
coelicolor M1146-pCAPSalbCΔamiA. Data from five replica cultures of each strain are shown alongside two 
replicas of SM12 medium-only control cultures. Several metabolites with early retention times are produced 
by S. coelicolor M1146-pCAPSalbC but not S. coelicolor M1146-pCAPSalbCΔamiA, but these masses are 
masked by other major media components in the chromatograms shown in Figure 33. Data obtained on a 
Shimadzu IT-TOF. 
 
In order to examine the fast-eluting metabolites in more detail, I repeated the LC-MS 
analysis using a polar C18 chromatography column, optimised for separation of polar 
metabolites, and applied a shallower methanol gradient to encourage later elution of the 
metabolites of interest (methods described in section 6.2.4.2.). This analysis confirmed 
that in addition to m/z 272.16, four other metabolites were produced by S. coelicolor 
M1146-pCAPSalbC but not the precursor peptide mutant. These metabolites were m/z 
647.32 (also observed as [M+2H]2+, m/z 324.16), m/z 510.27, m/z 409.22 and m/z 338.18 
(Figure 35), which could all represent larger pathway-related metabolites. Although this 
optimised chromatography approach led to the identification of putative pathway-related 
metabolites, further metabolite differences might still be missed based on limitations of 
the ionisation method and the solvent used for extraction. The newly-identified 
metabolites were examined by high-resolution LC-MS2 analysis which indicated that they 
contain similar fragment ions, suggesting that these metabolites are structurally related 
(Figure 36). These metabolites might therefore represent a group of related metabolites 






Figure 35: Comparison of extracted ion chromatograms of pathway-associated metabolites from S. 
coelicolor M1146-pCAPSalbC and S. coelicolor M1146-pCAPSalbCΔamiA. The four identified cluster-
associated metabolites are shown: m/z 647.32 (orange) (also observed as [M+2H]2+ m/z 324.16 (pink)), m/z 
510.27 (blue), m/z 409.22 (green) and m/z 338.18 (orange) with base shift applied. Base peak chromatogram 







Figure 36: High-resolution LC-MS2 data for pathway-related metabolites; m/z 647.32, m/z 510.27 and m/z 
409.22, obtained using a Waters Synapt G2Si. Common fragment ions are highlighted in red. 
 
Overall, these LC-MS analyses suggest that uncharacterised natural products that are 
polar in nature might be overlooked when standard metabolomic screening conditions 
are used that are not optimised for separation and detection of polar metabolites. It is 
also interesting that these metabolites were only observed in one of the media tested 
(SM12). This is a complex medium and there might be certain components that helped 
trigger production of the biosynthetic gene cluster. One of the reasons I chose to test 
SM12 is that it contains several protein-rich ingredients that I hypothesised would provide 




3.3.4. Insertional Disruption of the S. albus J1074 Biosynthetic Gene Cluster 
After identifying putative pathway products from heterologous expression of the model 
biosynthetic gene cluster, I was interested to see whether these same metabolites could 
be detected from the native producer- “wild type” S. albus J1074 (337)- using the same 
culture and metabolomic screening conditions. To obtain a negative control for 
metabolomic screening of S. albus J1074, I constructed a pathway mutant of the strain 
via insertional disruption of the biosynthetic gene cluster in vivo (methods described in 
section 6.4.3.). I chose this approach as although not as clean as obtaining a precise 
gene or whole cluster deletion, it was a quicker way to confirm the results already 
obtained from heterologous expression of the gene cluster. 
 
3.3.4.1. Construction of disruption vector 
To construct the S. albus J1074 mutant, I first cloned a DNA fragment corresponding to 
the genes encoding the hydrolase (amiC) and YcaO-domain protein (amiD) that 
physically overlap on the chromosome, ensuring that the predicted catalytic domains of 
the encoded proteins would be included in the disruption. Therefore, the gene cluster 
would be highly unlikely to be functional after recombining with this fragment. Once the 
disruption fragment was cloned, I ligated it into the suicide plasmid pKC1132 to create 
the construct pKCΔamiCD. After transforming this construct into E. coli DH5α, individual 
colonies obtained on selective agar were screened by PCR to confirm presence of the 
insert which was ~2 kbp in size (Figure 37). Plasmid DNA was isolated from individual 
clones that were positive for the insert and sequenced to confirm the presence of the 
disruption fragment.  
 
 
Figure 37: PCR screen of pKCΔamiCD disruption construct. Agarose gel image shows amplification of 
fragments from individual E. coli colonies transformed with the ligated pKCΔamiCD disruption construct. 





3.3.4.2. Conjugation of S. albus J1074 with pKCΔamiCD 
After confirming successful construction of pKCΔamiCD, the vector was introduced into 
E. coli ET1256 via triparental mating with E. coli TOP10-pUZ8002 (described in section 
6.2.1.3.) followed by intergenic conjugation with S. albus J1074 (described in section 
6.2.2.3.). Successful single crossover between pKCΔamiCD and the S. albus J1074 
chromosome was confirmed by colony PCR using primers that amplify the intact amiCD 
fragment from wild type sequences but not from the pathway disrupted mutants. PCR 
screening showed that the intact fragment was amplified from S. albus J1074 gDNA (2 
kbp), but not from pathway mutant exconjugants (S. albus-pKCΔamiCD), although non-
specific amplification was observed from these colonies (0.5 and 3 kbp) (Figure 38). This 
indicated successful disruption of the S. albus J1074 pathway. 
 
 
Figure 38: PCR screen of S. albus J1074-pKCΔamiCD exconjugants. Agarose gel image shows 
amplification of DNA fragments from individual colonies. The positive control in lane 1 (+C) shows 
amplification of the undisrupted gene region from wild type S. albus J1074. Samples 1-17 represent 
individual exconjugants from which amplification of a larger band indicate disruption of the gene region 
following insertion of pKCΔamiCD. 
 
3.3.4.3. Metabolomic screening of S. albus J1074 and S. albus-pKCΔamiCD 
Once the S. albus-pKCΔamiCD mutant had been constructed, the strain was grown 
alongside wild type S. albus J1074 under the same conditions as for heterologous 
expression experiments, using the same experimental conditions for LC-MS analysis. 
The metabolomic profiles of S. albus J1074 and S. albus-pKCΔamiCD were compared 
and interestingly, the putative pathway products identified from heterologous expression 
of the cluster were also detected from S. albus J1074 but not the S. albus-pKCΔamiCD 
mutant. This included the four putative pathway-related metabolites m/z 647.32, m/z 
510.27, m/z 409.22 and m/z 338.18. Interestingly however, the m/z 272.16 metabolite 
was detected in the S. albus mutant, and not the wild type strain (Figure 39). This could 
suggest that m/z 272.16 is not a main pathway product but might instead correspond to 
a biosynthetic intermediate produced by the mutant. The other four metabolites identified 
(m/z 647.32, m/z 510.27, m/z 409.22 and m/z 338.18) could be genuine products of the 
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cloned biosynthetic pathway, as they were detected from both the native and 
heterologous host of the biosynthetic gene cluster.  
 
It is interesting that the newly identified metabolites were detectable from the native 
producer without any manipulation of native pathway elements. Cryptic biosynthetic 
gene clusters that have not previously been characterised are often only “switched on” 
in the native producer after the manipulation of pathway regulators or promoters. In the 
case of S. albus J1074, I was able to detect the putative pathway products after 
replicating favourable growth and screening conditions identified during the previous 





Figure 39: Comparison of extracted ion chromatograms of pathway-associated metabolites from S. albus 
J1074 wild type and S. albus-pKCΔamiCD. Five cluster-associated metabolites are shown: m/z 647.32 
(orange) (also observed as [M+2H]2+ m/z 324.16 (pink)), m/z 510.27 (blue), m/z 409.22 (green), m/z 338.18 
(orange) and m/z 272.16 (brown) with base shift applied. Base peak chromatogram is shown in grey. Data 





3.3.5. Comparing Metabolites Produced by the Native and Heterologus 
Hosts 
In order to confirm that the metabolites detected from the native and heterologous hosts 
were indeed the same metabolites, I compared the MS2 data of the metabolite with the 
largest mass (observed as m/z 324.16 [M+2H]2+) from both S. coelicolor M1146-
pCAPSalbC and S. albus J1074. Although the LC-MS total ion current (TIC) peak shapes 
differ slightly in appearance, the identical fragmentation patterns observed in both 
samples suggest that the identified metabolite is structurally identical (Figure 40). 
 
 
Figure 40: Comparison of MS2 data for m/z 324.16 [M+2H]2+ from S. coelicolor M1146-pCAPSalbC S. albus 
J1074). Data obtained using a Shimadzu IT-TOF. 
 
3.3.5.1. GNPS networking analysis 
The putative pathway-related metabolites were identified from screening trials with both 
the native producer and heterologous host of the target biosynthetic gene cluster. LC-
MS data files relating to both of these strains were submitted to GNPS for metabolomic 
networking (described in section 2.1.2.2.). One of the resulting molecular networks 
connected many of the pathway-related metabolites identified during fermentation trials 
(m/z 510.27, m/z 409.22 and m/z 338.18). This suggested that these metabolites are 
structurally related based on the presence of similar fragmentation patters (Figure 41). 
Although the larger identified metabolite (m/z 647.32) was not included in this network, 
the presence of similar fragmentation patterns observed from high-resolution LC-MS2 
analysis between m/z 647.32, m/z 510.27 and m/z 409.22 (Figure 36) suggest that the 




Figure 41: Global Natural Products Social (GNPS) molecular network of pathway-associated metabolites. 
Obtained from analysis of a range of LC-MS data files obtained from fermentation of S. coelicolor M1146-
pCAPSalbC and S. albus J1074. The sub-network corresponding to the identified pathway-related 





3.3.6. Gene Deletions from the TAR Cloned S. albus J1074 Gene Cluster 
3.3.6.1. Deletion of biosynthetic genes from pCAPSalbC 
In order to further confirm that the newly identified metabolites were genuine products of 
the cloned gene cluster, and to investigate the involvement of individual biosynthetic 
genes, I constructed further gene deletions from the pCAPSalbC construct. 
Theoretically, any gene captured into the TAR cloned fragment could be involved in 
biosynthesis of the identified metabolites, therefore I deleted all genes that form the 
proposed biosynthetic gene cluster as well as the additional captured genes. As with the 
precursor peptide deletion, this was achieved using PCR targeting (309) (method 
described in section 6.4.4.). Individual deletions were made of genes encoding the 
oxygenase, MarR regulator (amiM), oxidoreductase (amiX), E1-ubiquitin-like enzyme 
(amiB), hydrolase (amiC), YcaO-domain protein (amiD), dehydrogenase (amiE) and 
peptide methionine reductase proteins. The four iron transporters were deleted as a 
combined genetic fragment, as were the two ABC transporters. This is because these 
genes are transcriptionally coupled, and each comprise a single transport system. The 
two transcriptionally coupled acetyltransferase genes were also deleted as a combined 
fragment. After PCR screening and DNA sequencing to confirm deletion of these genes 
from pCAPSalbC, the ten resulting deletion constructs were introduced into S. coelicolor 
M1146 via conjugation and the resulting mutant strains were fermented and screened 
under the same conditions as for the previous heterologous expression experiments. 
 
3.3.6.2. Metabolomic screening of gene deletion mutants 
LC-MS analysis of each mutant strain indicated that several gene deletions abolished 
production of the previously identified metabolites, suggesting that these genes encode 
essential biosynthetic proteins. These include the iron transporters (AmiF1-4), E1-
ubiquitin-like enzyme (AmiB), hydrolase (AmiC), YcaO-domain protein (AmiD) and the 
dehydrogenase (AmiE) (Figure 42 andFigure 43). I therefore proposed that these 
genes, along with the precursor peptide gene (amiA), make up a minimal biosynthetic 
gene cluster for the identified metabolites (Figure 44). The oxidoreductase gene deletion 
had an effect on streptamidine production but did not completely abolish biosynthesis 
(Figure 42). Gene deletions that had no effect on production of the identified metabolites 
included those encoding the oxygenase, MarR regulator, ABC transporters, peptide 
methionine reductase and acetyltransferases. Interestingly, some of the mutants 
appeared to over-produce some additional metabolites as observed when comparing 
their metabolomic profiles with that of S. coelicolor M1146-pCAPSalbC (carrying the 
intact gene cluster). These could be indicative of potential biosynthetic intermediates or 
shunt metabolites. One of these metabolites was m/z 272.16, which was previously 
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observed from the pathway-disrupted S. albus mutant. The other shunt metabolites 
observed include m/z 314.17, m/z 332.18 and m/z 354.16. The mass differences 
between these metabolites suggest they might be structurally related: a difference of 
18.01 between 314.17 and 332.18 reflects hydration, and the difference of 21.98 
between 332.18 and 354.16 indicates formation of a sodium adduct instead of a proton 
adduct. The importance of these shunt metabolites in biosynthesis of the fully modified 
RiPP product is discussed further in Chapter 4. 
 
 
Figure 42: LC-MS analysis of key biosynthetic gene deletions from pCAPSalbC. Extracted ion 
chromatograms indicate production of a putative key product of the S. albus J1074 biosynthetic gene cluster 
(m/z 324.16) compared with other over-produced metabolites that might be indicative of pathway 
intermediates (m/z 272.16, m/z 314.17 and m/z 332.18). Data obtained on a Shimadzu IT-TOF. 
 
 
Figure 43: Heat map of metabolite production in pathway mutants. Colour scale indicates the level of 
production of pathway-associated metabolites from S. coelicolor M1146-pCAPSalbC compared with 
individual pathway mutants. Data obtained on a Shimadzu IT-TOF and analysed by Profiling Solution. The 
ion intensities of metabolites produced by each mutant strain in triplicate were combined, averaged and 





Figure 44: Genetic region TAR cloned from S. albus J1074. The minimal biosynthetic gene cluster 
responsible for production of pathway-related metabolites is indicated, as identified from metabolomic 
screening of gene deletion mutants. Essential biosynthetic genes are indicated with filled arrows and 
nonessential biosynthetic genes are indicated with striped arrows.  
 
3.3.7. Genetic Complementation of Gene Deletions 
3.3.7.1. Construction of gene complementation vectors 
In order to confirm that the results from gene deletions were genuine and not due to off-
target effects, the deletion mutants that abolished metabolite production were genetically 
complemented (methods described in section 6.4.5.). The genes for the precursor 
peptide (amiA), E1-like protein (amiB), hydrolase (amiC), YcaO-domain protein (amiD) 
and dehydrogenase (amiE) were cloned into the expression vector pIJ10257, which 
contains an ermE* promoter. After PCR screening and DNA sequencing to confirm 
presence of the correct inserts, each construct was conjugated into the corresponding 
deletion mutant of S. coelicolor M1146-pCAPSalbC. Complementation was successful 
with all of these strains except for the precursor peptide mutant. This might be because 
precursor peptides in RiPP gene clusters have very specific transcriptional and 
translational regulation, and therefore making deletions in this region might disrupt this 
important functionality. To overcome this, I attempted to construct alternative 
complementation constructs for the precursor peptide, cloning longer stretches of 
sequence upstream of the precursor peptide into pIJ10257, in case an important 
promoter region was previously omitted. However, these constructs were not able to 
complement the gene deletion. Difficulty with complementing RiPP precursor peptide 
deletions has also been observed by other members of the lab group with the 
bottromycin and thiovarsolin pathways (124,331).  
 
3.3.7.2. Metabolomic screening of genetically complemented mutants 
Successful complementation of the YcaO, E1-like and dehydrogenase deletions resulted 
in restored production of the previously identified pathway metabolites (Figure 45). This 
suggests that the abolished production previously observed was genuinely caused by 
the gene deletions and not off-target effects in the mutant. Complementation of the 
hydrolase gene deletion however did not restore production of the putative pathway 
metabolites. I also considered whether there might be a problem with the original 
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hydrolase deletion construct design. As the hydrolase gene lies between two other co-
transcribed biosynthetic genes (Figure 44), deletion of amiC could have disrupted 
expression of these neighbouring pathway genes. I therefore re-designed the hydrolase 
gene deletion construct, reducing the size of the deleted region to ensure that promoter 
regions of nearby genes were not interrupted. However, this did not change the 




Figure 45: LC-MS analysis of genetic complementations of deletions from the pCAPSalbC construct. 
Extracted ion chromatograms of pathway-associated metabolites are indicated, (m/z 324.16 (pink), m/z 
510.27 (blue) and m/z 409.22 (green)) as well as  extracted ion chromatograms of putative biosynthetic 
intermediates (m/z 314.17 (dark blue) and m/z 332.18 (red)). Data obtained on a Shimadzu IT-TOF. 
 
3.4. Chapter Summary 
 
This chapter presents a range of genetic approaches that were undertaken to clone and 
study a model RiPP biosynthetic gene cluster from S. albus J1074. The genomic region 
containing the cluster was TAR cloned and heterologously expressed to identify putative 
pathway products, which were also detected from the native producer. A series of gene 
deletions were constructed to confirm which biosynthetic enzymes were involved in 
producing the identified metabolites, some of which were genetically complemented to 
confirm that these proteins were essential for biosynthesis. Together these results 
suggest that the four metabolites identified from LC-MS analyses (m/z 647.32, m/z 
510.27, m/z 409.22 and m/z 338.18) were genuine products of the previously 
uncharacterised RiPP biosynthetic gene cluster from S. albus J1074, and I could propose 




Overall, the results presented in this chapter demonstrate that previously unknown 
biosynthetic gene clusters identified by genome mining can be subsequently 
characterised through cloning, genetic manipulation and metabolomic screening of the 
pathway. In the future these approaches can continue to be applied to other newly 
identified gene clusters to help characterise novel metabolites. I also showed that by 
trialling different growth media, metabolomic screening conditions and chromatography 
methods, it is possible to identify metabolites that were previously not detected. This is 
particularly interesting in the case of S. albus J1074, which is an extensively studied 
strain that is commonly used as a heterologous host (299,300,329,338–341), and yet 
the metabolites identified in this study have not been previously reported. Variations in 
growth and screening conditions should therefore also be considered when screening 
other novel biosynthetic gene clusters in the future.  
 
The experiments described in this chapter led to the identification of a group of 
metabolites that appear to be genuine products of the novel biosynthetic gene cluster 
from S. albus J1074. The following chapter will describe the characterisation of these 
metabolites in further detail. 
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Chapter 4: Investigating the 
Structure, Biosynthesis and 





The data presented in Chapter 3 describe the identification of metabolites produced by 
a novel RiPP biosynthetic gene cluster. This chapter will focus on characterisation of the 
putative final product of this gene cluster, using a combination of purification techniques, 
structural analyses and biological investigations. Structural elucidation of natural 
products is an important aspect of their characterisation as it can provide clues about the 
biosynthetic steps of the associated natural product pathway. Another key goal of natural 
products research is to identify the biological activities of novel metabolites, which is also 
tightly linked to the molecular structure. 
 
4.1.1. Structural Characterisation of Natural Products 
Many different spectroscopic methods have been developed to aid structural elucidation 
work in organic chemistry. Early work involved X-ray crystallography, pioneered by Max 
von Laue in 1912, who discovered that bombarding crystals with X-rays resulted in 
characteristic diffraction patterns on a photographic plate (342). The use of this technique 
to solve molecular structures was widely demonstrated by Dorothy Crowfoot Hodgkin 
during the 1940s-‘60s, who solved the structure of important metabolites such as 
penicillin (343), vitamin B12 (344), insulin (345) and thiostrepton (140). More recently, 
nuclear magnetic resonance (NMR) has been widely adopted to solve structures of small 
metabolites. NMR provides information about the chemical shifts of atoms as atomic 
nuclei exhibit characteristic nuclear spin when exposed to electromagnetic radiation. The 
measurement of nuclear magnetic moments using magnetic resonance absorption was 
first demonstrated in 1938 by Rabi (346). 2D NMR was introduced in 1976 by Ernst (347), 
which provides further correlation data between atoms in a structure. A more recent 
technique developed for structural elucidation of small metabolites is microcrystal 
election diffraction (MicroED), which utilises CryoEM (electron cryo-microscopy) to solve 
structures of small metabolites (348). Solid ground powder is first applied to glass cover 
slides, which are then deposited on a carbon-copper grid, flash-frozen in liquid nitrogen 
and transferred to a cryoelectron microscope. Nanocrystals on the grid surface, 
approximately 100 nm in diameter, are continuously rotated at 140 degrees and imaged 
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to create a movie. From this, structural information is inferred. Structures can be solved 
to 1 Å resolution with data from a single nanocrystal (349). 
 
4.1.2. Biological Characterisation of Natural Products 
In terms of investigating antimicrobial activities of metabolites, a commonly used method 
to investigate antimicrobial activity is the agar disk-diffusion method, first developed in 
1940 to study the activity of penicillin (350). This method can be used to test the inhibitory 
activity of metabolites or extracts against a range of pathogens or indicator strains. This 
can give an initial indication of antimicrobial activity, but more accurate minimum 
inhibitory concentration (MIC) testing can be achieved using dilution methods (83), where 
the MIC is determined as the lowest concentration of antimicrobial agent that completely 
inhibits growth of the test organism (351). To overcome issues with ambiguity or 
subjectivity, several colorimetric-based assays have also been developed, such as the 
Alamar blue dye (resazurin) assay (352). In order to investigate other biological activities 
such as metal-binding, other assays have also been developed. A universal method for 
determining siderophore activity is the chrome azurol S (CAS) assay. Here, CAS and 
hexadecyltrimethylammonium bromide (HDTMA) form a tight complex with iron that 
produces a blue colour. When a siderophore is added, iron is removed from the complex 
resulting in a colour change from blue to orange (353). This colorimetric assay can be 
carried out on agar plates or in liquid, and has been further developed to investigate the 
chelation of other metal ions (354). Other assays have also been developed to detect 
the chelation of other metals such as the 4-(2-pyridylazo)-resorcinol (PAR) assay that 




4.2. Chapter Aims 
 
The pathway-related metabolites identified from metabolomic screening experiments 
(Chapter 3) are hypothesised to represent novel RiPP metabolites. As the biosynthetic 
gene cluster was previously uncharacterised, these RiPPs could harbour unique 
structural features or novel bioactivity. The overall aim of this chapter was to characterise 
these newly identified metabolites. To achieve this, the specific objectives of this chapter 
were: 
 
(i) Utilise metabolomic prediction tools to identify a putative core peptide from the 
metabolomic data 
(ii) Purify the putative final metabolite of the biosynthetic pathway 
(iii) Elucidate the structure of the purified metabolite using NMR 
(iv) Investigate the biosynthesis of the identified metabolite 
(v) Investigate the biological activity of the metabolite  
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4.3. Results and Discussion 
 
4.3.1. Core Peptide Prediction and Structural Hypotheses 
As discussed in previous chapters, analysis of MS and fragmentation data can help 
provide clues about the structural identity and amino acids present in a peptide. Before 
purifying the final pathway-related metabolite for structural elucidation, I made some 
initial structural and core peptide predictions based on the MS data I had already 
obtained. 
 
4.3.1.1. Core peptide prediction 
Considering the pathway-related metabolites that have been identified, I was interested 
to see how these might relate to a modified core peptide within the S. albus precursor 
peptide AmiA. To achieve this, I utilised a RiPP peptide mass calculator developed at 
the John Innes Centre by Andrew Truman and Govind Chandra (unpublished). I 
submitted the S. albus J1074 precursor peptide sequence along with the identified singly 
charged metabolite masses (m/z 647.32, m/z 510.27, m/z 409.22 and m/z 338.18). I then 
predicted the possible mass changes that might occur based on the biosynthetic 
enzymes in the pathway. This included mass losses such as 18.02 (corresponding to a 
dehydration that could be catalysed by the oxidoreductase amiX) and 2.02 
(corresponding to dehydrogenation that could be catalysed by the dehydrogenase 
AmiE). Interestingly, after submitting these data for analysis, the calculator mapped all 
the identified metabolites to within the same six-residue region of the precursor peptide: 
His-Leu-Ser-Ala-Thr-His. The metabolites related to this sequence as follows: m/z 
647.32 (HLSATH), m/z 510.27 (HLSAT), m/z 409.22 (HLSA) and m/z 338.18 (HLS) 
(Appendix Figure 88). This suggested that these masses relate to the same RiPP 
metabolite, with the smaller masses representing breakdown products or intermediates 
of the final metabolite. Going forward, I proposed that the final product of the pathway is 
a metabolite with m/z 647.32 (also observed as m/z 324.16 [M+2H]2+), as this was the 
largest mass identified. The peptide calculator indicated that several possible 
combinations of mass changes could theoretically match the final modified metabolite 
with the proposed core sequence, therefore the exact post-translational modifications 
could not be determined from this prediction tool. 
 
4.3.1.2. Initial structural hypothesis 
One of the possible mass changes calculated was for a single dehydration to occur within 
the proposed core sequence. Based on the biosynthetic genes present in the gene 
cluster, it would be plausible for a single dehydration to occur with the formation of an 
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oxazoline heterocycle, which would be consistent with ATP-dependent cyclodehydration 
catalysed by the YcaO-domain protein with the E1-like partner protein. This could take 
place on either the threonine or serine residue (Figure 46). However, the presence of 
additional dehydrogenases in the cluster would therefore seem redundant. The gene 
deletion experiments described in Chapter 3 indicated that one of the dehydrogenase 
enzymes appeared to be essential for biosynthesis of the final metabolite. It could 
therefore be possible that the oxazoline is oxidised to its corresponding oxazole, but this 
would require a further reduction in the metabolite to account for these mass changes. 
This could occur on one of the histidine rings for example, but this would be an unusual 
post-translational modification for a RiPP (Figure 46).  
 
 
Figure 46: Structural hypotheses for the putative final pathway metabolite (m/z 647.32). Structures based 
on exact mass, core peptide predictions and post-translational modification predictions. 
 
4.3.1.3. Molecular formula prediction 
The predicted modified peptides shown in Figure 46 have a chemical formula of 
C28H42N10O8. According to the Shimadzu formula predictor tool, this is the highest scoring 
and therefore most likely chemical formula based on the ion peaks of the putative 
metabolite (m/z 647.32). This formula is also supported by accurate mass data for this 
metabolite obtained on a Synapt G2Si (calculated [M+H]+ m/z 647.3260; observed m/z 
647.3251, Appendix Table 26). This could support the structural predictions presented, 
but these atoms could also be arranged in different ways. The exact structure of this 





4.3.2. Purification of Metabolite 
4.3.2.1. Small-scale purification trials 
Before attempting large-scale fermentations, I carried out some smaller-scale trials in 
order to identify optimal conditions for the best production titre of the target metabolite. 
First, I grew cultures of S. coelicolor M1146-pCAPSalbC and S. albus J1074 in 10 mL 
Falcon™ tubes and took samples each day for a period of 7 days. I then carried out LC-
MS analysis on the samples to determine how metabolite production changes over time 
(Figure 47). From this, it appeared that the ion intensity of m/z 324.16 ([M+2H]2+) in S. 
coelicolor M1146-pCAPSalbC was the highest at day 4, after which the ion intensity of 
other pathway metabolites (m/z 510.27 and m/z 409.22) increase before diminishing 
after day 6. In S. albus J1074, overall production of m/z 324.16 ([M+2H]2+) appears to be 
lower and peaks at a later time compared to S. coelicolor M1146-pCAPSalbC. I chose 
to focus on isolating the metabolite from S. coelicolor M1146-pCAPSalbC as production 
of the target metabolite appeared to be higher, and the lower metabolic background of 





Figure 47: Time course of pathway-associated metabolite production. Production of metabolites over a 4-




After this experiment, I trialled fermentations of S. coelicolor M1146-pCAPSalbC in a 
range of flask sizes (10 mL, 250 mL, 500 mL and 2 L) with different volumes of production 
media and analysed metabolite production at different time points. From this experiment, 
I found that metabolite production was only detected from 500 mL cultures grown in 2 L 
conical Duran flasks.  
 
4.3.2.2. Large-scale purification  
4.3.2.2.i. Liquid-liquid extraction 
Following small-scale trials, I grew four batches of 500 mL SM12 cultures for a large-
scale purification (methods described in section 6.5.1.). After four days of growth, the 
cultures were centrifuged and filtered, and the supernatant retained for purification. The 
fast elution of m/z 324.16 ([M+2H]2+) in previous LC-MS analyses indicated that the 
metabolite is highly polar, therefore I washed the culture extract with ethyl acetate 
followed by butanol to remove hydrophobic material from the extract, retaining the target 
metabolite in the aqueous fraction. This aqueous fraction was dried down and retained 
for further purification steps. 
 
4.3.2.2.ii. Solid phase extraction 
The dried aqueous fraction was injected onto a SNAP HP20 Silica normal phase 
cartridge on a Biotage for separation using a gradient of increasing methanol. Fractions 
containing the target metabolite (Appendix Figure 90) were then combined and dried 
for further purification steps. The LC-MS chromatograms of extracts taken at each stage 
of purification is shown in Figure 48. This indicates that there were still background 
metabolites present in the sample following Biotage separation, therefore the extract was 




Figure 48: LC-MS analysis of fractions obtained during purification of the target pathway metabolite (m/z 
324.16 [M+2H]2+). LC-MS data obtained on a Shimadzu IT-TOF. 
 
4.3.2.2.iii. High-performance liquid chromatography (HPLC) 
The extract obtained following solid phase separation was first injected onto a PFP2 
HPLC column, and fractions were manually collected when peaks appeared in the UV 
chromatogram (Appendix Figure 91). After analysing each fraction by LC-MS, I found 
that the peaks that appear between 12 and 15 minutes corresponded to elution of the 
target metabolite (Figure 49). Although the metabolite was almost pure at this stage, 
there was a small amount of background contamination as observed in the base peak 
chromatogram of the sample. Furthermore, the target metabolite appeared as two 
separate LC-MS peaks, and it was not clear whether these represented two different 
metabolites or structural isomers that might complicate the NMR analysis. It is also 
possible that the two LC-MS peaks represent different protonation states of the 
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metabolite. In order to investigate this, and to clean the sample as much as possible, I 
injected it onto a polar C18 HPLC column to see if the metabolites displayed better 
separation on a different column. I trialled a range of different organic solvent gradients 
with this column to see which one resulted in the best separation. From these trials, I 
found that applying an isocratic gradient of 10% methanol appeared to best separate the 
metabolites, based on the peak separation visible in the UV chromatogram at 210 nm 
(Appendix Figure 92). I manually collected fractions corresponding to each peak in the 
chromatogram, and LC-MS analysis indicated that I had purified the target metabolite 
that eluted as a single LC-MS peak (Figure 50). The total amount of pure compound 




Figure 49: LC-MS analysis of combined HPLC fractions containing the target pathway metabolite (m/z 
324.16 [M+2H]2+). Obtained following separation of extract on a semi-preparative Phenomenex Luna PFP(2) 
column, with a 2-10% gradient of MeOH. Data obtained on a Shimadzu IT-TOF. 
 
 
Figure 50: LC-MS analysis of pure metabolite obtained following a final HPLC purification step. Obtained 
following separation on a Luna Omega Polar C18 column with an isocratic gradient of 10% MeOH. Data 
obtained on a Shimadzu IT-TOF.  
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4.3.3. Structural Elucidation  
4.3.3.1. Nuclear magnetic resonance (NMR) analysis 
In order to elucidate the structure of the newly isolated RiPP, I carried out a series of 
NMR experiments (methods described in section 6.5.2.1.). Purified metabolite was 
dissolved in ~600 µL of DMSO-d6 and subjected to a range of 1D and 2D NMR 
experiments including 1H, 13C, correlation spectroscopy (COSY), heteronuclear single 
quantum correlation edited (HSQCed), heteronuclear multiple bond correlation (HMBC), 
total correlation spectroscopy (TOCSY), nuclear overhauser effect spectroscopy 
(NOESY) and HSQC-TOCSY. Detailed correlation data are shown in Figure 52, 1D 
NMR spectra are shown in Figures 54 and 55 and 2D NMR spectra are shown in 
Appendix Figures 99-102. A list of chemical shifts is shown in Table 2. The data 
obtained from NMR allowed me to piece together the structure of this metabolite, 
revealing that it does derive from the previously predicted HLSATH core peptide.  
 
4.2.2.1.i. Elucidating the peptide backbone 
The presence of the histidine residues was indicated through carbons with characteristic 
13C shifts of δC 118 ppm, δC 122 ppm and δC 134 ppm, which are similar to those in the 
imidazole rings of characterised histidine residues (356). The quaternary carbon of each 
ring was difficult to see via 1D 13C NMR, but 2D data revealed the presence of these 
carbons with characteristic chemical shifts (δC 132 ppm and δC 135 ppm). Adjacent 
residues could then be pieced together based on 2D correlations. Long-range HMBC 
correlations from each carbonyl connected atoms within each residue as well as with 
neighbouring residues. NOESY correlations, which connect atoms that are close 
together spatially, helped to connect amide protons with the CH of neighbouring 
residues. TOCSY correlations indicate which protons belong to a single spin system, 
which could therefore connect together all protons within each amino acid residue. These 
connections could be further confirmed through COSY correlations, which connect 
protons attached to neighbouring carbon atoms. HSQC-TOCSY correlations also 
confirmed which carbons and protons were present within a single residue. HSQC 
correlations confirmed which protons were attached to each carbon within the metabolite. 
 
4.2.2.1.ii. Elucidating the post-translational structural modification 
Although there were characteristic 13C and 1H shifts and correlations indicating the 
presence of the HLSATH peptide backbone, the exact identity of the post-translational 
modification was difficult to confirm. Although I initially predicted that there could be an 
oxazoline or oxazole ring in the metabolite, the chemical shifts of the serine side chain 
indicated that this residue was unmodified. Interestingly, the 13C shift for the sp2 carbon 
between Leu2 and Ser3 was δC 157.1 ppm, which differed from either an unmodified 
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amide carbonyl (expected δC ~170 ppm) or an oxazoline ring (expected δC ~140 ppm). 
Instead, this carbon chemical shift was similar to that of the corresponding carbons in 
the amidine rings of bottromycin (δC 157.9 ppm in CDCl3) (357) and klebsazolicin (δC 
156.8 ppm in DMSO-d6) (129), suggesting that an amidine ring might be present in the 
metabolite. Furthermore, the terminal NH2 group that would be present on an unmodified 
N-terminal histidine could not be seen by NMR. Overall, this suggested that an amidine 
ring was present between the N-terminal amine of His1 and the carbonyl of Leu2 (core 
peptide numbering). The NMR correlation data supported the presence of a six-
membered amidine ring, including HMBC correlations between C15-H9 (δH 8.05 ppm) 
and C15-H18 (δH 4.30-4.27 ppm) (Figure 53). A particularly diagnostic HMBC correlation 
could be seen between C15-H7 (δH 3.95-3.91 ppm), which would not fit an oxazoline-
containing structure due to the distance between these two atoms (Figure 51). An 
exocyclic double bond between C15 and N17 was inferred as NMR data did not reveal 
an amide proton attached to N17. 
 
Based on the widespread occurrence of homologous biosynthetic gene clusters in 
streptomycetes, and the presence of an amidine ring in the structure, I named this 
metabolite streptamidine. To reflect this, the genes within the biosynthetic pathway were 
also named according to the acronym ami. The discovery of a novel amidine-containing 
metabolite is particularly exciting as it is a rare structural feature to be found in natural 
products. To date, only two examples of amidine-containing RiPPs are known: 
klebsazolicin, which contains a six-membered amidine ring (129) and bottromycin, which 




Figure 51: A: Diagnostic HMBC correlation for the amidine ring in streptamidine. The correlation between 
C15 (δC 157.9 ppm) and H7 (δH 3.95-3.91 ppm) is too long a distance to support the presence of an 






Figure 52: Detailed correlation data for the structural elucidation of streptamidine. 
 
 
Figure 53: Structure of streptamidine in relation to the precursor peptide AmiA. Leader, core and follower 
regions of the precursor peptide are highlighted along with key HMBC correlations that support the presence 




Table 2: NMR chemical shift assignments for streptamidine in DMSO-d6 
C/N 
number 




Multiplicity Coupling Constant 
in Hz 
1 His1 -- -- --  
2 His1 134.7 7.48 s  
3 His1 --    
4 His1 131.6a -- --  
5 His1 121.0b 6.67 s  
6 His1 32.6 2.84, 2.75 dd, dd J6a,6b = 14.1, J6a,7 = 5.2, 
J6b,7 = 7.4 
7 His1 58.8 3.95-3.91 m  
8 His1 170.7 -- --  
9 Leu2 -- 8.05 s  
10 Leu2 51.0 3.82 d J10,11a = 10.8 
11 Leu2 45.9 1.41-1.35, 
0.77-0.71 
m, m  
12 Leu2 23.8 1.64-1.57 m  
13 Leu2 21.4 0.82 d J12,13 = 6.4 
14 Leu2 24.1 0.78 d J12,14 = 6.6 
15 Leu2 157.1 -- --  
16 His1 --    
17 Ser3 -- -- --  
18 Ser3 57.1 4.30-4.27 m  
19 Ser3 62.2 3.62 d J18,19 = 5.9 
20 Ser3 171.4 -- --  
21 Ala4 -- 8.09 d J21,22 = 7.0 
22 Ala4 48.9 4.41-4.35 m  
23 Ala4 18.7 1.25 d J22,23 = 7.1 
24 Ala4 172.9 -- --  
25 Thr5 -- 7.88 d J25,26 = 8.6 
26 Thr5 59.3 4.14 dd J25,26 = 8.6, J26,27 = 3.6 
27 Thr5 66.9 4.02-3.98 m  
28 Thr5 19.9 1.00 d J27,28 = 6.3 
29 Thr5 170.0 -- --  
30 His6 -- 7.78 d J30,31 = 7.5 
31 His6 53.5 4.27-4.24 m  
32 His6 29.2 2.97, 2.82 dd, dd J32a,32b = 14.8, J31,32a = 5.1, 
J31,32b = 7.4 
33 His6 134.1a -- --  
34 His6 117.1b 6.81 s  
35 His6 -- -- --  
36 His6 135.1 7.54 s  
37 His6 --  --  









Figure 54: Full proton spectrum for streptamidine recorded in DMSO-d6. Chemical shifts for each proton 
in streptamidine are indicated, along with the integration of each peak. Data obtained on a Bruker Ascend 









































Figure 55: Full carbon spectrum for streptamidine in DMSO-d6 with numbered atoms. Data obtained on a 
Bruker Ascend 600 MHz instrument. 
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4.3.3.2. Structural confirmation using a fluorescamine-binding assay 
Although the NMR data clearly supported the presence of an amidine ring in 
streptamidine, I was interested to prove this further by testing for the presence or 
absence of the terminal amine group. To achieve this, I carried out a binding assay of 
fluorescamine (4-phenylspiro-[furan-2(3H),1-phthalan]-3,3′-dione) with purified 
streptamidine (method described in section 6.5.2.2.). Fluorescamine is a reagent that 
reacts with free primary amine groups to produce a fluorescent complex. If the proposed 
structure of streptamidine is correct, the metabolite should not react with fluorescamine 
as it does not contain a free primary amine group. If the metabolite contained an oxazole 
or oxazoline however, there would be a primary amine group free to form a 
fluorescamine-bound complex. As a control, I mixed unmodified L-histidine with 
fluorescamine, which formed the expected complex as indicated by LC-MS analysis (m/z 
416.12). The multiple peaks observed could be a consequence of multiple protonation 
states or stereoisomers. However, streptamidine did not react with fluorescamine to form 
any observable complex by LC-MS, or any fluorescence detected by UV (Figure 56). 




Figure 56: A: LC-MS analysis of fluorescamine reaction with L-histidine and streptamidine. B: 
Corresponding UV trace of samples obtained with the PDA detector. Data obtained on a Shimadzu IT-TOF.  
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4.3.3.3. Determination of stereochemistry of streptamidine 
Once the structure of streptamidine was confirmed, I was interested to determine the 
exact stereochemical configuration of the metabolite. To achieve this, I carried out a 
Marfey’s analysis on a sample of the pure metabolite (methods described in section 
6.5.2.3.). This involved hydrolysis of streptamidine into its individual amino acid 
components, followed by derivatisation with Marfey’s reagent L-FDAA (Nα-(2,4-dinitro-5-
fluorophenyl)-L-alaninamide). The derivatised components could then be compared with 
L- and D- amino acid standards derivatised with the same reagent. As streptamidine 
derives from a ribosomal pathway, and there are no epimerases in the biosynthetic gene 
cluster, it would be expected that the component amino acids are present in L- form. The 
results of the Marfey’s analysis revealed that histidine, serine and threonine were indeed 
present in L- form. Alanine was also present in L- form, although there were traces of D-
alanine in the hydrolysed streptamidine sample. Interestingly however, leucine was 
detected in equal amounts of both L- and D- configuration (Figure 57), suggesting that 
streptamidine might exist in two isoforms.  
 
 
Figure 57: LC-MS analysis of Marfey's analysis of streptamidine. The top panel shows the hydrolysed 
streptamidine sample where constituent amino acids have been derivatised with Marfey's reagent. Below 
this are the LC-MS chromatograms obtained from derivatisation of individual amino acid standards of L- and 
D- amino acids. 
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The Marfey’s analysis was complicated by the observation of unusual adducts via LC-
MS: although histidine was detected as a proton adduct ([M+H]+, m/z 408.12), the other 
amino acids were detected as potassium and acetonitrile adducts ([M+K+MeCN]+) in 
both the amino acid standards and the hydrolysed sample. The structure of streptamidine 
with all amino acids in L- configuration is shown in Figure 58. 
 
 
Figure 58: Stereochemistry of streptamidine. Structures show configuration of streptamidine with L-amino 
acids. 
 
4.3.3.4. Spontaneous isomerisation of streptamidine 
The result of the Marfey’s analysis suggests that streptamidine exists as two isoforms, 
with epimerisation occurring on the leucine residue. This could explain why streptamidine 
was observed as two separate peaks by LC-MS analysis during previous metabolomic 
analysis (e.g. Figure 49). Interestingly, when streptamidine was analysed by NMR, 
additional signals could be observed in the spectra during the time period that NMR 
experiments were being carried out. A comparison of the proton spectra obtained before 
and after the long 2D experiments were carried out shows that additional proton signals 
are present in the second spectrum (Figure 59). This indicates that streptamidine might 
be spontaneously isomerising over time. Furthermore, the additional NMR signals are 
observed within the region of the leucine residue and amidine ring, supporting the idea 





Figure 59: Comparison of 1H NMR spectra before and after isomerisation of streptamidine. The red spectrum 
shows proton signals of the freshly purified metabolite, whereas the black spectrum shows proton signals 
after the metabolite has isomerised over time. Areas of the spectrum where additional proton signals are 
present are highlighted in green boxes. 
 
4.3.3.5. MicroED analysis of streptamidine 
In order to finally confirm the structural configuration of streptamidine, a “mixed isomer” 
sample of streptamidine has been submitted for a preliminary MicroED (microcrystal 
election diffraction) (348,349) analysis to be completed in November 2020 at the 
Diamond Light Source. Due to this approach of capturing single crystals of the metabolite 
on a grid, it is possible that this analysis may allow visualisation of one or both of the 
proposed streptamidine isomer structures, allowing final confirmation of the structure of 
streptamidine. 
 
4.3.3.6. Structures of streptamidine-related pathway metabolites 
As well as streptamidine, several other pathway-related metabolites were identified 
during the metabolomic screening described in Chapter 3. Once the structure of 
streptamidine had been elucidated, I could then look back at the other metabolites 
identified to see how they might be structurally related. In Chapter 3 (Figure 36), I 
showed that the four pathway-related metabolites (m/z 647.32, m/z 510.27, m/z 409.22 
and 338.18) all appear to be related based on similar fragmentation patterns and core 
peptide predictions. As such, the identified masses are likely to represent amidine-
containing peptides derived from HLSAT (m/z 510.27), HLSA (m/z 409.22) and HLS (m/z 
338.18) (Figure 60). The predicted structures of the HLSAT- and HLSA-derived 
metabolites are also supported by accurate mass data for the metabolites obtained on a 
Synapt G2Si (calculated m/z 510.2671, observed m/z 510.2668; calculated m/z 
409.2194, observed m/z 409.2195; Appendix Table 26). The common MS2 fragment 
ions observed from all four metabolites are annotated in Figure 61, which also support 
the proposed structures of these metabolites. The HLS-derived metabolite (m/z 338.18) 
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was not detected in sufficient intensity by high resolution LC-MS to obtain accurate mass 




Figure 60: A; Predicted structures of streptamidine-related metabolites. Structures were inferred from the 
elucidated structure of streptamidine as well as high resolution LC-MS2 data for the related metabolites. B: 






Figure 61: High-resolution LC-MS2 data for putative pathway-related metabolites. Data for m/z 647.32, m/z 
510.27 and m/z 409.22, obtained using a Waters Synapt G2Si. Common fragment ions are highlighted in 





4.3.3.7. Is streptamidine the final pathway product? 
The pathway-related metabolites identified and described above were repeatedly 
detected by LC-MS following several independent fermentations of S. coelicolor M1146-
pCAPSalbC and S. albus J1074. Although the largest metabolite identified was that of 
streptamidine (singly charged m/z 647.32), this hexapeptide represents a small core 
region in between both a follower and leader region of the precursor peptide. Although 
there are examples of RiPPs containing both follower and leader regions, we wondered 
whether there could be a larger pathway-related metabolite being produced that was not 
being detected during my LC-MS experiments. With this in mind, LC-MS samples of S. 
coelicolor M1146-pCAPSalbC and S. coelicolor M1146-pCAPSalbCΔamiA extracts were 
analysed by other mass spectrometers optimised for detection of larger peptides and 
proteins. This included a MALDI-TOF analysis (carried out by Carlo de Oliveira Martins) 
and a Synapt G2Si analysis followed by a comparative metabolomics analysis using 
Progenesis (carried out by Gerhard Saalbach). The results of these additional mass 
spectrometry analyses did not reveal any additional larger masses that might be 






4.3.4. Investigating the Biosynthesis of Streptamidine 
Following structural confirmation of streptamidine, I was interested to investigate the 
biosynthesis of the metabolite, and how this relates to the RiPP tailoring enzymes 
present in the biosynthetic pathway. As amidine rings are rare structural features, there 
is limited information about how these are biosynthesised in RiPPs. Furthermore, with 
the elucidation of a single post-translational modification, the roles of individual RiPP 
tailoring enzymes within the streptamidine pathway would be interesting to investigate. 
 
4.3.4.1. Biosynthetic shunt metabolites 
As discussed in Chapter 3, deletion of the dehydrogenase gene (amiE) led to increased 
production of three particular metabolites: m/z 272.16 (peptide A), m/z 314.17 (peptide 
B) and m/z 332.18 (peptide C) (Figure 62). As this gene deletion could be 
complemented, these metabolites were not produced as a result of polar effects of the 
deletion. I therefore hypothesised that these peptides could provide clues about the 
biosynthetic mechanism of amidine ring formation. Peptides A and B share a common 
MS2 fragment (141.01) observed by high-resolution LC-MS analysis (Appendix Figure 
103), suggesting that these metabolites are structurally related. The exact mass of 
peptide C (calculated m/z 332.1816, observed m/z 332.1818) indicated that it could 
correspond to an acetylated Leu-Ser-Ala tripeptide, which would be consistent with a 
region within the streptamidine core peptide. To confirm this, I obtained a synthetic 
standard of an N-acetylated LSA tripeptide, and compared its LC-MS trace to that of an 
extract of S. coelicolor-pCAPSalbCΔamiE. I also spiked the ΔamiE extract with the 
synthetic standard. The co-elution of peptide C at the same retention time in all three 
samples (observed as a sodium adduct m/z 354.16), indicated that this metabolite does 
indeed correspond to the LSA tripeptide (Figure 63). Based on this, I hypothesised 
putative structures for peptides A and B, whose masses could theoretically correspond 
to a dehydrated LSA peptide (peptide A, m/z 272.16) and an acetylated dehydrated LSA 
tripeptide (peptide B, m/z 314.17). I therefore proposed that the dehydration of this 
peptide could correspond to oxazoline heterocycle formation on the central serine 





Figure 62: Predicted structures of streptamidine-related shunt metabolites. Inferred from accurate mass 
data and the sequence of the streptamidine core peptide. Data obtained on the Shimadzu IT-TOF. 
 
 
Figure 63: LC-MS analysis of S. coelicolor M1146-SalbCΔamiE culture extract spiked with synthetic 
standard of N-acetylated LSA peptide. Extracted ion chromatogram of m/z 354.16 (orange) indicates 
expected mass of sodium adduct of N-acetylated LSA, and the fragmentation pattern supports this structure. 
This mass elutes in both samples at ~3.75 min, indicating that this same peptide is produced by the 
dehydrogenase mutant. Data obtained on a Shimadzu IT-TOF. 
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4.3.4.2. Biosynthetic mechanism of amidine formation 
The production of putative oxazoline-containing intermediates could suggest that an 
intermediate ring structure is formed prior to ultimate formation of the amidine ring. 
Interestingly, this parallels one of the possible biosynthetic mechanisms proposed by 
Travin et al for amidine ring formation in klebsazolicin (Figure 64), which occurs between 
Ser1 and Gln2 of the KlpA precursor peptide (205). While attempting to dissect amidine 
biosynthesis by site-specific mutagenesis of the precursor, Travin et al noticed an 
important role of the hydroxyl group on the side chain of Ser3: if this residue was mutated 
to any amino acid other than threonine, the amidine cycle is not produced. A biosynthetic 
mechanism was therefore suggested involving formation of an intermediary structure 
following attack of the side chain of Ser3 on the Gln2 carbonyl, before immediate attack 
from the N-terminal amine group causing rearrangement and ultimate formation of the 
amidine ring (205). Based on this, I proposed a similar biosynthetic mechanism for 
streptamidine (Figure 65).  
 
 






Figure 65: Proposed mechanism of amidine ring formation in streptamidine. Based on predicted 
intermediates produced by dehydrogenase mutant. The yellow box represents a route that goes via a stable 
oxazoline intermediate prior to leader/follower peptide removal, where AmiE potentially has a structural role 
within an AmiBDE complex for proper amidine formation but is not needed for initial ATP-dependent 
oxazoline formation. The green box represents a route where the leader/follower peptide is removed first, 
thereby providing a free N-terminal amine for cyclisation via an O-phosphorylated hemiorthoamide. In the 
absence of AmiE, the final amidine forming step could potentially be disrupted. 
 
4.2.4.3. Dissecting the roles of RiPP tailoring enzymes in streptamidine 
biosynthesis 
The gene deletion experiments described in Chapter 3 suggested that four RiPP tailoring 
enzymes in the streptamidine biosynthetic pathway were essential for biosynthesis of the 
metabolite, as deletion of their genes abolished production. These were the E1-like 
protein (AmiB), the hydrolase (AmiC), the YcaO-domain protein (AmiD) and the 
dehydrogenase (AmiE) (Chapter 3, Figure 42 Figure 43). 
 
4.2.3.3.i. Role of YcaO-domain protein AmiD and E1-like protein AmiB 
In klebsazolicin biosynthesis, a YcaO-domain protein catalyses amidine formation with 
cooperation from the E1-like partner protein. I therefore propose that AmiB and AmiD 
are responsible for amidine formation in streptamidine (Figure 65). Interestingly, YcaO-
domain proteins have been shown to be both mono- and bi-functional in their catalytic 
activity. In klebsazolicin biosynthesis, a single YcaO-domain protein (KlpD) catalyses 
both amidine ring and oxazoline heterocycle formation (205). In bottromycin 
biosynthesis, two distinct YcaO-domain proteins separately catalyse thiazoline formation 
(BtmE) and macroamidine formation (BtmF) (204,358). In streptamidine, an amidine ring 
is formed, but the presence of an unmodified threonine residue in the metabolite 
suggests that azoline heterocycle formation is not catalysed by AmiD. This protein might 
therefore be a mono-functional enzyme responsible only for amidine ring formation. The 
112 
 
amino acid sequence of YcaO-domain proteins can also give further clues about their 
catalytic activity. For example, Dunbar et al showed that azoline-forming YcaO-domain 
proteins contain a conserved PxPxP motif at the C-terminus. Truncation of these 
residues, or mutation of adjacent residues, led to abolished catalytic activity of BalhD, an 
azoline-forming YcaO from Bacillus sp. A1 (196). The C-terminus of the streptamidine 
YcaO protein AmiD has a sequence of PAPHM, which is similar but does not match the 
precise motif reported to be present in azoline-forming proteins. An alignment and MEME 
analysis of all the YcaO-domain proteins associated with the streptamidine-like gene 
clusters identified in Chapter 2 shows that the majority of these sequences have a 
conserved proline-rich LAPPPHM motif at the C-terminus (Figure 66). This suggests 
that a proline-rich region might also be important for amidine ring catalysis. 
 
 
Figure 66: MEME analysis of all streptamidine-like YcaO-domain proteins. The eight final residues at the C-
terminus of each YcaO-domain protein associated with streptamidine-like precursor peptides were submitted 
for analysis to determine whether a proline-rich sequence was abundant, which is characteristic of azole-
forming YcaO proteins. 
 
An alignment of YcaO protein sequences from several different RiPP pathways is shown 
in Figure 67, including examples of proteins involved in catalysis of azoline formation 
(KlpD, BmbD, TsrH, TruD and McbD), amidine formation (AmiD, KlpD and BmbE) and 
thioamide formation (TvaH). The key catalytic residues of YcaO-domain proteins are 
conserved across these sequences. As highlighted on the alignment figure, the C-
terminal PxPxP motif identified by Dunbar et al is present in azoline-forming YcaO 
proteins such as TsrH and TruD, but absent from the bi-functional klebsazolicin YcaO 
(KlpD) and the azoline-forming YcaO from the S. bottropensis bottromycin pathway 
(BmbD). This suggests that this proline-rich sequence motif might not be a precise 







Figure 67: Sequence alignment of YcaO-domain proteins involved in biosynthesis of diverse RiPP post-
translational modifications: AmiD from the streptamidine pathway, BmbD and BmbE from the bottromycin 
pathway, TsrH from the thiostrepton pathway, TvaH from the thioviridamide pathway, TruD from the 
patellamide pathway, KlpD from the klebsazolicin pathway and McbD from the microcin B17 pathway. 
Alignment produced using Muscle (264) and Espript (359). Key catalytic residues are highlighted in blue 





4.2.3.3.ii. Role of hydrolase enzyme AmiC 
The gene deletion experiments showed that deletion of AmiC abolishes production of 
streptamidine, and no additional metabolites were observed that gave clues about the 
function of this protein. However, the hydrolase should hypothetically responsible for 
removing the leader and follower peptide from the streptamidine core peptide. This 
should occur prior to amidine formation, as a free N-terminal amine on His1 is required 
for cyclisation with the Leu2 carbonyl (Figure 65).  
 
4.2.3.3.iii. Role of the dehydrogenase enzyme AmiE 
Although gene deletion experiments showed that the dehydrogenase is essential for 
streptamidine biosynthesis, it was unexpected that this enzyme should be required 
because of the lack of any oxidation in the metabolite. Due to overproduction of shunt 
metabolites in the ΔamiE mutant (Figure 62), it is possible that instead of a catalytic role, 
AmiE is fulfilling a key structural role for proper cyclisation activity. In order to assess 
whether AmiE is similar to other characterised azole-forming dehydrogenases, its 
sequence was compared with that of the dehydrogenase McbC, involved in biosynthesis 
of microcin B17 (Figure 64, analysis carried out by Andrew Truman). This revealed that 
the two proteins only share ~10% identity. However, Phyre2 (267) analysis indicated that 
AmiE has a HY motif that structurally aligns with the catalytic KY residues of McbC (360), 
indicating catalytic potential for AmiE (Figure 68). A possible explanation for the role of 
AmiE is that it is catalytic, but a reductase reverses this activity. Alternatively, AmiE could 
oxidise another part of the streptamidine precursor peptide that is hydrolysed from the 
streptamidine core region. In order to fully determine the role of this enzyme, further 






Figure 68: Secondary structure alignment of AmiE with McbC (PDB 6GOS) from the microcin B17 pathway 
generated with Phyre2 (267). Catalytic residues identified by Ghilarov et al. (360) in McbC are highlighted. 
 
4.2.4.4. Mutational analysis of streptamidine core peptide  
The data presented throughout this chapter show that an amidine ring is present between 
His1 and Leu2 of the streptamidine core peptide, possibly following a biosynthetic 
mechanism involving intermediate formation of an oxazoline ring on Ser3. To investigate 
this biosynthetic hypothesis further, I made a single base mutation of the streptamidine 
core peptide on the pCAPSalbC construct, changing the TCC (Ser3) codon to TGC 
(Cys3’). This was achieved by transforming a recombinogenic strain of E. coli HME68 
carrying pCAPSalbC with a long oligonucleotide containing the desired codon mutation 
(method described in section 6.4.6.). Colonies obtained following transformation were 
screened by PCR using primers that bind ~300 bp either side of the target codon (Figure 
69). Amplified DNA was then purified and sequenced to identify colonies containing a 
mixed population of wild type (TCC, Ser) and mutant (TGC, Cys) plasmid (Figure 70A). 
Plasmid DNA from colonies containing a mixed population was retransformed into E. coli 
DH5α cells, and the colonies obtained were screened for presence of a clean TCC to 





Figure 69: PCR screen of E. coli HME68-pCAPSalbC colonies transformed with a mutant oligonucleotide. 
Agarose gel image shows amplificaiton of the target DNA region containing the precrusor peptide gene from 
individual colonies.  
 
 
Figure 70: Sequence files obtained following PCR screen of colonies following mutagenesis of pCAPSalbC. 
A: Mixed plasmid population of “wild type” and mutant pCAPSalbC following transformation of E. coli HME68-
pCAPSalbC with mutant oligonucleotide. B: Single population of clean pCAPSalbCSer3Cys mutant obtained 
following transformation of mixed plasmid population into E. coli DH5α and screening of single colonies. 
 
The mutated pCAPSalbC construct (pCAPSalbCSer3Cys) was transferred into S. 
coelicolor M1146 for metabolomic screening with comparison to S. coelicolor M1146-
pCAPSalbC and S. coelicolor M1146-pCAPSalbCΔamiA. However, due to time 
constraints the metabolomic profiles of these strains have not been fully analysed. The 





4.3.5. Prevalence of Streptamidines in Nature 
As described in Chapter 2, homologues of the streptamidine biosynthetic gene cluster 
are widely distributed in nature, particularly in Actinobacteria. Some of the pathways 
contain identical biosynthetic machinery to streptamidine, and so will hypothetically 
produce an identical metabolite. Many of the gene clusters, however, harbour diverse 
genetic architectures and precursor peptide sequences. It is therefore likely that a suite 
of diverse, yet structurally related metabolites are produced by this novel gene cluster 
family. The gene clusters appeared to fall into two distinct subgroups, which correlated 
with the two sub-networks of precursor peptide sequences (Figure 71). After elucidating 
the structure of streptamidine, I could then compare the identified core peptide to that of 
similar precursor peptides (motif B). In total, I identified 11 variations of the core peptide 
sequence, from which I predicted the final structures of metabolites that might be 
produced by this gene cluster family (Figure 72). In all of the motif B-containing core 
peptides, the Ser3 residue is conserved, supporting the hypothesis that this residue plays 
an important role in biosynthesis. 
 
The precursor peptides containing motif A correspond to biosynthetic gene clusters that 
contain two YcaO-domain proteins. It is therefore probable that the RiPP metabolites 
produced by these pathways harbour at least two separate YcaO-catalysed post-
translational modifications. The fact that these precursor peptides are not rich in Ser, Thr 
or Cys residues is interesting, as these amino acids are usually transformed during 
YcaO-mediated catalysis such as azoline formation. It is therefore possible that one of 
these YcaO-domain proteins harbours unique catalytic potential. Many of the similar 
gene clusters also lack an encoded dehydrogenase, indicating that azole formation is 
unlikely. For this reason, it is difficult to predict what these structures might look like, and 
the pathways will require further characterisation. 
 
Following precursor peptide-based predictions, I was also interested to see if 
streptamidine-like metabolites could be detected from public mass spectrometry 
datasets. To achieve this, MASST was utilised to carry out a search of mass spectral 
databases (analysis carried out by Andrew Truman). Interestingly, this analysis identified 
a metabolite with identical mass and MS2 fragmentation to streptamidine in a marine 
actinomycete MS dataset collected by the Dorrestein lab (Figure 73), MassIVE 
MSV000078679). Although no further information could be found about the identity of 
this potentially related metabolite, this supports the idea that streptamidine-like gene 






Figure 71: Networks of streptamidine-like precursor peptides identified from RiPPER analysis, in relation to 
the genetic architecture of corresponding biosynthetic gene clusters. 
 
 
Figure 72: Putative structures of streptamidine-like metabolites based on variations of core peptide 




Figure 73: MASST analysis of streptamidine. Spectral match to the MS2 spectrum of [streptamidine+2H]2+ 
(m/z 324.16) identified using MASST (Mass Spectrometry Search Tool) (361) at GNPS (Global Natural 
Products Social Molecular Networking). The hit is found in multiple samples of MassIVE Dataset 
MSV000078679 (“Zhang lab_microbes library_MS130001~9”), which is defined as an actinomycete dataset. 





4.3.6. Biological Role of Streptamidines in Nature 
As streptamidine-related RiPPs are so widespread in nature, it is likely that they are 
playing an important biological or ecological role. Interestingly, klebsazolicin and 
bottromycin both act as antibiotics via ribosome inhibition. For both metabolites, the 
presence of the intact amidine ring has been shown to be essential for this activity, based 
on mutational studies of the biosynthetic machinery (129,204). This suggests that 
amidines might be an important structural feature for antimicrobial metabolites. With this 
in mind, I carried out a series of bioactivity assays with both pure streptamidine and with 
microbial extracts expressing the streptamidine gene cluster. 
 
4.3.6.1. Antimicrobial assays 
4.3.6.1.i. Assays with pure metabolite 
Pure streptamidine was used for diffusion assays to test for microbial inhibition (method 
described in section 6.5.3.1.). Plugs were taken out of agar plates that had been overlaid 
with a range of indicator strains (Table 3), and wells were filled with 50 µL streptamidine 
(1 mg/mL in H2O) alongside 50 µL of an appropriate positive control (kanamycin, 
apramycin or nalidixic acid (1 mg/mL)) and a negative control (H2O). For all strains 
tested, no inhibition was observed, whilst inhibition was observed from the positive 
control antibiotics (Figure 74). 
 
 
Figure 74: Bioassay plates generated during antimicrobial testing of streptamidine. Plugs were taken from 
agar plate overlaid with each indicator strain: S. scabies (A),  E. coli ATCC25922 (B), Pseudomonas 
fluorescens (C) and Bacillus subtilis 168 (D), which were then separately loaded with 50 µL streptamidine 
(1 mg/mL in H2O), 50 µL H2O as a solvent control and 50 µL of kanamycin (1 mg/mL) as a positive control. 
S1 and S2 represent two separate stocks of streptamidine from separate purifications. 
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4.3.6.1.ii. Competition assays 
As well as testing pure streptamidine, I also carried out competition assays by spotting 
an inoculum of indicator strains alongside S. albus J1074, S. albusΔamiCD, S. coelicolor 
M1146-pCAPSalbC and S. coelicolor M1146-pCAPSalbCΔamiA. This was to confirm 
whether streptamidine, or any other metabolite produced by strains expressing the 
biosynthetic gene cluster, might display inhibitory activity. However, there was no 
observable difference in inhibition between positive and negative controls (Figure 75). 
 
Table 3: List of microorganisms tested during bioactivity assays 
Organism tested Description 
Inhibition 
observed 
Escherichia coli ATCC25922 Gram-negative bacterium None 
E. coli NR986 
Gram-negative bacterium (mutant with 
increased membrane permeability) (362) 
None 
Pseudomonas aeruginosa PA01 Gram-negative bacterium None 
Pseudomonas fluorescens Gram-negative bacterium None 
Bacillus subtilis 168 Gram-positive bacterium None 
Micrococcus luteus Gram-positive bacterium None 
Mycobacterium smegmatis MC2155 Gram-positive bacterium None 
Streptomyces scabies Gram-positive bacterium None 
Streptomyces cattleya Gram-positive bacterium None 
Candida utilis Fungus None 
 
 
Figure 75: Bioassay plate generated during co-culture experiments. Extracts of S. albus J1074 and S. albus 
mutant were spotted on SM12 agar alongside extracts of a range of indicator strains to assess for 
antimicrobial activity of the streptamidine-producing strain. 
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4.3.6.2. Metal-binding assays 
Although antimicrobial activity testing was inconclusive, another interesting feature of 
streptamidine biosynthesis is the presence of iron transporters in the biosynthetic 
pathway. Gene deletion experiments showed that these were essential for the production 
of streptamidine. Based on this, it was possible that streptamidine might exhibit metal-
binding activity. To test for siderophore (iron-binding) activity, I first carried out a CAS 
assay (method described in section 6.5.3.2.). When mixing CAS solution with increasing 
concentrations of streptamidine, there was no observable colour change suggesting that 
streptamidine does not bind iron. To further test the hypothesis that streptamidine could 
bind metals, 20 µL streptamidine (15 mM) was separately mixed with 500 µL of a range 
of metal salts (FeCl3, CoCl2, CuCl2, MgCl2, MnSO4, NiSO4, ZnCl2; 10 mM) and the 
solutions were analysed by LC-MS to see whether any metal-bound complexes were 
formed, based on the appearance of masses that correspond to a putative metal-bound 
complex. This approach has been successfully used to identify metal-bound complexes 
of other natural product siderophores in our lab (Javier Santos-Aberturas, unpublished). 
However, upon LC-MS analysis, no metal-bound complexes of streptamidine could be 
observed. 
 
4.3.6.3. Developmental assays 
Aside from antimicrobial and metal-binding activity, it is also possible that streptamidine 
plays a more subtle biological role in signalling and development. When growing S. albus 
J1074 wild type and mutant in various media, there was no phenotypic difference 
between the two strain. However, I was interested to see whether there was any 
phenotypic difference in growth under different stress-induced conditions. In order to test 
this, I made variations of SM12 agar medium containing high levels of salt (250 mM NaCl 
and 500 mM NaCl) to test growth under osmotic pressure (Figure 76), as well as 
variations of SM12 agar at a range of pHs (pH 4, pH 5, pH 6, pH 7 and pH 8) to test 
whether growth is affected under more acidic conditions. For each condition, I created 
serial dilutions of S. albus J1074 and S. albusΔamiCD strains, which I spotted onto each 
agar test plate. After assessing growth over a period of 10 days, there did not appear to 
be any difference in growth between S. albus J1074 and S. albusΔamiCD under any of 





Figure 76: Spot assay plate generated during investigation of developmental effects of streptamidine. Serial 
dilutions of the two producing strains and two corresponding mutant strains were spotted onto SM12 agar 
containing a high salt concentration (500 mM NaCl) to assess whether streptamidine contributed any 
protective effect in comparison to the negative controls. 
 
 
4.4. Chapter Summary 
 
The work described in this chapter shows the characterisation of one member of a large 
related RiPP family. Streptamidine is a novel RiPP metabolite containing a structurally 
rare N-terminal amidine ring, which has previously only been characterised in the RiPPs 
klebsazolicin and bottromycin. Analysis of shunt metabolites and investigation of 
individual biosynthetic proteins within the streptamidine biosynthetic gene cluster 
allowed for predictions to be made about the roles of each of these RiPP tailoring 
enzymes in biosynthesis of streptamidine. Analysis of precursor peptide homologous 
with diverse core peptide sequences also highlighted that there are likely to be several 
analogues of streptamidine-like metabolites produced by diverse Actinobacteria. 
Although the bioactivity of this metabolite could not be determined through the 
experiments carried out, the widespread nature of this RiPP family suggest an important 
biological role for the producing species. Overall, this work suggests that amidine-
containing RiPPs are much more prevalent than previously appreciated, and further 
investigation of this novel RiPP family will help shed light on the biosynthesis, structure 








5.1. Genome Mining for RiPPs 
 
5.1.1. Streptamidine Discovery 
The discovery of streptamidine was a result of utilising a tailored gene-led genome 
mining tool for RiPP natural products, searching for novel pathways containing the RiPP 
tailoring YcaO-domain enzymes. The success of this genome mining analysis in 
unveiling hundreds of previously uncharacterised biosynthetic gene clusters, including 
that of streptamidine which harbours a rare structural feature, demonstrates that bespoke 
RiPP genome mining is a promising approach for the discovery of structurally novel 
natural products in the future. It is particularly interesting that this gene cluster was 
discovered from strains such as S. albus J1074, whose metabolic capacity has been well 
studied (299,300) and yet streptamidine has not been previously reported. This suggests 
that genome mining has the potential to unveil many more biosynthetic gene clusters for 
natural products from both well-characterised species as well as from underexplored 
genera.  
 
5.1.2. Future Work with RiPPER and YcaO-containing Pathways 
Streptamidine is just one exemplar from a large family of novel RiPP metabolites. This 
thesis focused on the characterisation of this particular biosynthetic gene cluster in detail, 
but it would be interesting to investigate the products of related biosynthetic gene clusters 
in the future. It is particularly interesting that a group of homologous pathways contained 
two YcaO-domain proteins, suggesting that the resulting RiPPs contain additional post-
translational modifications that might correspond to further structural novelty. 
Considering YcaO-domain proteins, the RiPPER analysis presented in Chapter 2 
mapped a significant number of these enzymes to previously uncharacterised 
biosynthetic gene clusters, but the genetic context of many YcaO-domain proteins still 
remains uncharacterised. Therefore, further analysis of these enzymes could reveal 
even more biosynthetic and structural diversity. Attempts to study one of the identified 
biosynthetic gene clusters related to streptamidine from Rhodococcus erythropolis were 
carried out but early work was disrupted by the Covid-19 pandemic. As well as YcaO-
domain proteins, RiPPER could also be used in the future to identify novel precursor 
peptides associated with a range of other RiPP tailoring enzymes used as the protein 
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‘bait’. Based on the large amount of untapped diversity we identified from our analysis of 
Actinobacterial YcaO-domain proteins, it is highly likely that further analyses with 
RiPPER will uncover a vast number of other previously uncharacterised RiPPs. This in 
turn will help identify novel metabolites with potentially novel biochemical features. 
 
 
5.2. Pathway Cloning and Engineering 
 
5.2.1. Cloning and Genetic Manipulation 
The streptamidine biosynthetic gene cluster was characterised after TAR cloning and 
heterologously expressing the pathway from S. albus J1074, and the native producer 
was also genetically manipulated to investigate pathway-related metabolism (described 
in Chapter 3). Although the streptamidine pathway was successfully cloned using TAR 
cloning, the process was challenging and yielded a high number of false-positive 
colonies despite the use of 5-FOA-based selection. The technique has also proved 
difficult for several other natural product gene clusters (personal communication from the 
lab group and other researchers at conferences). Further optimisation of this method 
may therefore be required to enable efficient cloning of gene clusters in the future, or 
other more recently developed methods could also be used, such as Cas9-assisted 
targeting of chromosome segments (CATCH) (327) or direct pathway cloning (DiPaC) 
(322). In the native producer of streptamidine (S. albus J1074), a homologous 
recombination-based disruption was carried out to produce a pathway mutant. Although 
this approach yielded complementary results to heterologous expression of the pathway, 
cleaner deletions of biosynthetic gene clusters could also be made using approaches 
such as CRISPR-Cas9-based genome editing. This particular approach is being 
increasingly improved for work in Streptomyces species (317,363). Individual gene 
deletions were successfully created within the TAR cloned streptamidine pathway using 
PCR-targeting (309), which is an efficient method for genetic deletions from plasmids. In 
order to study gene clusters in their native context, another alternative approach could 
be the use of CRISPR interference (CRISPRi) (364) to silence individual genes in the 
genomes of native producers of a gene cluster. 
 
5.2.2. Synthetic Biology 
RiPP gene clusters are highly amenable to synthetic biology approaches due to their 
biosynthetic logic. This has been demonstrated in this thesis for example, with the 
mutation of core peptide amino acids using mutant oligonucleotide-directed mutagenesis 
via the mutS-deficient strain E. coli HME68. Core peptide mutations could also be 
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introduced by expressing a mutant copy of the precursor gene in the pCAPSalbCΔamiA 
mutant in an expression vector such as pIJ10257. However, as I was not able to 
successfully genetically complement this deletion with the native gene, I chose to utilise 
this alternative approach to mutagenesis. Previous work in our lab group has also 
demonstrated the use of yeast-mediated pathway refactoring to generate alternative 
metabolites related to a target RiPP such as bottromycin (331). Other RiPP families have 
also been subject to core peptide mutagenesis to generate analogues of the native 
metabolites. For example, Young et al utilised single-site mutagenesis for codon 
randomisation in thiopeptides (365) and Ruffner et al employed multiple site sequence 
randomisation to mutate the core peptide of the cyanobactin trunkamide (366). Similarly, 
a library of lanthipeptide analogues was created by Yang et al which helped to identify 
an inhibitor of protein-protein interactions (367). Together, genetic engineering and 
synthetic biology approaches can be seen as a chemical toolbox to help produce a range 
of ‘unnatural’ RiPP natural products. It was suggested by Travin et al, who discovered 
the antibiotic RiPP klebsazolicin, that it could be possible to rationally design hybrid 
antibiotics containing a common ribosome-targeting ‘warhead’, with variable uptake 
structures that control the specificity of the mode of action (129). Overall, there is exciting 
potential for the use of synthetic biology to engineer and alter RiPP pathways in order to 
produce alternative structures and improved bioactivity of natural products. 
 
 
5.3. Structure and Biosynthesis of Streptamidine 
 
5.3.1. Importance of Amidines in Nature 
As shown in Chapter 4, streptamidine harbours a structurally rare amidine ring. As well 
as the RiPP antibiotics klebsazolicin and bottromycin (129,146), a handful of other non-
RiPP amidine-containing metabolites with diverse bioactivities have also been reported 
from nature (Figure 77). Efrapeptins are a group of peptides containing bicyclic amidines 
(368) that are produced by the soil hyphomycete fungus Tolypocladium niveum (369) via 
an NRPS pathway (370). Efrapeptins display antifungal and insecticidal activity (371) 
and have also been shown to inhibit mitochondrial ATPase (372). A group of structurally 
similar metabolites called neoefrapeptins have also been reported, which are produced 
by the fungus Geotrichum candidum (368). These peptides also contain a bicyclic 
amidine at the C-terminus and display insecticidal activity (373). Other amidine-
containing metabolites include ectoine, which contains a six-membered amidine (368) 
and is produced by several species of halophilic bacteria. L-aspartate-β-semialdehyde 
and L-glutamate are converted into ectoine via the intermediates 2-oxoglutarate and L-
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2,4-diaminobutyrate (374). Ectoine acts as a protectant against osmotic and cold stress 
(375). Pyrostatins are metabolites produced by Streptomyces sp. SA-3501 that were 
originally reported to contain a five-membered amidine and inhibit N-acetyl-beta-D-
glucosaminidase (376). This was recently refuted however, and a comparison of NMR 
data suggested that pyrostatins A and B are structurally identical to 5-hydroxectoine and 
ectoine respectively (377). Flustramine C is a marine natural product isolated from the 
bryozoan Flustra foliacea, which contains an amidine moiety within a brominated 
pyrroloindole structure (378). Several possible pathways have been suggested for the 
biogenesis of flustramine C via prenylation of the precursor deformylflustrabromine 
(379). Flustramine C is secreted from bryozoa into surrounding water and is thought to 
play an important role in ecological interactions (378), or to control bacterial growth on 
the surface of bryozoa (368). As well as the bioactivities of these metabolites, amidines 
may also play important roles in nature in the control of basicity, coordination and as a 
source of nitric oxide (368).  
 
 
Figure 77: Chemical structures of amidine-containing metabolites: efrapeptin C, ectoine, pyrostatin A and 
flustramine C, alongside the RiPPs bottromycin, klebsazolicin and streptamidine. 
 
5.3.2. Bioactivity of Streptamidine 
One major limitation of genome mining for natural products is that there is no guarantee 
that an identified biosynthetic gene cluster will produce a metabolite with a particular 
bioactivity. This has been highlighted in this thesis, as the biological function of 
streptamidine was not determined from the bioactivity assays that were carried out. As 
discussed, characterised examples of amidine-containing metabolites are known to 
exhibit a range of important biological functions, and it is possible that streptamidine is 
playing an important biological role that was overlooked during this research. The 
bioassay experiments presented in this thesis do not represent an exhaustive list of 
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possible bioactivities, and this could therefore be further investigated in the future. For 
example, insecticidal, antiplasmoidal and antiviral activities were not tested for, and there 
could be other developmental or signalling roles of streptamidine that are more difficult 
to determine under laboratory conditions. It is also possible that streptamidine displays 
narrow-spectrum antimicrobial activity, and that the range of indicator strains tested were 
not sufficient to detect this activity. The amidine-containing RiPPs bottromycin and 
klebsazolicin inhibit bacterial ribosomes, therefore it would be interesting to probe 
whether streptamidine has any specific ribosome-interfering activity. This could be tested 
using an in vitro reporter assay such as that used by Travin et al during investigation of 
klebsazolicin activity (129). A limitation of carrying out extensive bioactivity assays is that 
a large amount of pure metabolite is required. Streptamidine was difficult to purify in high 
quantities, therefore there was not a sufficient amount of pure metabolite to submit for 
wide-scale activity screening. 
 
5.3.3. Biosynthesis of Streptamidine 
In Chapter 4, a biosynthetic mechanism of streptamidine was proposed, based on results 
from gene deletion experiments and comparison of biosynthetic machinery in known 
RiPPs. As amidine-containing RiPPs are rare, further confirmation of streptamidine 
biosynthesis would be interesting to investigate. An avenue of research that was not fully 
explored during this thesis is the biochemical characterisation of proteins involved in the 
biosynthetic pathway. Expression and purification of individual proteins could give in vitro 
evidence that the precursor peptide and tailoring enzymes function together to produce 
streptamidine, and to determine the order of biosynthetic steps. Mutational analysis of 
key residues and analysis of interactions with the precursor peptide could also be carried 
out in the future. Unfortunately, a problem commonly occurred within the field is that 
YcaO-domain proteins are often insoluble and challenging to purify, making it difficult to 
study their biochemistry (personal communication within the lab group and other 
researchers). Further limitations of in vitro work are that reaction conditions might be too 
dissimilar to natural biosynthesis in vivo. For example, additional unknown co-factors 
might be required for certain enzymes to function, which could mean that the natural final 
product is not properly produced. Individually purified enzymes would also be present at 
a much higher concentration compared with natural conditions and might therefore 
behave in unusual ways. However, it would be interesting to complement the work 








Overall, the work presented in this thesis demonstrates how a novel genome mining 
approach was utilised to unveil a large family of previously unknown RiPP metabolites 
from Actinobacteria, highlighting that we are still scratching the surface of the huge 
biosynthetic capabilities of microorganisms. The use of cloning and genetic tools led to 
the identification and characterisation of a structurally rare amidine-containing metabolite 
from S. albus J1074 and allowed biosynthetic proposals to be made. Future work 
investigating the biosynthesis and bioactivity of streptamidine, along with genome mining 
for further RiPP pathways, will help to increase our understanding about how these 
fascinating natural products are biosynthesised in nature, and why they are produced so 
widely in the microbial world. Furthermore, the use of amidine-containing metabolites as 
novel medicinal agents such as antibiotics represents an exciting potential for 
streptamidine and related RiPPs in the future, which is particularly important at a time 










Table 4: Strains used during study. 




MATα, his3-Δ1, trp1-Δ1, ura3-Δ1, lys2, 
ade2-101, met14 ciro 
TAR cloning 
E. coli DH5α (Invitrogen) F− ϕ80 lacZΔM15 Δ(lacZYA-
argF)U169 recA1 endA1 hsdR17 (rk−, 






dam-13::Tn9 dcm-6 hsdM CmlR, 
carrying helper plasmid pUZ8002 
Conjugations involving 
ApraR constructs 
E. coli ET12567/pR9604 
(381) 
dam-13::Tn9 dcm-6 hsdM CmlR, 
carrying helper plasmid pR9604 
Conjugations involving 
KanR constructs 
E. coli DH5α/BT340 
(309) 
E. coli DH5α carrying BT340 plasmid. Gene deletions 
E. coli BW25113/pIJ790 
(309) 
(Δ(araD-araB)567, ΔlacZ4787(::rrnB-
4), lacIp-4000(lacIQ), λ-,rpoS369(Am), 
rph-1, Δ(rhaD-rhaB)568, hsdR514. 
Plasmid: pIJ790 [oriR101], 
[repA101(ts)], araBp-gam-be-exo 
Gene deletions 
E. coli HME68 (382) W3110 galKtyr145UAG ΔlacU169 [λ 
cI857 Δ(cro-bioA)] ΔmutS 
Mutagenesis of core 
peptide amino acids 
Streptomyces albus 
J1074 (337) 
Restriction-defective derivative (R-M-) 
of S. albus G 




Δact Δred Δcpk Δcda Heterologous 
expression of gene 
cluster 
Streptomyces laurentii Wild type Heterologous 
expression of gene 
cluster 
Streptomyces lividans Wild type Heterologous 





Table 5: Streptomyces strains constructed during study. 
Strain Description Application 
Streptomyces albus 
J1074ΔamiCD 
S. albus J1074 pathway mutant with 
disrupted hydrolase and YcaO genes 
Comparison with 
S. albus J1074 
‘wild type’  
Streptomyces lividans-
pCAPSalbC 
S. lividans carrying cloned gene 
cluster from S. albus J1074 
Heterologous 




S. laurentii carrying cloned gene 
cluster from S. albus J1074 
Heterologous 




S. coelicolor M1146 carrying cloned 
gene cluster from S. albus J1074 
Heterologous 




S. coelicolor M1146 carrying S. albus 






S. coelicolor M1146 carrying S. albus 





S. coelicolor M1146 carrying S. albus 





S. coelicolor M1146 carrying S. albus 





S. coelicolor M1146 carrying S. albus 






S. coelicolor M1146 carrying S. albus 






S. coelicolor M1146 carrying S. albus 






S. coelicolor M1146 carrying S. albus 






S. coelicolor M1146 carrying S. albus 





S. coelicolor M1146 carrying S. albus 
J1074 BGC with combined 







S. coelicolor M1146 carrying S. albus 
J1074 BGC with peptide methionine 





S. coelicolor M1146 carrying S. albus 







S. coelicolor M1146 carrying S. albus 
J1074 BGC with complemented E1-





S. coelicolor M1146 carrying S. albus 






S. coelicolor M1146 carrying S. albus 
J1074 BGC with complemented 




S. coelicolor M1146 carrying S. albus 
J1074 BGC with mutated core peptide 

















ARSH4/CEN6-Trp1, pUC ori, C31 
int-attP-oriT-aph, URA3, ADH1 









oriT, non-conjugative, flippase 
recognition target (FRT) sites 
Apramycin 
Gene deletions via 
PCR targeting 









pSalbCAP Kanamycin Capture vector for TAR cloning of streptamidine BGC 
pCAPSalbC Kanamycin Vector containing the TAR cloned streptamidine BGC 
pCAPSalbCΔamiA Kanamycin pCAPSalbC with deletion of precursor peptide gene 
pCAPSalbCΔamiD Kanamycin pCAPSalbC with deletion of YcaO gene 
pCAPSalbCΔamiB Kanamycin pCAPSalbC with deletion of E1-like gene 
pCAPSalbCΔamiE Kanamycin pCAPSalbC with deletion of dehydrogenase gene 
pCAPSalbCΔamiC Kanamycin pCAPSalbC with deletion of hydrolase gene 
pCAPSalbCΔamiX Kanamycin pCAPSalbC with deletion of oxidoreductase gene 
pCAPSalbCΔamiT1-2 Kanamycin 
pCAPSalbC with deletion of set of ABC transporter 
genes 
pCAPSalbCΔamiF1-4 Kanamycin 
pCAPSalbC with deletion of set of iron transporter 
genes 
pCAPSalbCΔPM Kanamycin pCAPSalbC with deletion of peptidyl methionine gene 
pCAPSalbCΔOxyg Kanamycin pCAPSalbC with deletion of oxygenase gene 
pCAPSalbCΔAT Kanamycin 
pCAPSalbC with deletion of both acetyltransferase 
genes 
pCAPSalbCSer3Cys Kanamycin pCAPSalbC with core peptide Ser3 to Cys3 mutation 
pKCΔamiCD Apramycin 
Construct for disruption of S. albus BGC in native 
host 
pIJamiD Hygromycin Construct for complementation of YcaO deletion 
pIJamiB Hygromycin Construct for complementation of E1 deletion 
pIJamiE Hygromycin 




6.1.3. Chemicals and Media 
Unless otherwise stated, all chemicals and media components were purchased from 
Sigma Aldrich, except for the following: agar (Melford), NaCl, glucose and sorbitol (Fisher 
Scientific), yeast extract (Merck), soya flour (Holland and Barrett) and peptone (BD 
Biosciences). Ultrapure water was obtained using a Milli-Q purification system (Merck). 
All media and was autoclaved prior to use and chemical solutions were filter sterilised 
using a 0.22 µM syringe filter. 
 
Table 8: Antibiotics used during study. 
Antibiotic Solvent Final concentration 
Kanamycin Water 50 µg/mL 
Apramycin Water 50 µg/mL 
Carbenicillin Water 50 µg/mL 
Chloramphenicol Ethanol 25 µg/mL 
Nalidixic acid Water 25 µg/mL 
Hygromycin PBS (phosphate-buffered saline) 50 µg/mL 
 
 
Table 9: Solutions used for TAR cloning. 
Solution Ingredients per 100 mL, made up with milliQ H2O 
10x nitrogen bases 1.9 g YNB-AA, 1.9 g CSM-Trp, 5 g NH4SO4 
100x adenine 1 g adenine, 74 mM HCl 
SPE 10 mM HEPES buffer pH 7.5, 100 mM EDTA pH 8, 18.2 g sorbitol 
SOS 15 mM CaCl2, 0.25 g yeast extract, 18.2 g sorbitol, 1 g peptone 
STC 10 mM Tris/HCl pH 7.5, 10 mM CaCl2, 18.2 g sorbitol 
PEG 10 mM Tris/HCl pH 7.5, 10 mM CaCl2, 20 g PEG8000 
 
 
Table 10: Buffers used during study. 
Buffer Ingredients, made up with milliQ H2O 









Table 11: Media used during study. 
Medium Application 
Ingredients per 1 L, made up with milliQ 
H2O 
LB (lysogeny broth) E. coli, culture 
10 g Bacto-tryptone, 5 g yeast extract, 10 
g NaCl, adjusted to pH 7 with NaOH 
L (lennox) broth E. coli, culture 
10 g tryptone, 5 g yeast extract, 5 g NaCl, 
1 g glucose (John Innes Centre recipe) 
DNA (difco nutrient 
agar) 
E. coli, culture 4 g Difco Nutrient Broth powder, 10 g agar 
SOB 
E. coli, preparation of 
electrocompetent cells 
20 g tryptone, 5 g yeast extract, 0.58 g 
NaCl, 0.186 g KCl, 2.03 g MgCl2.6H2O, 
2.46 g MgSO4.7H2O 
SOC 
E. coli, chemical 
transformation of cells 
20 g tryptone, 5 g yeast extract, 0.58 g 
NaCl, 0.186 g KCl, 2.03 g MgCl2.6H2O, 




16 g tryptone, 10 g yeast extract, 5 g 
NaCl, adjusted to pH 7.4 with NaOH 
TSB (tryptic soy 
broth) 
Streptomyces, culture 
17 g tryptone, 3 g phytone, 5 g NaCl, 2.5 
g K2HPO4, 2.5 g glucose  




20 g mannitol, 20 g soy flour, 100 mM 
CaCl2, 20 g agar 
YPD (yeast peptone 
dextrose) 
Saccharomyces, culture 
10 g yeast extract, 20 g peptone, 20 g 





5 g (NH4)2SO4, 1.7 g YNB-AA, 20 g 
glucose, 0.74 g CSM-Trp (20 g agar), 
0.004% adenine 
Top selective agar 
Saccharomyces, TAR 
cloning selection 
182 g sorbitol, 22 g dextrose, 30 g agar, 





182 g sorbitol, 22 g dextrose, 20 g agar, 




103 g sucrose, 0.25 g K2SO4, 10.12 g 
MgCl2.6H2O, 10 g glucose, 0.1 g 
casamino acids, 2 mL trace element 






10 g soy flour, 50 g glucose, 4 g peptone, 
4 g beef extract, 1 g yeast extract, 2.5 g 








10 g glucose, 20 g soy peptone, 5 g meat 
extract, 5 g NaCl, 0.01 g ZnSO4.7H2O, 






15 g starch, 5 g yeast extract, 10 g soy 
flour, 5 g NaCl, 3 g CaCO3, 25 μg/mL 
CoCl2 
MacConkey agar  
E. coli, mutagenesis 
red/white selection 
17 g peptone, 3 g protease peptone, 10 g 
lactose monohydrate, 1.5 g bile salts, 5 g 
NaCl, 0.03 g neutral red, 0.001 g crystal 






All primers were ordered from Eurofins Genomics or Integrated DNA Technologies (IDT) 
and purified by HPSF. Screening primers were ordered with a synthesis scale of 0.01 
µmol and longer oligonucleotides for PCR targeting and capture vector construction were 
ordered with a synthesis scale of 0.05 µmol. Oligonucleotides for precursor peptide 
mutagenesis were ordered as 4 nmol ‘ultramers’ from IDT. 
 
Table 12: Primers used during study. Restriction enzyme cut sites are underlined. 




















Salb_ClusScr_Fw GCAGGACGGAACCGAGGGATG Screening for 
cluster capture 
 











































































































































































































pIJ10257_Fw TTCGAGTGGCGGCTTGCG Screening for 
pIJ10257 insert 
 
pIJ10257_Rv CAAACGGCATTGAGCGTCAGC  Screening for 
pIJ10257 insert 
 
PPDel_screen_Fw GCGGCTGGCCGGTCTGTTAC Screening 
precursor peptide 
gene deletion  
 
PPDel_screen_Rv CGGCTGCTGGTCACGGAAACC  
CyclDel_screen_Fw GGTGCCGCGGACGACAAGTAG Screening E1-like 
gene deletion  
 
CyclDel_screen_Rv GTCGTACGGGGTGCGGATCAG  
YcaODel_screen_Fw ACCAGGCTGCGCGTCGAGA Screening YcaO 
gene deletion  
 
YcaODel_screen_Rv AGGTGGTCGAGGTCGACGGG  




HydrDel_screen_Rv GTGCCGAGCGAGACCCGGT  
DehyDel_screen_Fw TCGACCTGACCACCGAGGACG Screening 
dehydrogenase 
gene deletion  
 
DehyDel_screen_Rv ACCAGGGCGAGCAGGGCG   
OxidoDel_Screen_Fw CATCCCTCGGTTCCGTCCTG Screening 
oxidoreductase 
gene deletion  
 
OxidoDel_Screen_Rv AGCACCCTGATCCGGCTGAC  




Salb_oxyg_scr_Rv GAAAGGCCCAGCTGGGCGTC  
140 
 




Salb_IronTr_scr_Rv GAACGGCGTGGCGACTGCC  




Salb_ABCTr_scr_Rv GTGCGTGCGCGTGTACGCAC  






Salb_PepMet_scr_Rv CGCATGTCGATGCCAGTCGG  




Salb_acet_scr_Rv GGCCCCCTTCGCGTGTACG  
MarR_screen_Fw TCAGCCCGACCGGTCCTG Screening MarR 
deletion 
 













SalbPPmut_FWScr GCCGAAGTGCTGGGTGTCGAG Screening core 
peptide mutation 
 






6.2. General Methods 
 
6.2.1. E. coli 
6.2.1.1. Growth and maintenance 
Unless otherwise specified, E. coli cells were grown in solid or liquid LB medium at 37 
°C. ‘Overnight’ cultures and incubations were carried out for 16-18 hours or until colonies 
were visible on agar plates. Colonies on agar plates were stored at 4 °C and liquid culture 
stocks were stored in 50% glycerol at both -20 °C and -80 °C. 
 
6.2.1.2. Transformation 
Plasmid and single stranded DNA fragments were transformed into recipient E. coli cells 
via either chemical or electrical transformation, as stated in each protocol. 
 
6.2.1.2.i. Chemical transformation 
2-5 µL of DNA was used to transform 50-100 µL chemically competent cells. Cells mixed 
with DNA were incubated on ice for 2 minutes before being heat shocked for 45 seconds 
at 42 °C in a water bath. Cells were then immediately transferred back to ice for 2 minutes 
before adding 300 µL SOC medium. Cells were then incubated for 1 hour at 37 ˚C with 
shaking at 250 rpm. Between 100 µL-300 µL cell culture were then spread on LB agar 
plates with appropriate antibiotic selection. 
 
6.2.1.2.ii. Making electrocompetent cells 
Unless otherwise stated, electrocompetent cells were made as follows: a single colony 
or 30 µL of the desired cell stock was inoculated into 10 mL LB + 10 µL of the appropriate 
antibiotic and grown overnight at 37 °C with shaking at 250 rpm. 200 µL of the overnight 
culture was then used to inoculate 15 mL LB in a 50 mL Falcon™ tube + 15 µL of the 
appropriate antibiotic selection and grown at 37 °C until the OD600nm reached between 
0.2-0.4. Cells were harvested by centrifugation at 4,500 × g in a Sorvall® Biofuge primo 
centrifuge for 5 minutes at 4 °C and pellets were resuspended in 30 mL ice cold 10% 
glycerol. This step was repeated two more times, resuspending the pellets in 15 mL and 
1 mL of 10% ice cold glycerol successively. 50 µL aliquots were transferred into 
microcentrifuge tubes and stored at -80 °C or used immediately for transformation. 
 
6.2.1.2.iii. Electroporation 
If previously prepared and stored at -80 °C, the vial of electrocompetent cells was thawed 
on ice for 3 minutes. 1-1.5 µL of DNA was added to 50 µL electrocompetent cells which 
were then transferred into a 2 mm electroporation cuvette. The outside of the cuvette 
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was dried, and it was inserted into a Bio-Rad Gene Pulser™ with the pulse generator set 
to 25 μFD, 2.5 kV, and 200 Ω. The pulse was delivered, and the cuvette was immediately 
placed on ice before adding 1 mL cold LB. The cells were transferred back to a 
microcentrifuge tube and were incubated for an hour at 250 rpm, 37°C. Between 200 µL-
1 mL of the transformation mix was then spread on LB agar plates with appropriate 
antibiotic selection and grown overnight at 37°C. 
 
6.2.1.3. Triparental mating 
Individual 10 mL cultures of cells carrying a plasmid to be transformed and target 
recipient cells were grown overnight in the appropriate conditions. 20 µL of each culture 
were then spotted together on an LB plate with no selection and grown at the appropriate 
temperature for four hours. The resulting patches of cells were picked with an inoculation 
loop and streaked onto an LB plate containing the appropriate antibiotic selection and 
incubated overnight at 37°C to obtain single colonies. 
 
6.2.1.4. Plasmid isolation 
Single colonies were picked and inoculated into 10 mL LB containing appropriate 
antibiotic selection and grown for 16 hours at 37 ˚C with shaking at 250 rpm. Cultures 
were then centrifuged for 5 minutes at 1,538 × g in an Eppendorf Centrifuge 5810. 
Plasmid DNA was then extracted using a Promega Wizard Plus SV Minipreps DNA 
Purification System, following the corresponding protocol. DNA was eluted in 50 µL H2O.  
 
6.2.2. Streptomyces Species 
6.2.2.1. Growth and maintenance 
Unless otherwise specified, all Streptomyces strains were grown at 28 °C in solid SFM 
for spore growth, solid SFM supplemented with 10 mM MgCl2 for conjugations, liquid 
TSB for seed cultures and liquid SM12 media for fermentations. Other media used during 
screening trials include liquid R5, BPM and SM14 (Table 11). Liquid cultures were grown 
at 28 °C with shaking at 250 rpm. Spores and mycelium stocks were kept at −20 °C and 
−80 °C in 20% glycerol. 
 
6.2.2.2. Genomic DNA extraction 
For genomic DNA extraction from Streptomyces species, cultures were prepared by 
inoculating 40 µL of spores from concentrated stocks in 50 mL TSB contained in 250 mL 
flasks with springs. Cultures were grown for 48 hours at 28 ˚C with shaking at 250 rpm. 
30 mL of each culture was centrifuged for 5 minutes at 1,538 × g in an Eppendorf 
Centrifuge 5810. Cell pellets were washed twice by resuspending in 5 mL H2O and 
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centrifuging for 5 minutes at 1,538 × g in an Eppendorf Centrifuge 5810. Mycelial pellets 
were stored at -30 ˚C overnight and then resuspended in 5 mL SET buffer (Table 10) 
with 100 µL lysozyme (50 mg/mL in H2O) and incubated for 30 minutes at 37 ˚C. 
Following this, 140 µL proteinase K (20 mg/mL in H2O) and 600 µL SDS (10% solution 
in H2O) was added and mixed before incubating for 2 more hours at 55 ̊ C with occasional 
inversion. 2 mL of 5 mM NaCl was then added before cooling the suspension to 37 ˚C. 
5 µL of chloroform was then added and the suspension was slowly mixed for 30 minutes 
at 20 ˚C. Cells were then centrifuged for 15 minutes at 4,500 × g in a Sorvall® Biofuge 
primo centrifuge at 4 ˚C. The supernatant was slowly extracted into a fresh tube to which 
2 mL H2O and 5 mL chloroform was added. This was then centrifuged for 15 minutes at 
4,500 × g at 4 ˚C. The supernatant was transferred to a fresh tube to which 6 mL 
isopropanol was added and incubated for 5 minutes at room temperature. The DNA was 
then spooled with a sealed glass pipette and inoculated into 500 µL 70% ethanol. The 
ethanol was then extracted, and the DNA was left to air dry overnight before 
resuspending in 1 mL of H2O. 
 
6.2.2.3. Conjugation 
Transfer of DNA from E. coli to Streptomyces cells was achieved via intergenic 
conjugation. Target DNA was first transformed into E. coli ET12567 cells containing a 
helper plasmid (pUZ8002 (KanR) or pR9604 (CarbR)). Single colonies were then picked 
to inoculate a 10 mL LB culture containing selective antibiotics for the donor strain, helper 
plasmid and incoming plasmid, which was grown overnight at 37 °C. 200 µL of the 
overnight culture was then used to inoculate a fresh LB culture containing the selective 
antibiotics, which was grown for approximately 4 hours at 37 °C. The E. coli cultures 
were then centrifuged for 5 minutes at 1,538 × g in an Eppendorf Centrifuge 5810, the 
supernatant removed, and the cell pellets resuspended in 1 mL LB. Cells were then 
transferred to a 1.5 mL Eppendorf tube and centrifuged for 1 minute at 7,900 x g in an 
Eppendorf Centrifuge 5424 R. This wash step was repeated once more, before 
resuspending the final cell pellet in 150 µL LB. Meanwhile, 30 µL of a concentrated stock 
of Streptomyces spores was mixed with 30 µL 2xYT medium and heat shocked for 10 
minutes at 50 °C in a water bath. Once cooled, the spores were mixed with the E. coli 
cells and 150 µL of the suspension was spread onto SFM agar plates containing 10 mM 
MgCl2. These plates were incubated at 28 °C for 16-18 hours and each overlaid with 1 
mL sterile H2O containing 33 µL nalidixic acid and 33 µL of the selective antibiotic. Once 
dried, the plates were incubated at 28 °C for 3-4 days or until exconjugants were visible. 
Single colonies were then picked and re-streaked onto SFM plates containing the 




6.2.3. Cloning and Sequencing 
6.2.3.1. Polymerase Chain Reaction (PCR) 
6.2.3.1.i Analytical PCR from Streptomyces exconjugants 
A patch of Streptomyces cells was picked with a sterile toothpick and inoculated in 180 
µL 50 mM NaOH. Samples were then boiled for 10 minutes and neutralised with 20 µL 
1 M Tris/HCl pH 8. The samples were then centrifuged for 15 seconds at 15,871 × g. 
The supernatant was then used as DNA template in a colony PCR detailed in Tables 13 
and 14, using a Takara Terra PCR Direct Polymerase Mix. 
 
Table 13: Reaction conditions for Streptomyces colony PCR with Takara Terra PCR Direct Polymerase mix. 
Solution Volume 
Buffer 12.5 µL 
Primer 1 0.75 µL 
Primer 2 0.75 µL 
Enzyme mix 0.5 µL 
DNA template 2.5 µL 
H2O 8 µL 
Total 25 µL 
 
 
Table 14: PCR cycling conditions for Streptomyces colony PCR. 
Step Temperature Time Number of cycles 
1 98 ˚C 2 min x1 
2 98 ˚C 10 sec  
x34 3 60 ˚C 15 sec 
4 68 ˚C 2 min 
5 68 ˚C 3 min x1 






6.2.3.1.ii. E. coli colony PCR 
Single colonies from agar plates were picked with sterile toothpicks and inoculated in 50 
µL sterile H2O to be used as template DNA in a PCR. The PCR conditions shown in 
Tables 15 and 16 were used with a Bio-Rad T100 ThermoCycler. 
 
Table 15: Reaction conditions for E. coli colony PCR with G2 Taq polymerase. 
Solution Volume 
GoTaq green buffer 5 µL 
MgCl2 2 µL 
dNTPs 10 mM 0.5 µL 
Primer 1 (forward) 10 pmol/µL 0.5 µL 
Primer 2 (reverse) 10 pmol/µL 0.5 µL 
G2 Taq DNA polymerase 0.25 µL 
dH2O 15.25 µL 
Template DNA 1 µL 
Total 25 µL 
 
 
Table 16: PCR cycling conditions for E. coli colony PCR. 
Step Temperature Time Number of cycles 
1 98 ˚C 3 min x1 
2 98 ˚C 20 sec  
x30 3 60 ˚C 1 min 
4 72 ˚C 30 sec per kbp DNA 
5 72 ˚C 5 min x1 









6.2.3.1.iii. High fidelity PCR for cloning 
High fidelity cloning was carried out using Q5 DNA polymerase, with conditions as shown 
in Tables 17Table 18 and 18 with a Bio-Rad T100 ThermoCycler. 
 
Table 17: Reaction conditions for PCR cloning of genes from Streptomyces genomic DNA. 
Solution Volume 
Q5 buffer 10 µL 
dNTPs 1 µL 
Template gDNA 1.5 µL 
Primer 1 2.5 µL 
Primer 2 2.5 µL 
GC enhancer 10 µL 
Q5 polymerase 0.5 µL 
H2O 22 µL 
Total 50 µL 
 
 
Table 18: PCR cycling conditions for cloning of genes from Streptomyces genomic DNA. 
Step Temperature Time Number of cycles 
1 94 ˚C 2 min x1 
2 94 ˚C 45 sec  
x35 3 55 ˚C 45 sec 
4 72 ˚C 20 sec per kbp DNA 
5 72 ˚C 5 min x1 






6.2.3.2. Agarose gel electrophoresis 
DNA samples were run on 0.8% agarose gels in 1x TBE (Tris/Borate/EDTA) buffer 
stained with 3 µL ethidium bromide per 100 mL agarose. DNA samples were loaded onto 
gels with 1 µL loading dye per 6 µL of sample, with reference to a 2-log 1 kbp DNA ladder 
(NEB). Samples were analysed under UV light. 
 
6.2.3.3. Purification of DNA from agarose gel 
DNA bands were excised from agarose gels and purified using a GE Healthcare illustra 
GFX PCR DNA and Gel Band Purification Kit following the supplied protocol, eluting the 
DNA in 20-30 µL elution buffer. 
 
6.2.3.4. Purification of DNA from PCR mixtures 
DNA amplified by PCR was purified directly from reaction mixtures using a Qiagen 
QIAquick PCR purification kit following the supplied protocol, eluting the DNA in 50 µL of 
elution buffer per 50 µL of initial PCR mixture. 
 
6.2.3.5. DNA digestions 
All restriction enzymes were purchased from New England Biolabs (NEB). DNA was 
digested with the appropriate restriction enzymes using 0.5 µL enzyme per 1 µg DNA. 
Digestions were made up to a 50-100 µL total volume of 10% CutSmart® Buffer in H2O 
and incubated for 4 hours or overnight at 37 °C. 
 
6.2.3.6. Ligations 
An insert:vector ratio of 3:1 and 5:1 was calculated for each ligation reaction and the 
appropriate volume of digested insert and vector was mixed in a total reaction volume of 
10 µL H2O with 1 µL Invitrogen T4 Buffer and 1 µL Invitrogen T4 DNA ligase. Reactions 




All DNA samples were sequenced by Eurofins genomics using a Mix2Seq Kit with the 
appropriate sequencing primers (Table 12). For plasmids, 15 µL of DNA at a 
concentration of 100 ng/µL was added to 2 µL of primer at a concentration of 10 pmol/µL. 
DNA purified from PCR mixtures were sequenced with the same primers that were used 
to amplify the DNA fragment in the PCR. In each case 15 µL of sample at a concentration 
of 5 ng/µL was added to 2 µL of primer at a concentration of 10 pmol/µL. DNA sequences 
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were analysed using NCBI nucleotide BLAST, Vector NTI and AlignX. Sequencing 
chromatograms were analysed using Chromas. 
 
6.2.4. Mass Spectrometry 
6.2.4.1. Preparation of mass spectrometry samples from culture extracts 
Unless otherwise stated, samples from bacterial culture extracts for LC-MS analysis 
were prepared as follows: 1 mL of culture was mixed with one volume of methanol 
(MeOH) and agitated for 30 min at room temperature. The mixture was then centrifuged 
for 5.5 min at 15,871 × g to remove debris, and 800 μL of the supernatant was transferred 
to a 2 mL glass LC-MS vial for subsequent analysis. 
 
 
6.2.4.2. Standard LC-MS analysis 
Unless otherwise stated, all LC-MS analysis was carried out on a Shimadzu Nexera X2 
UHPLC coupled to a Shimadzu IT-TOF mass spectrometer. Samples were injected onto 
a Phenomenex Luna Omega 1.6-µm Polar C18 column (50 mm by 2.1 mm, 100 Å) set 
at a temperature of 40 °C and eluting with a linear gradient of (B) methanol from 0–60% 
in (A) H2O + 0.1% formic acid over 6 minutes with a flow rate of 0.6 mL/min. Positive 
mode mass spectrometry data was collected between m/z 200 and 2,000. MS2 data was 
also collected.  
 
6.2.4.3. High resolution LC-MS2 analysis 
High resolution LC-MS2 data were acquired by Gerhard Saalbach and Carlo de Oliveira 
Martins (John Innes Centre). Data were acquired on a Synapt G2-Si mass spectrometer 
equipped with an Acquity UPLC (Waters). Samples were injected onto an Acquity UPLC 
BEH C18 column, 1.7 μm, 1 × 100 mm (Waters) and eluted with a gradient of (B) 
acetonitrile/0.1% formic acid in (A) H2O/0.1% formic acid with a flow rate of 0.08 mL/min 
at 45 °C. The concentration of B was kept at 1% for 1 min followed by a gradient up to 
60% B over 10 min, and up to 99% over 2 min MS data were collected with the following 
parameters: resolution mode, positive ion mode, scan time 0.5 s, mass range m/z 50–
1200 (calibrated with sodium formate), capillary voltage = 3.0 kV; cone voltage = 40 V; 
source temperature = 110 °C; desolvation temperature = 250 °C. Leu-enkephalin was 
used to generate a lock-mass calibration with m/z = 556.2766 measured every 30 







6.3. Bioinformatics and Genome Mining 
 
6.3.1. Analysis of YcaO-domain Proteins 
6.3.1.1. Retrieval of YcaO-domain proteins from Actinobacteria 
All standalone YcaO-domain proteins from Actinobacteria were identified in NCBI 
Genbank using CDART (Conserved Domain Architecture Retrieval Tool) (301). 
Sequences were retrieved and proteins smaller than 350 AA were excluded from further 
analysis. The remaining proteins were analysed and filtered using EFI-EST (302), 
selecting a sequence similarity network (SSN) with a 95% maximum identity cut-off. The 
SSN was visualised with Cytoscape software version 2.8.3  (385). Accession numbers 
of all proteins in the SSN were submitted to Batch Entrez to retrieve sequence files for 
further analysis. 
 
6.3.1.2. Sequence alignments and phylogenetic tree building 
The YcaO protein sequence files were aligned using MUSCLE (264) on the CIPRES 
Science Gateway (https://www.phylo.org/). This alignment was then used to construct a 
maximum likelihood tree using RAxML-HPC2 on XSEDE with default settings on the 
CIPRES Science Gateway. The tree was visualised and annotated with the interactive 
Tree Of Life (iTOL) (386). 
 
6.3.2. Genome Mining 
6.3.2.1. RiPPER 
The 1,514 YcaO-domain protein sequences that were obtained were used as the input 
for RiPPER (https://github.com/streptomyces/ripper) (124) with default settings. The 
captured genomic regions were visualised in Artemis (261). 
 
6.3.2.2. Whole genome comparative analysis 
antiSMASH v5, PRISM v4, RiPPMiner, BAGEL v4 and DeepRiPP (full workflow) were 
used to analyse the whole genome sequence of Streptomyces albus J1074, using default 
settings. 
 
6.3.3. Analysis of Precursor Peptides 
6.3.3.1. Precursor peptide analysis 
RiPPMiner (peptide) and DeepRiPP (NLPPrecursor) were used to analyse precursor 




6.3.3.2. Sequence alignments 
Multiple sequence alignments of precursor peptides were performed using Clustal W 
(265) via the MEGA7 software (387), with gaps manually removed. Default alignment 
settings were employed (multiple alignment: gap opening penalty= 10, gap extension 
penalty=0.2; protein weight matrix= Gonnet, residue-specific penalties= ON, 
hydrophobic penalties= ON, gap separation distance= 4, end gap separation= OFF, use 
negative matrix= OFF, delay divergent cutoff= 30%).  
 
6.3.3.3. Identification of motifs 
Sequence motifs were searched for using the MEME tool (388) in the MEME suite 
version 5.1.1 (https://meme-suite.org/index.html). The settings were employed as 
follows: classic mode, site distribution= ‘Any Number of Repetitions’ number of motifs to 
search for= 5 or 1.  
 
6.3.3.4. Evolutionary networking 
Peptide similarity networking of the precursor peptide sequences were created using 
EGN (Evolutionary Gene and genome Network) (298) and visualised with Cytoscape 
version 2.8.3 (385).  
 
6.3.3.5. Comparison of gene cluster architectures  
The S. albus J1074 putative minimal biosynthetic gene cluster was submitted to 
MultiGeneBlast (https://multigeneblast.sourceforge.net/) (308) to identify homologous 
gene clusters.  
 
6.3.4. Analysis of S. albus J1074 Biosynthetic Gene Cluster 
Biosynthetic protein functions were analysed using a combination of blastP 







6.4. Characterising the S. albus J1074 Gene Cluster 
 
6.4.1. TAR Cloning 
6.4.1.1. Construction of capture vector 
A vector to capture the gene cluster from S. albus J1074 genomic DNA (gDNA) was 
constructed by Gibson assembly between a linearised pCAP03 vector (332) and two 
single-strand oligonucleotides (Salb_TAR_fw and Salb_TAR_rv) (Table 12). The 
forward and reverse oligonucleotides had 34 and 36 nucleotide homology sequences 
with pCAP03 respectively, and were designed to generate a vector with 50 and 49 
nucleotide homology sequences with upstream and downstream regions of the gene 
cluster respectively, either side of an AvrII restriction site. pCAP03 was digested with 
XhoI and NdeI, and 100 ng linearised plasmid and 10 pmol of each oligonucleotide were 
incubated with 5 µL ligase-free Gibson assembly reaction mixture (100mM Tris/HCl pH 
7.5, 10 mM MgCl2, 0.2 mM each dNTPs, 10 mM DTT, 1 mM NAD, 5% PEG-8000, 0.1125 
units T5 exonuclease, 0.375 units Phusion polymerase, 10 µL total reaction volume) 
(Table 19) and incubated at 50 °C for 2 hours in a Bio-Rad T100 ThermoCycler. 10 μL 
of each assembly reaction was then transformed into E. coli DH5α by chemical 
transformation. Transformants were selected on LB + Kan agar. 
 











1 3 µL (100 ng) 1 µL (0.1 pmol) 1 µL (0.1 pmol) 5 µL - 10 µL 
2 3 µL (100 ng) 1 µL (1 pmol) 1 µL (1 pmol) 5 µL - 10 µL 
3 3 µL (100 ng) 1 µL (10 pmol) 1 µL (10 pmol) 5 µL - 10 µL 
Control 3 µL (100 ng) - - 5 µL 2 µL 10 µL 
 
 
Colonies containing the correctly assembled capture vector were identified by analytical 
PCR using the screening primers pCAP_sp and pCAP_asp. Plasmid DNA was isolated 
and sequenced using the same primers. 
 
6.4.1.2. DNA digestion 
Genomic DNA from S. albus J1074 was digested with NsiI and SmlI, and the capture 
vector was linearised between the capture arms with AvrII. DNA was digested with the 
appropriate restriction enzymes for 5 hours at 37 ˚C with occasional inversion according 
to Table 20. 
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Table 20: DNA digestion for TAR cloning. 
Digestion DNA 
amount 
AvrII NsiI SmlI CutSmart buffer H2O 
S. albus gDNA 25 µg  15 µL 15 µL 50 µL Up to 500 µL 
pSalbCap 25 µg 15 µL   50 µL Up to 500 µL 
 
6.4.1.3. Spheroplast transformation 
Digested material was transformed into S. cerevisiae VL6–48N by spheroplast 
polyethylene glycol (PEG)-8000 transformation, using the following method adapted 
from the Moore TAR 2.0 protocol (335): 
 
Fresh yeast colonies were obtained by streaking S. cerevisiae onto YPD agar plates and 
incubating at 30 ˚C for 3 days. A yeast starter culture was made by inoculating a single 
colony into 10 mL YPD liquid medium and incubating at 28 ˚C for 16 hours with shaking 
at 250 rpm. 1 mL of starter culture was then inoculated in 50 mL YPD in a 250 mL flask 
and incubated at 28 ˚C for 6 hours with shaking at 250 rpm, at which point the OD600nm 
had reached 0.85. The culture was then incubated on ice for 10 minutes before being 
transferred to a 50 mL Falcon™ tube and centrifuging for 3 minutes at 1,800 × g, 4 ˚C. 
The cell pellet was resuspended in 50 mL ice cold H2O and centrifuged for 3 minutes at 
1800 × g, 4 ˚C. The cell pellet was then resuspended in 50 mL ice-cold 1 M sorbitol and 
incubated at 4 ˚C overnight. The cell suspension was then inverted and centrifuged for 
3 minutes at 1,800 × g, 4 ˚C. The cell pellet was resuspended in 20 mL SPE (Table 9), 
40 µL 2-mercaptoethanol (BME) and 5 µL zymolyase (5 U/μL, Zymo Research). Cells 
were then incubated for 30 minutes at 30 ˚C and inverted every 5 minutes to reach a 
spheroplast level of 80-95%. The level of spheroplasting was quantified by comparing 
the OD600nm of cells mixed with 1 M sorbitol and 2% SDS in 1:5 ratios. Cold 1 M sorbitol 
was added up to a total volume of 50 mL, and cells were centrifuged for 10 minutes at 
600 × g, 4 ˚C. The cell pellet was resuspended in 3 mL STC (Table 9) by slowly pipetting 
with a 10 mL pipette, and then incubated at room temperature for 10 minutes. 200 µL 
spheroplasts were mixed with 500 ng linearised capture vector and 3 µg digested gDNA 
per transformation and incubated at room temperature for 10 minutes. 800 µL 20% PEG-
8000 was added to each transformation and inverted 10 times before being incubated at 
room temperature for 20 minutes. Cells were then microcentrifuged for 10 minutes at 
700 × g, 4 ˚C. Cell pellets were resuspended in 800 µL SOS (Table 9) and incubated for 
40 minutes at 30 ˚C. Each cell suspension was added to 15 mL melted top selective agar 




6.4.1.4. Screening for captured gene cluster 
100 individual colonies which grew on the selective agar plates were picked and re-
streaked as small patches onto fresh SD-Trp plates and incubated for 2 days at 30 ˚C. 
After incubation, a small region from each patched colony was picked and inoculated in 
400 µL 1 M sorbitol. 20 colonies were pooled into one screening sample. 1 µL zymolyase 
was added to each pool and samples were incubated at 28 ˚C with shaking at 250 rpm 
for 1 hour. Samples were then boiled for 10 minutes in a heat block and microcentrifuged 
(15 seconds, 1,000 × g) and 1 μL supernatant from each pool was then used as DNA 
template for an analytical PCR screen. Positive controls were set up containing S. albus 
J1074 gDNA (108 ng/µL) as a template, using the screening primers Salb_TARscr_Fw 
and Salb_TARscr_Rv (Table 12). Plasmid DNA from four positive clones was isolated 
and transformed into electrocompetent E. coli DH5α. An analytical digest of the purified 
construct was also carried out with the restriction enzymes HindIII-HF and SrfI to confirm 
the presence of the entire biosynthetic gene cluster.  
 
6.4.2. Heterologous Expression 
E. coli ET12567/pR9604 was transformed with pCAPSalbC by electroporation, and 
transformants were then used to transfer pCAPSalbC into the heterologous hosts S. 
coelicolor M1146, S. lividans and S. laurentii by intergeneric conjugation (described in 
section 6.2.2.3.). Nalidixic acid and kanamycin-resistant exconjugants containing 
integrated pCAPSalbC were verified by analytical PCR using the screening primers 
Salb_TARscr_Fw and Salb_TARscr_Rv (Table 12). 
 
6.4.3. Gene Cluster Disruptions 
A fragment of DNA corresponding to the overlapping amiC and amiD genes was cloned 
by high fidelity PCR with Q5 polymerase (section 6.2.3.1.iii. High fidelity PCR for cloning.) 
using the primers Salb_YHMut_Fw and Salb_YHMut_Rv (Table 12). The amplified DNA 
fragment was purified from agarose gel and digested with EcoRI and HindIII. The 
pKC1132 plasmid was also digested with EcoRI and HindIII and ligated with the digested 




















1.4 µL (50 ng) 6 µL 1:3 2 µL 0.25 µL 0.35 µL 10 µL 
1.4 µL (50 ng) 10 µL 1:5 4 µL 0.5 µL 4.1 µL 20 µL 
1.4 µL (50 ng) - Control 2 µL 0.25 µL 6.35 µL 10 µL 
 
The resulting DNA construct was isolated and transferred into S. albus J1074 via 
intergenic conjugation with E. coli ET12567/pUZ8002 selected with apramycin and 
nalidixic acid. Exconjugants resistant to apramycin were validated by colony PCR 
(section 6.2.3.1.i .) using screening primers Salb_YHMut_ScrFw and 
Salb_YHMut_ScrRv to confirm that the YcaO and hydrolase genes had been disrupted. 
These primers bind within the disrupted region to confirm whether or not the target 
genetic region is intact. 
 
6.4.4. Gene Deletions 
Mutations of the S. albus J1074 biosynthetic gene cluster were carried out using PCR-
targeting (309). First, the pCAPSalbC construct was transformed into E. coli BW25113 
cells carrying the λRed plasmid pIJ790 and transformants were selected on LB + Chlor 
+ Kan + Apra grown at 30 °C. Resistance cassettes were then amplified by high-fidelity 
PCR from pIJ773-OriT, a version of pIJ773 modified to have the OriT removed. All 
primers used for gene deletions are listed in Table 12. The forward primer was designed 
to contain a 20 bp sequence homologous to the start of the apramycin resistance gene 
(aac(3)IV) alongside a 59 bp sequence homologous to the gene upstream of the target 
gene deletion, including the ATG start codon of the target gene. The reverse primer was 
designed to contain a 19 bp sequence homologous to the end of aac(3)IV alongside a 
58 bp sequence homologous to the gene downstream to the target gene deletion, 
including the ACT reverse stop codon of the target gene. Amplified resistance cassettes 
were purified and transformed into E. coli BW25113/pIJ790/pCAPSalbC and 
transformants were selected on LB + Chlor + Kan + Apra grown at 37 °C. Plasmid DNA 
was isolated from single colonies and transformed into E. coli DH5α cells carrying the 
BT340 plasmid. Flp-FRT recombination-mediated excision of the disruption cassette was 
then induced by streaking single colonies onto LB agar and incubating overnight at 42 
°C. Single colonies in which the excision had taken place were screened for by patching 
colonies onto both LB+ Kan and LB+ Apra + Kan agar plates. The PCR-targeting mutant 
versions of pCAPSalbC were introduced into S. coelicolor M1146 by E. coli 
ET12567/pR9604-mediated intergeneric conjugation and selected by resistance to 




Constructs for the complementation of mutants were obtained by high-fidelity PCR 
amplification of each of these genes, using the primers listed in Table 12. The PCR 
products were digested with NdeI and HindIII and cloning by ligation into pIJ10257 
(HygR) (384) digested with NdeI and HindIII. Ligation mixtures were transformed into 
chemically competent E. coli DH5α and the plasmids were isolated and sequenced. The 
constructs were introduced into the corresponding S. coelicolor M1146-pCAPSalbC 
mutants by E. coli ET12567/pR9604-mediated intergeneric conjugation. Exconjugants 
were selected by resistance to nalidixic acid, kanamycin and hygromycin. 
 
6.4.6. Core Peptide Mutations 
Amino acids within the streptamidine core peptide were mutated using a Lambda-Red-
mediated recombination strategy in E. coli cells deficient in mismatch repair. E. coli 
HME68 cells were grown in 10 mL L with chloramphenicol and grown overnight at 30 °C 
with shaking at 250 rpm. 300 µL of this culture was used to inoculate 15 mL LB with 
chloramphenicol, which was grown for four hours at 30 °C with shaking at 250 rpm. 
Recombineering activity was induced by incubating the cells for 20 minutes in a 42 °C 
water bath with shaking. Cells were then made electrocompetent and transformed with 
the pCAPSalbC construct. A 63 bp oligonucleotide (SalbPP_Ser3CysRV) was designed 
containing the desired amino acid mutation flanked by 30 bp regions of homology on 
either side. E. coli HME68-pCAPSalbC cells were then co-transformed with 1 µL (4 pmol) 
of the mutant oligonucleotide and 1 µL (4 pmol) of oligo100 (Table 12), which produces 
Gal+ recombinants of HME68 cells. Recombinant cells were selected for using red/white 
screening on MacConkey agar containing 1% galactose grown for 2 days at 30 °C. Red 
colonies were picked and re-streaked as patches on MacConkey agar containing 1% 
galactose and grown for a further 2 days at 30 °C. Mutations were then screened for by 
high-fidelity PCR using screening primers (SalbPPmut_FWScr and SalbPPmut_RVScr) 
binding ~300 bp each side of the desired mutation. DNA from PCR reactions was purified 
and sequenced, and mixed populations of ‘wild type’ and mutant strains were identified 
from sequencing data by identifying duplicated peaks for both the ‘wild type’ and mutant 
amino acid codon in the sequence chromatogram. Plasmid DNA from corresponding 
cells was isolated and transformed into E. coli DH5α cells, and individual mutant clones 
were screened for as before. Mutant plasmids were transformed into corresponding S. 




6.4.7. Fermentation and Metabolomic Screening 
6.4.7.1. Production cultures 
Seed cultures of S. coelicolor M1146-pCAPSalbC were prepared by fermentation in a 50 
mL flask containing 5 mL of TSB with kanamycin selection for 48 hours. 500 μL seed 
culture was used to inoculate 10 mL SM12, SM14, BPM and R5 in 50 mL Falcon tubes 
with caps replaced by foam bungs. Control strains carrying the TAR clone with a 
precursor peptide gene deletion were cultured in the same way for comparison. All 
fermentations were conducted in triplicate and incubated at 28 °C with shaking at 230 
rpm. At day four of growth, samples were taken as described in section 6.2.4.2.   
 
6.4.7.2. Untargeted metabolomic analysis 
Untargeted comparative metabolomics was carried out on data from triplicate samples 
using Profiling Solution 1.1 (Shimadzu) with an ion m/z tolerance of 100 mDa, a retention 
time tolerance of 0.1 min and an ion intensity threshold of 70,000 units. 
 
6.4.7.3. Metabolite networking 
Global Natural Products Social Molecular Networking (100) (GNPS; 
http://gnps.ucsd.edu) was used to construct the metabolite networks from data acquired 
on the Shimadzu IT-TOF using the following GNPS settings: Parent Mass Tolerance = 1 
Da, Min Pairs Cos = 0.6, Min Matched Peaks = 3, Network TopK = 15, MSCluster = ON, 
Minimum Peak Intensity = 25, Filter Precursor Window = OFF, Filter Library = OFF, and 




6.5. Purification and Characterisation of Streptamidine 
 
6.5.1. Purification of Metabolite 
6.5.1.1. Large scale cultures 
Four 2-litre flasks containing 0.5 L of SM12 were each inoculated with 25 mL of S. 
coelicolor M1146-pCAPSalbC TSB seed culture grown for 48 hours at 28 °C. After four 
days fermentation at 28 °C with shaking at 250 rpm, the cultures were centrifuged to 
remove debris, combined and filtered to yield approximately 1.5 L of crude extract.  
 
6.5.1.2. Liquid extraction 
The crude extract was washed with ethyl acetate (3 x 1.5 litres) and the aqueous layer 
was separated from the organic layer. The aqueous layer was extracted with 1-butanol 
(3 x 1.0 litres) and the final aqueous layer was separated from the organic layer. The 
original solvent was removed using a Buchi rotary evaporator. 
 
6.5.1.3. Solid phase extraction 
The aqueous extract was concentrated in vacuo to approximately 50 mL and subjected 
to solid-phase extraction (SPE) chromatography on a 400 g SNAP Ultra HP20 cartridge 
connected to a Biotage using a gradient of H2O-MeOH (100:0 to 0:100) at a flow rate of 
20 mL/min. Fractions were analysed by LC-MS (as described in section 6.2.4.2.) and 
those containing streptamidine were combined, methanol was removed and the samples 
were freeze-dried.  
 
6.5.1.4. High performance liquid chromatography (HPLC) 
Samples obtained from Biotage purification were resuspended in H2O and subject to 
semi-preparative HPLC using a Phenomenex Luna PFP(2) column, 5 μm, 250 x 10 mm, 
with a gradient of 0.1% aqueous formic acid-MeOH (98:2 to 90:10) over 35 minutes at a 
flow rate of 2 mL/min. Fractions were collected based on the appearance of peaks in the 
UV chromatogram monitored at 210 nm, and then analysed by LC-MS (as described in 
section 6.2.4.2.) to determine the retention time of streptamidine. Fractions containing 
streptamidine were combined and freeze dried. A final purification step was then carried 
out using a semi-preparative Luna Omega Polar C18 column, 5 μm, 250 x 10 mm, with 
an isocratic gradient of aqueous 0.1% formic acid-MeOH (90:10) for 16 minutes followed 
by a wash gradient from 90:10 to 5:95 over 5 minutes and a flow rate of 2.8 mL/min. 
Streptamidine eluted in two phases corresponding to two peaks in the UV chromatogram 
monitored at 210 nm, which were separately collected, analysed by LC-MS, freeze-dried 
and retained for NMR analysis. 
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6.5.2. Structural Elucidation 
6.5.2.1. NMR (Nuclear Magnetic Resonance) 
Pure streptamidine (1.4 mg) corresponding to the first HPLC UV peak was dissolved in 
600 µL DMSO-d6 from an individual vial and subjected to a series of 1D and 2D nuclear 
magnetic resonance (NMR) experiments on a Bruker Ascend 600 MHz instrument at 298 
K. The NMR experiments carried out were Proton (64 scans), Carbon (25,000 scans), 
HSQCed (100 scans), HMBC (64 scans), COSY (16 scans), TOCSY (32 scans) and 
HSQC-TOCSY (64 scans). Spectra were analysed using Bruker TopSpin 3.5 and 
Mestrelab Research Mnova 14.0 software, with assistance from Sergey Nepogodiev. 
 
6.5.2.2. Fluorescamine-binding assay 
3 µL of fluorescamine ((4-phenylspiro-[furan-2(3H),1-phthalan]-3,3′-dione) (Sigma-
Aldrich), 3 mg/mL in acetone) was separately mixed with 3 µL of L-histidine (1 mg/mL in 
H2O) and 3 µL of streptamidine (1 mg/mL in H2O), in a total volume of 500 µL H2O within 
a 1.5 mL glass LC-MS vial. Samples were then analysed by LC-MS as described in 
section 6.2.4.2.  
 
6.5.2.3. Marfey’s analysis 
500 µg of pure streptamidine was hydrolysed for 16 hours with 100 µL 6 M HCl at 100 
°C in a sealed glass vial contained within a heated sand block. The HCl was dried off 
under a stream of N2 for 1 hour at room temperature, with assistance from Martin Rejzek. 
The hydrolysed sample was mixed with 20 µL 1 M NaHCO3 and 40 µL Marfey’s reagent 
(L-FDAA (Nα-(2,4-dinitro-5-fluorophenyl)-L-alaninamide) 1% solution in acetone) and 
incubated at 40 °C for 1 hour. The reaction was then neutralised with 20 µL 1 M HCl. 
The samples were diluted with 500 µL 50% acetonitrile and centrifuged for 1 minute at 
15,871 × g to remove debris. For derivatisation of amino acid standards, 50 µL of each 
L- and D- amino acid (histidine, leucine, serine, alanine, threonine, 2 mg/mL in H2O) was 
mixed with 20 µL 1 M NaHCO3 and 40 µL L-FDAA in a 1.5 mL Eppendorf tube and 
incubated at 40 °C for 1 hour. The reaction was then neutralised with 20 µL 1 M HCl. 
The samples were diluted with 1 mL 50% acetonitrile and centrifuged for 1 minute at 
15,871 × g to remove debris. 1 µL each sample were injected onto a Kinetix 1.6-µm C18 
column (50 mm by 2.1 mm, 100 Å) set at a temperature of 40 °C and eluting with a linear 
gradient of (B) 50% acetonitrile from 5-50% in (A) 0.1% formic acid in H2O over 6 minutes 
with a flow-rate of 0.6 mL/min. Samples were analysed on a Shimadzu Nexera X2 





6.5.3.1. Antimicrobial assays 
Ten mL cultures of each indicator strain (Table 3) were grown in LB (YPD for C. utilis) 
overnight at 37 °C (30 °C for C. utilis). 100 µL of each culture was then used to inoculate 
a 10 mL subculture of each strain in the same medium, which were grown for 5 hours at 
37 °C (30 °C for C. utilis). 1 mL of each culture was then mixed with 14 mL molten LB 
agar, which was poured into plates. Once solidified, three 1 cm diameter plugs were 
taken from each agar plate, which were then separately loaded with 50 µL streptamidine 
(1 mg/mL in H2O), 50 µL H2O as a solvent control and 50 µL of an appropriate 
antibiotic/antifungal agent as a positive control (kanamycin, apramycin or nalidixic acid 
(1 mg/mL)). Plates were incubated overnight at 37 °C (30 °C for C. utilis). 
 
6.5.3.2. Metal binding assays 
6.5.3.2.i. CAS assay 
For the CAS assay, 500 μL of CAS assay solution (prepared as described by Alexander 
and Zuberer (390)) was mixed with 10 µL increasing concentrations of streptamidine 
from 1.5 µM to 25 µM.  
 
6.5.3.2.ii. LC-MS metal binding assays 
For LC-MS binding assays, solutions of 10 mM metal salts were prepared (FeCl3, CoCl2, 
CuCl2, MgCl2, MnSO4, NiSO4, ZnCl2, dissolved in 10 mM HCl) and 500 μL of each were 
mixed with 20 µL streptamidine (15 µM). Samples were then analysed by LC-MS as 
described in section 6.2.4.2.  
 
6.5.4. MASST Analysis 
Streptamidine-like metabolites were searched for using a MASST search (361) at GNPS 
(https://gnps.ucsd.edu/ProteoSAFe/static/gnps-splash.jsp) with the following settings: 
parent mass tolerance = 2 Da; min matched peaks = 5; ion tolerance = 0.5 Da; score 
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Figure 78: Genome mining output from RiPPMiner analysis of S. albus J1074 genome. 
 
 





Figure 80: Genome mining output from DeepRiPP analysis of S. albus J1074 genome. 
 
 



















Figure 83 (below): Alignment of streptamidine-like precursor peptides associated with precursor network 1, 
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Figure 85 (below): MultiGeneBlast output from analysis of Streptomyces albus (albidoflavus) J1074 











Figure 86: (A) Vector map of pCAPSalbC with the HindIII and SrfI restriction sites highlighted. (B) ‘Virtual 
gel’ image of expected DNA bands obtained from an analytical restriction digest of pCAPSalbC with HindIII 




Figure 87: Screenshot of DNA alignment obtained from sequencing of pSalbCAP construct. The expected 
vector sequence matches the sequences obtained from forward and reverse screening of the plasmid 





Table 22: Selected metabolomic data showing metabolites produced by S. coelicolor M1146-SalbC 
compared with the precursor peptide mutant (SalbCΔPP) and medium only (SM12). Analysis carried out 




Table 23: Selected metabolomic data showing metabolites produced by S. coelicolor M1146-SalbC 
compared with pathway mutants (ΔamiB, ΔamiC, ΔamiD, ΔamiE, ΔamiX) and medium only (SM12). Analysis 





Ion m/z 510.2674 324.17 272.1603 314.1695 647.33 409.2343
Ion RT 1.09 0.869 2.423 2.48 0.989 1.302
S. coelicolor  M1146:pCAPSalbC1 2499654 2207472 996032 873422 298441 260134
S. coelicolor  M1146:pCAPSalbC2 1922639 2825998 846665 962465 268447 281377
S. coelicolor  M1146:pCAPSalbC3 2372999 2730479 990778 1160814 307189 214862
S. coelicolor  M1146:pCAPSalbCΔPP1 0 0 0 0 0 0
S. coelicolor  M1146:pCAPSalbCΔPP2 0 0 0 0 0 0
S. coelicolor  M1146:pCAPSalbCΔPP3 0 0 0 0 0 0
SM12 0 0 0 0 0 0
Ion m/z 324.1659 510.2698 314.1696 647.3248 332.1785 272.1582 354.1602 510.2688
Ion RT 1.398 1.55 3.025 1.392 3.023 2.983 3.034 1.202
SalbC1 2262279 1475999 1042037 544662 393459 387710 280038 205147
SalbC2 2214873 1171449 847530 545338 329963 410005 252484 197976
ΔamiA1 0 0 0 0 0 0 0 0
ΔamiA2 0 0 0 0 0 0 0 0
ΔamiA3 0 0 0 0 0 0 0 0
ΔamiB1 0 0 0 0 0 0 0 0
ΔamiB2 0 0 0 0 0 0 0 0
ΔamiB3 0 0 0 0 0 0 0 0
ΔamiC1 0 0 0 0 0 0 0 0
ΔamiC2 0 0 0 0 0 0 0 0
ΔamiC3 0 0 0 0 0 0 0 0
ΔamiD1 0 0 0 0 0 0 0 0
ΔamiD2 0 0 0 0 0 0 0 0
ΔamiD3 0 0 0 0 0 0 0 0
ΔamiE1 0 0 1605224 0 887866 796578 443885 0
ΔamiE2 0 0 2048790 0 1116939 1351619 483075 0
ΔamiE3 0 0 1588020 0 712023 943842 389179 0
Δami 1 1057241 810404 2825272 290000 1980880 1570774 649966 172142
Δami 2 1172300 763166 2569195 237703 1813192 1699116 604358 149342
Δami 3 1139022 660021 2451654 223171 1386092 1560029 585720 169857
SM12 1 0 0 0 0 0 0 0 0
211 
 
Table 24: Selected metabolomic data showing metabolites produced by S. coelicolor M1146-SalbC 
compared with pathway mutants: iron transporter deletion (ΔamiF1-4), oxygenase deletion (ΔOxy), peptide 
methionine sulfoxide reductase deletion (ΔPM), MarR deletion (ΔMarR), ABC transporter deletion (ΔT1-2) 




Table 25: Selected metabolomic data showing metabolites produced by S. albus J1074 wild type compared 
with the pathway-disrupted mutant (S. albus YH mutant) and medium only (SM12). Analysis carried out as 




Ion m/z 324.1652 409.2112 510.2665
Ion RT 1.335 1.393 1.503
SalbC1 2262502 304396 104359
SalbC2 2715880 547614 294043
SalbC3 2252375 234775 110043
ΔamiF1 4 1 0 0 0
ΔamiF1 4 2 0 0 0
ΔamiF1 4 3 0 0 0
ΔamiT1 2 1 389484 152524 0
ΔamiT1 2 2 206483 130887 0
ΔamiT1 2 3 0 0 0
ΔPM1 3046506 497514 158387
ΔPM2 2325230 368514 126083
ΔPM3 2642271 313950 131314
ΔOxy1 2638215 170407 167448
ΔOxy2 3555376 183279 222399
ΔOxy3 141632 0 0
ΔMarR1 3931198 929006 1113021
ΔMarR2 2664038 446943 268230
ΔMarR3 4194032 711481 524694
ΔAT1 2608474 174412 300238
ΔAT2 129689 0 0
ΔAT3 0 0 0
Ion m/z 324.1662 647.3265 510.2657 409.2192 272.1584 314.1664
Ion RT 1.755 1.738 2.521 0.8 3.978 4.044
S. albus  J1074 WT1 2971974 544327 309829 0 316550 0
S. albus  J1074 WT2 3324012 573868 307114 300468 249284 0
S. albus J1074 WT3 3246270 484952 259442 252018 297315 0
S. albus  YH mutant1 0 0 0 0 1822945 265587
S. albus  YH mutant2 0 0 0 0 0 0
S. albus  YH mutant3 0 0 0 0 0 315791




Figure 88: Output from RiPP peptide mass calculator, after entering masses identified from metabolomic 
screening alongside putative mass changes and the S. albus J1074 core peptide sequence. 
 
 
Figure 89: Screenshot of output of Shimadzu formula prediction tool, when analysing the putative final 




Figure 90: Fractions from Biotage purification that contain the target metabolite. 
 
 





Figure 92: UV chromatogram obtained following semi-prep HPLC purification of semi-pure material from 
previous HPLC purification step. Samples were subjected to a 10% methanol isocratic gradient. The target 







Figure 93: 2D NMR correlations used to elucidate the structure of streptamidine. Coloured arrows represent 







Figure 94: Structure of streptamidine with HMBC and COSY NMR correlations shown in green arrows 
(HMBC) and blue lines (COSY). 
 
 






































Figure 97: Amide and histidine proton signals for streptamidine recorded in DMSO-d6. 

























Figure 103: MS2 fragmentation data for predicted dehydrated LSA (m/z 272.1595) and predicted acetylated 
and dehydrated LSA (m/z 314.1711), obtained using a Waters Synapt G2Si. 
 
 
Table 26: Accurate masses for streptamidine and related metabolites, obtained using a Waters Synapt G2Si. 




C28H42N10O8 324.1666 ([M+2H]2+) 324.1666 0.00 
647.3260 647.3251 1.39 
Predicted modified 
HLSAT 
C22H35N7O7 510.2671 510.2668 0.59 
Predicted modified HLSA C18H28N6O5 409.2194 409.2195 -0.24 
Predicted dehydrated 
LSA 
C12H21N3O4 272.1604 272.1595 3.31 
Predicted acetylated and 
dehydrated LSA 
C14H23N3O5 314.1710 314.1711 -0.32 







Table 27: Accurate masses for streptamidine and related metabolites, obtained using a Shimadzu IT-TOF. 
Description Formula Calc. [M+H]+ Obs. m/z Error (ppm) 
Streptamidine (modified 
HLSATH) 
C28H42N10O8 647.3260 647.3255 0.77 
Predicted modified HLSAT C22H35N7O7 510.2671 510.2688 -3.33 
Predicted modified HLSA C18H28N6O5 409.2194 409.2175 4.64 
Predicted dehydrated LSA C12H21N3O4 272.1604 314.171 0.00 
Predicted acetylated and 
dehydrated LSA 
C14H23N3O5 314.1710 272.1613 -2.94 







Figure 104: plasmid map of pKC1132, suicide vector used for disruption of the streptamidine biosynthetic 
gene cluster in Streptomyces albus J1074. 
 
 
Figure 105: plasmid map for pIJ10257, expression vector used for complementation of gene deletions and 




Figure 106: plasmid map for pCAP03, vector used for capture of the streptamidine biosynthetic gene cluster. 
 
 
Figure 107: plasmid map for pIJ773ΔoriT, plasmid used as template for amplification of resistance cassette 
during PCR targeting experiments. 
